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Two major oligosaccharides, lipoarabinomannan (LAM) and arabinogalactan (AG), 
are important constituents of the cell wall of Mycobacterium tuberculosis, the 
causative bacterial pathogen of tuberculosis. The AG, which is attached to long chain 
lipids, provides a very effective hydrophobic barrier against the penetration of anti-
mycobacterial drugs. The LAM and AG consist of varying numbers of 
arabinofuranose residues. The biosynthesis of the arabinan portion of both is 
postulated to involve multiple arabinofuranosyltransferases (AraT's), which catalyse 
the step-wise coupling of the donor decaprenolphosphoarabinose (DPA) to growing 
oligosaccharides.
 
We have synthesized a series of arabino glycosyl sulfamides as 
potential inhibitors of mycobacterial cell wall biosynthesis. In this work sulfamide 
was used as an isostere of phosphate and varied the hydrophobic substituents as 
mimics of the polyprenol chain of DPA. However, arabino N-glycosyl sulfamides, 
sulfonamides, and sulfamates unexpectedly and spontaneously converted from the 
furanose to the pyranose form in an aqueous solution. To remedy this, a series of 
glycosyl sulfamides which lacked the 5-hydroxyl group were synthesized in order to 
fix these materials in the furanose form. All compounds were synthesised and tested 
for anti-mycobacterial activity using the Alamar Blue (AB) assay. Compounds 
displayed low to moderate activity against M. smegmatis.  
The recently discovered enzyme Mycobacterium tuberculosis thymidine 
monophosphate kinase (TMPKmt), catalyses the phosphorylation of thymidine 
monophosphate (dTMP) to give thymidine diphosphate (dTDP), and is indispensable 
for the growth and survival of M. tuberculosis, as it plays an essential role in the DNA 
synthesis. Therefore, inhibition of TMPKmt may be an attractive avenue for the 
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development of novel anti-tuberculosis agents. Possible sulfamide structures were 
screened using in silico induced-fit docking methods as dTMP analogues with 
TMPKmt X-ray crystal structure (PDB accession code: 1N5K). From these docking 
results, a selection of compounds was synthesized and the evaluated for any anti-
mycobacterial activity. However, none of the compounds showed promising 
inhibitory activity against M. smegmatis. 
A novel reduction method was accidentally discovered during the synthesis of 6-
amino-D-mannose pyranose, using iodide and Amberlite IR 120 ion exchange resin 
(H
+
 form). During this process, D-mannose was first selectively iodinated using an 
Appel reaction, subsequent nucleophilic substitution using NaN3. Following that 
reaction, in order to remove the imidazole, the reaction mixture was filtered through 
Amberlite IR 120 ion exchange resin (H
+
 form), and then concentrated in vacuo. 
Interestingly, the final product was identified as the amine. As it is simple, efficient, 
and mild reduction method for the conversion of azides into amines, the reaction 
condition was optimized using NaI/Amberlite IR120 (H
+
 form), and tolerance of the 










I would like to sincerely thank my supervisor, Prof. Antony Fairbanks, for the 
opportunity to work in his laboratory and for his incredible guidance, encouragement 
and advice over the past few years. I am grateful for his patience, support and ideas 
throughout the writing of this thesis.  
I would like to thank to my co-supervisor Dr. Chris Fitchett for his support and 
guidance. 
I would like to thank Dr. Moritz Lasse for his guidance and support in biological 
assay. 
I would also like to thank Dr. Wanting Jiao for performing the molecular docking 
studies for this work.  
I would like to thank the past and present members of the Fairbanks group, Evan, 
Yusuke, Andrew, Davey, Pragya, Govind, Vivek, Stewart (also proofreading my 
thesis and providing valuable inputs), Jesse, Akshita, Sivasinthuja, Jude, Pretti, 
Hélène, Aoife, Patrycja, Maryne, Claudia and Cormac for the wonderful time I had in 
both the lab and office. I am grateful to Ruhamah, Rohul, Janadari, Siji, Rakesh, 
Carline, Chami and Akhil for their endless support and friendship.  
The academic and technical members of the Chemistry Department have been 
extremely helpful and I would like to thank them all. Many thanks to Dr. Matt Polson 
for performing the X-ray crystallographic studies and safety advice in this project. 
Thanks to Drs. Marie, Amelia and Alexander for processing numerous mass samples 
and for assistance with HPLC. Special thanks to Marie for helping with the NMR 
techniques. Thanks also extend to Rob, Wayne, Nick, Gill, and Laurie. 
vii 
 
Travel grants from the department of chemistry and Evans fund for attending 
conferences were very much appreciated. Thanks also go to the department of 
chemistry for the Grant in aid award 2016 and UC doctoral scholarship for financially 
supporting me while I did my research.  
I would like to thank my mother, brother, sister in law and brother in law for their 
unconditional love and support. 
Finally, I would like to thank my husband, Suthagar, for his unconditional love, 




The following abbreviations have been used in this thesis: 
General: 
δ  chemical shift 
νmax  wavenumber 
ºC  degrees Celsius 
µm  micrometer 
µM  micromolar 
AB assay  alamar blue assay 
Å  Angstrom 
Ac  acetyl 
AcCl  acetylchloride 
AG  arabinogalactan 
anti-TB  anti-tuberculosis 
aq  aqueous 
Araf  arabinofuranose 
AraT's  arabinofuranosyltransferases 
Ar  aromatic 
at  apparent triplet (in NMR) 
ATP  adenosine triphosphate 
AZT-MP  3‟-azido-3‟-deoxythymidine monophosphate 
BF3.Et2O  boron trifluoride diethyl etherate 
Bn  benzyl 
br.  broad (in NMR) 
Bz  benzoyl 
c  concentration 
Calcd.  calculated 
CEC  cation exchange chromatography 
cm  centimeter 
COSY  correlation spectroscopy 
d  doublet (in NMR) 
D2O  deuterated water 
ix 
 
DAST  diethylaminosulfur trifluoride 
DCM  dichloromethane 
dCTP  deoxycytidine triphosphate 
dTMP  deoxythymidine monophosphate 
dUTPase  deoxyuridine triphosphatase 
dTDP  deoxythymidine diphosphate 
dd  doublet of doublets (in NMR) 
DEPT  distortionless enhancement by polarization transfer 
DIPEA  N,N-diisopropylethylamine 
DMA  dimethylacetamide 
DMF  dimethylformamide 
DMSO  dimethylsulfoxide 
e.g.  exempli gratia (for example) 
DPA  decaprenyl phosphoarabinose 
DPPR  decaprenylphosphoryl-5-phosphoribose 
DPR  decaprenylphosphorylribose 
DS-TB  drug-susceptible tuberculosis 
DTBMP  di-tert-butylmethylpyridine 
dTTP  deoxythymidine triphosphate 
EMB  ethambutol 
ESI  electrospray ionization 
et al.  et alia (and others) 
EtOAc  ethyl acetate 
EtOH  ethanol 
g  gram(s) 
Galf  galactofuranose 
GalT's  galactofuranosyltransferases 
Galp  galactopyranose 
GlcNAc  N-Acetylglucosamine 
h  hour(s) 
HIV  human immune deficiency virus 
HRMS  high resolution mass spectrometry 
x 
 
HPLC  high performance liquid chromatography 
HMBC  heteronuclear multiple bond correlation spectroscopy 
HSQC  heteronuclear single quantum coherence spectroscopy 
Hz  Hertz 
INH  isoniazid 
IR  infrared 
J  coupling constant 
Ki  inhibitor constant 
L  litre 
LAM  lipoarabinomannan 
Log P  logarithm partition coefficient 
LM  lipomannan 
LB  lysogeny broth 
LB/T  lysogeny broth/tween 
lit.  literature 
M  molar 
m  multiplet (in NMR) 
m  meta 
m.p.  melting point 
m/z  mass/charge ratio 
M
+
  molecular mass ion 
Man  mannose 
mAGP  mycolylarabinogalctan peptodooglycan   
Manp  mannopyranose 
ManLAM  mannan capped lipoarabinomannan 
mbar  millibar 
M. bovis  Mycobacterium bovis 
m-CPBA  3-chloroperbenzoic acid 
MDR-TB  multidrug resistant tuberculosis 
Me  methyl 
MeCN  acetonitrile 
MeOH  methanol 
xi 
 
mg  milligram(s) 
MHz  megahertz 
MIC  minimum inhibitory concentration 
min  minute(s) 
mL   milliliter(s) 
mM   millimolar 
mmol   millimole 
mol   mole 
mol. sieves   molecular sieves 
MPI anchor   mannosyl phosphate inositol anchor 
M. smegmatis   Mycobacterium smegmatis 
MS   mass spectrometry 
M. tuberculosis    Mycobacterium tuberculosis 
NADH   nicotinamide adenine dinucleotide hydride 
NeuAc   N-acetylneuraminic acid 
nm   nanometer 
nmol   nanomole 
NMR   nuclear magnetic resonance 
NOE   nuclear overhauser effect 
O/N   overnight 
OD600   optical density of a sample measured at wavelength of 600 nm 
p   para 
Pd/C   palladium on carbon 
PDB   protein data bank 
PEG  polyethylene glycol 
Ph  phenyl 
ppm  parts per million 
pRpp  5-phosphoribosyl-1-pyrophosphate 
p-TSA  para-toluenesulfonic acid 
py  pyridine 
PZA  pyrazinamide 
q  quartet (in NMR) 
xii 
 
quant.  quantitative 
R  generic organic group, unless specified 
RIF  rifampicin 
Rf  retention factor 
RMSD  root-mean-square deviation 
RP-HPLC  reverse phase high performance liquid chromatography 
rpm  revolutions per minute 
rt  room temperature 
s  singlet (in NMR) 
sec  second(s) 
t  tertiary 
t  triplet (in NMR) 
TB  tuberculosis 
TBS  tert-butyldimethyl silyl ether 
TBAF  tert-n-butylammonium fluoride 
TDR-TB  total drug resistant tuberculosis 
TEA  triethylamine 
TEG  triethylene glycol 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
t.l.c.  thin layer chromatography 
TMSOTf  trimethylsilyl trifluoromethanesulfonate 
TMPKmt  thymidine monophosphatekinase Mycobacterium tuberculosis 
TMSN3  trimethyl silyl azide 
TrCl  tritylchloride 
UDP-Galf  uridine diphosphate galactofuranose 
UGM  UDP-galactopyranosemutase 
UV  ultraviolet 
v/v  volume by volume 
w/v  weight by volume 
XDR-TB  extensively drug resistant tuberculosis 




Asp  Aspartic acid 
Glu  Glutamic acid 
Phe  Phenylalanine 
Asn  Asparagine 
Pro  Proline 
Gln  Glutamine 
Arg  Arginine 
Val  Valine 
Trp  Tryptophan 
Tyr  Tyrosine 
 Chapter 1 
1 
 
Chapter 1 Introduction 
 
 1.1  General introduction 
 
Tuberculosis (TB) is one of the primary infectious diseases worldwide, especially in 
developing countries. Mycobacterium tuberculosis is recognised as the causative 
agent for TB.
1
 TB has existed since ancient times and remains a major threat to 
human health; up to one-third of the world‟s population is latently infected and 10.4 
million new cases and 1.4 million deaths were reported in 2016.
2
 People infected by 
Human Immune deficiency Virus (HIV) are at an especially high risk of contracting 
TB due to their compromised immune system. In many countries, the rate of increase 
of infection is exacerbated by both poor public health and apparent synergism with 
HIV.
2,3
 The resurgence of the disease has prompted interest in increasing 
understanding of the disease and the development of new anti-mycobacterial agents 
against drug-resistant tuberculosis.  
1.2   Biological background 
1.2.1  General aspects of tuberculosis 
 
TB is an infectious disease primarily affecting the lungs, but it can infect and damage 
the other organs such as the kidneys and heart.
2
 M. tuberculosis infections can be 
either of an active or latent form; people with active TB show all the signs and 
symptoms, such as fever, weight loss, and a cough that last for more than two weeks, 
and can pass the bacteria to others through air.
4,5
 Latent TB bacteria are inactive, but 
remain alive in the body and become active later. Reactivation of latent TB is a high 
risk factor for disease development, particularly those co-infected with HIV.  
 















Latent TB is not infectious; approximately only 5% of these patients will go on to 
develop the active form of the disease by immune suppression, as in the case of HIV. 
Up to 95% of the people with drug-susceptible TB (DS-TB) recover upon treatment, 
whereas 5% relapse.  If untreated high mortality results (Figure 1.1).
3
  
A typical current anti-TB treatment involves isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA), and ethambutol (EMB) for the first 2 months, followed by INH 
and RIF for a further 4 months (Figure 1.2).
2,6,7
  The emergence and spread of drug 
resistant strains, namely multidrug-resistant (MDR), extensively drug resistant 
(XDR), and totally drug-resistant (TDR-TB) strains, has become a major global 
issue.
2,8,9
 MDR-TB is defined as a TB infection that expresses resistance to the first-
line anti-TB drugs, INH and RIF. Treatments for MDR infections are significantly 
more difficult, expensive, and have considerable side effects.   
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XDR-TB is resistant to INH and RIF, as well as resistant to fluoroquinolones and to 
any one of the following second-line injectable drugs: amikacin, capreomycin, or 
kanamycin.
10
 Moreover, recently TDR-TB has emerged which is resistant to all 
current anti-TB drugs. Cases of TDR-TB have become prevalent in China, India, 
Africa, and Eastern Europe.  The biomolecular targets and mode of action of the first-




Figure 1.2 First-line anti-TB drugs. 
 
Table 1.1 Biomolecular targets and mode of action of existing Mtb drugs
11
  
Anti-TB drugs Target Mode of action 
Isoniazid Enoyl-acyl carrier protein 
reductase 
Inhibits cell wall mycolic 
acid biosynthesis 
Rifampicin β subunit of RNA polymerase 
Inhibits RNA synthesis 
Pyrazinamide Fatty acid synthase 
Inhibits protein 
translation and membrane 
energetics 
Ethambutol Arabinofuranosyltransferases Inhibits cell-wall 
arabinogalactan synthesis 




Recently, the World Health Organisation (WHO) has reclassified the anti-TB drugs 
into five groups (Table 1.2),
2
 based on data for safety, efficacy, administration, and 
drug class. Currently, first-line drugs (Group 1) have been recommended in four-drug 
combinations, and group 2, 3, and 4 (second-line drugs) are reserved for the treatment 
of drug resistant TB. Group 5 (third-line drugs) have undefined roles or unclear 
efficacy with long-term safety concerns.  
Table 1.2 The WHO classification of anti-TB drugs.
2,12 
Group Drugs 
































Group 5. Drugs with limited 
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The emergence of drug resistant strains of M. tuberculosis is caused mainly by 
inappropriate use of antimicrobial drugs, premature treatment interruption and use of 
ineffective drug formulations. Historically, the cell wall structure of M. tuberculosis is 
well understood and it has been an effective target for many drugs. However the 
multi-layered, hydrophobic nature of the cell envelope results in low cellular 
permeability and acts as a barrier against hydrophilic antibacterial drugs.  
1.2.2  Cell wall structure of M. tuberculosis 
 
The mycobacterial cell wall (Figure 1.3) is composed of carbohydrate-containing 
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The two major cell wall oligosaccharides, lipoarabinomannan (LAM) and 
arabinogalactan (AG), are essential to mycobacterial survival and growth.
13,15
 The AG 
complex consists of a polymer of galactofuranose (Galf) and an Araf residue 
covalently linked to the peptidoglycan at the reducing end by way of an α-L-Rha-
(1→3)-α-GlcNAc-OPO3 diglycosylphosphoryl bridge,
16
 and is esterified at the non-
reducing end with mycolic acids; the complex is called mycolylarabinogalactan-
peptidoglycan (mAGP).
17
 Peptidoglycan consists of a polymer formed from 
alternating units of N-acetylglucosamine and N-glycolylmuramic acid (Figure 1.4).
18
 
Tetrapeptide side chains are attached to N-glycolylmuramic acid, and cross-linked to 
the polysaccharide chain (AG) via phosphodiester links to some of the muramic acid 

























An unusual structural feature of these glycans is that all of the arabinose and galactose 
residues are in the furanose ring form.
20
 The galactan component of AG is made up of 
approximately 30 Galf residues with alternating β-(1→5) and β-(1→6) linkages 
combined in a linear fashion. Approximately 70 Araf residues are linked to the linear 
galactan backbone at the position 5 of some of the β-(1→6) linked Galf residues.
21,17
 
The majority of the arabinan chains are composed of α-5-linked α-D-Araf residues 
with branching introduced by 3,5-α-D-Araf linked residues (Figure 1.5).
22
 The non-
reducing termini of the arabinan chains have a [β-D-Araf-(1→2)-α-D-Araf]2-3,5-α-D-
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Araf-(1→5)-α-D-Araf hexa-arabinofuranosyl motif (Figure 1.6).
17,23
 Mycolic acids 
(long-chain α-alkyl β-hydroxy fatty acids) are attached in clusters of four on two-










Figure 1.6 Structure of the non-reducing terminus hexa-arabinofuranosyl motif. 
 
 LAM is a polymer of mannopyranose (Manp) and arabinofuranose (Araf) residues, 
and is the extended form of lipomannan (LM). It is non-covalently attached to the 





























The backbone, common to both LAM and LM, contains linear α-(1→6) mannosyl 
residues (21-34 Manp residues) linked with 5-10 units of single α-(1→2) 
mannopyranosyl side chains. In the case of LAM, the mannan is linked to an arabinan 
polymer, containing approximately 55-70 Araf residues with α-(1→5) linkages.
27,28
 
The arabinan termini of LAM, isolated from M. tuberculosis are extensively capped 




1.2.3  Arabinan biosynthesis 
 
The structure of the mycolic acid-arabinogalactan-peptidoglycan complex of M. 
tuberculosis is fairly well understood. However, identification and isolation of 
enzymes for the biosynthesis of the cell envelope are crucial to eradicate the drug 
resistance strains. The biosynthesis of the mycobacterial cell wall requires several 
different sugar-processing enzymes. Glycosyltransferases, for example 
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arabinofuranosyltransferases (AraT's), are responsible for the assembly of the 
glycans.
30
 The ManP's and GalT's are involved in the biosynthesis of LAM and 
galactan respectively. The biosynthesis of this arabinan is postulated to involve a 
family of AraT's that produce β-(1→2), α-(1→3), and α-(1→5)  arabinofuranosyl 
linkages.  
1.2.3.1  Arabinofuranosylsyltransferases 
 
For both AG and LAM, several arabinofuranosyltransferases (AraT's) are involved in 
arabinan biosynthesis. These enzymes belong to two characterized classes of 
enzymes: Emb (EmbA, EmbB, and EmbC), and Aft (AftA, AftB, AftC, and AftD). 
None of the arabinofuranosyltransferases (AraT's) have been successfully expressed. 
However, the AraTs have been identified through arabinofuranosyltransferase assays 
(cell free-assays) using mycobacterial cell wall preparations and synthetic arabinan 
acceptors.
31,32,33 
Individual genetic disruption of Emb proteins in M. smegmatis 
revealed that both EmbA and EmbB are involved in the formation of the hexa-
arabinofuranosyl motif of AG,
34,35
 whereas EmbC is involved in the elongation of the 
arabinan portion of LAM.
36
 In vitro assays using cell wall galactan as an acceptor 
demonstrated AftA is required for the transfer of the first Araf to the galactan domain 
of AG.
37
 Deletion studies of AftB and AftC in M. smegmatis revealed that are 
involved in the terminal β-(1→2) capping
38
 and internal α-(1→3) branching
39
 of AG 
respectively. In vitro assays using cell-free extracts from M. smegmatis demonstrated 
AftD is involved in the internal α-(1→3) branching on linear α-(1→5) linked 
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A typical AraT-catalyzed reaction (Figure 1.9) involves the coupling of an 
oligosaccharide acceptor with decaprenolphosphoarabinose (DPA) to afford an 
elongated oligosaccharide.
32, 42,43
 The polysaccharide AG is assembled as a polyprenol 
diphosphate intermediate (polyprenol-P-P-GlcNAc), which is then attached to 









Figure 1.9 Typical AraT's catalysed reaction for arabinan biosynthesis. 
 
The biosynthesis of DPA begins with 5-phosphoribosyl-1-pyrophosphate 1.1 (pRpp) 
which is converted to decaprenylphosphoryl-5-phosphoribose 1.2 (DPPR), in a 
reaction catalysed by decaprenylphosphoryl-5-phosphoribose synthase (Rv3806c), 
which is then dephosphorylated by a phosphatase to give decaprenylphosphoryl ribose 
1.3 (DPR). Subsequently, DPR is epimerized to DPA 1.5. Crick et al. initially 
proposed that this epimerization occurs via an oxidation-reduction process catalysed 
by two enzymes;
44
 DprE1 (Rv3790), which functions as a decaprenylphosphoryl-β-D-
ribose oxidase, and DprE2 (Rv3791), which functions as a decaprenylphosphoryl-D-
2-keto-erythropentose reductase.
45
 Interestingly, Meniche et al. have reported that a 
third enzyme (Rv2073c) may also be involved the epimerization process (Figure 
1.10).
46
    























As discussed earlier, the structures of the cell wall are unique to mycobacteria and are 
crucial to mycobacterial viability. Inhibition of the biosynthesis of the polysaccharide 
of the cell wall, therefore represents an attractive target for the development of anti-
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TB agents. Previous studies have attempted inhibition of various glycosyl 
transferases,
47,48,49
 and of the Galp/Galf mutase enzyme involved in the isomerization 
of pyranose/furanose during the assembly of the galactan cell wall 
component.
50,51,52,53,54
 In particular, the discovery of metabolically stable analogues of 
DPA which may act as potent inhibitors of AraT's is an attractive strategy for drug 
development.  
1.3   The design of DPA analogues as inhibitors of 
arabinofuranosyltransferases 
 
A particular advantage of developing analogues of DPA as therapeutic agents is that 
glycoconjugates of arabinofuranose and galactofuranose are not found in mammals, 
which means such compounds should not interfere with normal mammalian sugar 
processing in vivo. Therefore, such arabinose residues may be predicted to have no 
toxic side effects to mammalian cells, which mean that a higher dosage could be used 
to exterminate infection and also to reduce the treatment periods; another desirable 
advance as current treatment takes approximately six months.
55,56
 A further advantage 
of this approach is that it should be possible to fine-tune the pharmacokinetic 
properties of any lead drug candidate because there is ample scope for structural 
modification of the basic DPA skeleton.  
The pharmacokinetic properties of drugs are crucial for their absorption, distribution, 
metabolism and excretion in the human body. The properties have been derived by 
„Lipinski‟s rule of 5‟. These rules conclude that an orally active drug is more likely to 




 The molecular weight of the compound is less than 500 Daltons. 
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 The octanol-water partition coefficient of the compound (logP) is less than 
5. 
  Not more than five hydrogen bond donors. 
 Not more than ten hydrogen bond acceptors.  
Tuning of these properties is important for the effective development of a medicine 
since molecular features such as hydrophobicity are important in terms of metabolic 
processing of a drug when administered in humans. Thus, the eventual optimisation of 
a lead-DPA analogue into an effective orally bioavailable drug may be easier to 
achieve than for other alternative molecular targets. The DPA donor analogues could 
be expected to be potent anti-mycobacterial agents because DPA is a substrate for 
many AraT's, and these compounds are therefore expected to inhibit several enzymes, 
in the same way that EMB targets two or more Emb proteins. Analogues of DPA 
would be expected to block a number of biosynthetic steps, unlike analogues of the 
glycosyl acceptors each of which is recognized by a specific AraT. 
In order to design mimics of DPA the replacement of the highly polar labile glycosyl 
phosphate and the hydrophobic decaprenyl moiety with a suitable isostere is 
required.
59,60





 and several others
65 
for the isosteric 











 sulphonamides 1.11 and 
sufenamides 1.12.
65
 Recently, Legentil et al.
66
 developed 
galactofuranosidesderivatives 1.13 which lack a phosphate or phosphate isostere, yet 
which displayed moderate inhibitory activity (Figure 1.11).  




Figure 1.11 Decaprenylphosphoarabino and galactofuranose analogues reported by 
Fairbanks et al. and others. 
 
Anti-mycobacterial activities of these stable DPA analogues are presumed to arise 
from inhibition of AraT's, and thus inhibition of cell wall biosynthesis, which affects 
mycobacterial growth and survival. In fact, the currently used antibiotics ethambutol 
(MIC >4 µg/mL)
67
 and isoniazid (MIC 0.1 µg/mL) block cell wall assembly.
68
  MIC 
stands for the minimum inhibitory concentration, and is the lowest concentration of 
antimicrobial drug that inhibit the visible growth of the mycobacteria: the lower the 
MIC the more potent the compound is against the bacterium. MIC values are typically 
determined by using a microplate “Alamar Blue” assay (AB). The AB assay is a 
rapid, inexpensive, and high-throughput assay for antimycobacterial drug screening.
69
 





 reported a series of DPA analogues 1.18 a-f with varying lengths of 
prenyl side chains, which were synthesized as shown in Scheme 1.1. 
Scheme 1.1 The synthesis of prenylphosphoarabinofuranoside DPA analogues 1.18a-
f by Besra et al.
31
; (i) 2-cyanoethyl-N,N-diisopropylchlorophosphorylamidite, EtN
i
Pr2, 
DCM, -78 °C; (ii) Polyprenol a-f, tetrazole; (iii) H2O2, THF; (iv) KOH, MeOH; (v) 
Separate by SiO2; (vi) NH4OH, MeOH. 
 
The synthesis of 1.15 was achieved by the reaction of 2-cyanoethyl N,N-
diisopropylchlorophosphorylamidite and protected arabinose 1.14. Various 
polyprenols were coupled to 1.15 using tetrazole activation, creating a mixture of 
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anomers which were separated by chromatography (1.16a-f and 1.17a-f) after 
oxidation and base deprotection. The final deprotection of the β-anomers 1.16a-f 
yielded prenylphosphoarabinose 1.18a-f. The β-anomers 1.18a-f were tested using an 
AraT's assay (cell free assay). It was found that only long-chain prenyl chains 1.18a-c 
were recognized as arabinose donor by the active site of AraT's. Thus it was 
suggested that hydrophobicity of the side chain plays a vital role in substrate 
recognition. 
In 2002, Lowary et al.
42
 synthesized a series of C-phosphonate analogues 1.25a-f as 
shown in Scheme 1.2. 
 
Scheme 1.2 Synthesis of C-phosphonate analogues of DPA 1.25a-f by Lowary et 
al.
42
; (i) NaH, RI, DMF, rt; (ii) 1.22a-f, Grubbs catalyst, DCM, 40 °C; (iii) 
KOC(O)N=NC(O)OK, AcOH, MeOH, 40 °C; (iv) H2, Pd/C, MeOH, rt.  




The analogues 1.23a-f were achieved by an olefin cross metathesis reaction between 
C-phosphonate 1.20 and a series of alkenes 1.22a-f using Grubbs catalyst. The C-
phosphonate 1.20 was obtained from lactone 1.19 in five steps. The alkenes 1.22a-f 
were synthesized from alcohol 1.21 under standard alkylation conditions. The alkene 
of C-phosphonate analogues 1.23a-f was reduced and subsequent catalytic 
hydrogenation afforded the target compounds 1.25a-f. The C-phosphonate analogues 
1.25a-f were then tested against M. tuberculosis using an AB assay. Compound 1.25f 
displayed promising anti-mycobacterial activity (3.13 µg/mL). However, compounds 
1.25a-1.25e failed to inhibit mycobacterial growth.  
Given this success, a series of C-phosphonic acid 1.26a-e and glycosyl sulfone 1.27a-
g analogues (Figure 1.12) were also synthesized by Lowary et al. 
61
  




The synthesis of the series of glycosyl sulfones is shown in Scheme1.3 and Scheme 
1.4. 




Scheme 1.3 Synthesis of glycosyl sulfones 1.27a-e by Lowary et al.; (i) KSAc, DMF, 
rt; (ii) LiAlH4, Et2O, rt; (iii) For 1.32a, c & d: RI, NaH, DMF, rt; For 1.32b: RI, n-
BuLi, Et2O, 0 °C to rt; For 1.32e: TsO(CH2)19CH3, n-BuLi, THF, 0 °C to rt; (iv) m-
CPBA, DCM, rt; (v) H2, Pd/C, MeOH, AcOH.  
 
The glycosyl sulfones 1.27a-d were synthesized from iodide 1.29, which was 
prepared in two steps from commercially available arabinose 1.28. The reaction of 
iodide 1.29 with thioacetate yielded 1.30. Subsequent deacylation, alkylation, 
oxidation and catalytic hydrogenation afforded glycosyl sulfones 1.27a-e (Scheme 
1.3).  
 




Scheme 1.4 Synthesis of glycosyl sulfones 1.27f-g by Lowary et al.
61
; (i) 3,4-
dihydropyran, p-TsOH, THF, rt; (ii) CH3(CH2)15I, NaH, DMF, rt; (iii) AcOH, THF, 
H2O, 65 °C; (iv) p-TsCl, KH, 18-crown-6, THF, rt; (v) 1.31, KH, 18-crown-6, THF, 
rt; (vi) m-CPBA, DCM, rt; (vii) H2, Pd/C, MeOH, AcOH, rt; (viii) A, n-BuLi, THF; 
(ix) NaIO4, MeOH, H2O, 70 °C; (x) H2, Pd/C, MeOH, AcOH, rt. 
The synthesis of oxygenated derivative 1.27f began with commercially available 1,10-
decanediol 1.33, which was selectively protected using 3,4-dihydropyran and p-TsOH 
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to afford mono protected alcohol 1.34. Subsequent alkylation of alcohol 1.34, 
deprotection, and tosylation afforded 1.37. Tosylate 1.37 was coupled with thiol 1.31 
in the presence of KH and 18-crown-6 providing the thioether 1.38. Oxidation and 
catalytic hydrogenation yielded the glycosyl sulfone 1.27f (Scheme 1.4). The 
compound 1.27g was achieved by alkylation of 1.31, and subsequent oxidation and 
catalytic hydrogenation afforded the desired product (Scheme 1.4). 
The phosphonic acid 1.26a-e and glycosylsulfone analogues 1.27a-g were tested 
against M. tuberculosis (H37Rv) using fluorescence based Alamar Blue assay. 
However, none of the compounds showed a promising activity as C-phosphonate 
analogue 1.25f.  
 Fairbanks et al. synthesized a series of glycosyl triazoles 1.45a-f and glycosyl 
sulfones 1.48a-g as shown in Scheme 1.5 and Scheme 1.6 respectively.  
  




Scheme 1.5 Synthesis of glycosyl triazoles 1.45a-f as DPA analogues reported by 
Fairbanks et al.
63
; (i) NaN3, Bu4NHSO4, DCM, NaHCO3 1:1; (ii) 1a-f, CuI, DIPEA, 
110 °C; (iii) NaOMe, MeOH-THF.  
 
The benzoylated arabinoside 1.42 was reacted with NaN3 to give the corresponding 
glycosyl azide 1.43 as an anomeric mixture (α:β, 1:2); the desired β-anomer was 
separated by flash column chromatography. Cu(I) catalysed Huisgen cycloaddition of 
azide 1.43 and alkyne 1a-f in the presence of CuI and diisopropylethylamine (DIPEA) 
gave the triazole 1.44a-f. Finally, deprotection with NaOMe yielded desired glycosyl 
triazoles 1.45a-f (Scheme 1.5).  
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Scheme 1.6 Synthesis of glycosyl sulfones 1.53a-g as DPA analogues reported by 
Fairbanks et al.
64
; (i) AcCl, MeOH, rt; (ii) NaH, BnBr, DMF, rt; (iii) 80 % AcOH, 
115 °C; (iv) Ac2O, py, rt; (v) TMSBr, DCM, -40 °C to rt; (vi) RSH, 2,4,6-tri-tert-




The synthesis of glycosyl sulfones 1.53a-g began with D-arabinose, which was treated 
with acetyl chloride and MeOH to give methyl arabinofuranoside via Fischer 
glycosylation, which was then benzylated to give fully protected arabinoside 1.47. 
Subsequent acid-catalysed hydrolysis, acetylation, and bromination afforded glycosyl 
bromide 1.50. The protected glycosyl sulfones 1.51a-g were prepared by the reaction 
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of glycosyl bromide and the corresponding thiols in the presence of TTBP. 
Subsequent oxidation and deprotection afforded glycosyl sulfones 1.53a-g (Scheme 
1.6).   
The glycosyl triazoles 1.45a-f and glycosyl sulfones 1.53a-g were tested against M. 
bovis. Compounds 1.45b, 1.45e and 1.53e displayed moderate anti-mycobacterial 
activity with MIC of 62 µg/mL. However, compound 1.45d was more than twice as 
active (MIC 31 µg/mL). These results demonstrate that the length of the hydrophobic 
side chain can strongly influence the activity of the compound.  
In related work, von Itzstein et al. synthesized a series of galactofuranosyl 
sulfenamides 1.60a-e and sulfonamides 1.63a-e as shown in Scheme 1.7.  
Scheme 1.7 Synthesis of galactofuranosyl sulfonamides and sulfenamides reported by 
von Itzstein et al.
70
; (i) BF3.OEt2, HSAc, 0 °C to rt or SnCl4, HSAc, 0 °C to rt; (ii) 
HNR'2, BrCH(CO2Et)2, MeOH, rt; (iii) m-CPBA, DCM, reflux; (iv) NaOMe, MeOH, 
rt; (v) NaOMe, MeOH, rt.    
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As starting materials, tetra-O-acetylated 1.54 and benzoylated 1.55 galactofuranoside 
were reacted with the thioacetic acid in the presence of catalytic SnCl4 or BF3.OEt2 to 
provide thioacetate derivatives 1.56 and 1.57 respectively. β-sulfenamides 1.58a-e 
were achieved by the reaction of glycosyl thioacetates 1.56 and 1.57 with 
bromomalonate and corresponding secondary amines, which were then deprotected 
under Zemplen reaction conditions to give target sulfenamides 1.59a-e. Oxidation of 
sulfenamides 1.58a-e using m-CPBA, and subsequent deacetylation (1.60a-d) and 
benzoylation (1.60e) yielded sulfonamides 1.61a-e. The sulfenamide 1.59a-e and 
sulfonamide 1.61a-e derivatives were tested against M. smegmatis using AB assay. 
Sulfenamides 1.59c-d and sulfonamide 1.61c displayed strong inhibitory activity 
against M. smegmatis with MICs of 4 µg/mL, 1 µg/mL and 2 µg/mL respectively.  
The sulfamide functional group has previously found use in the design of other 
pharmacological agents in a wide variety of applications.
71
 Aldrich et al.
72,73,74 
 have 
reported the use of sulfamide as an isosteric replacement for phosphate in a search for 
anti-mycobacterial agents. Previous work
 
has led us to believe that a sulfamide may 
be a good isostere for the replacement of the phosphate of DPA, for example as in 
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1.4  Design dTMP analogues as inhibitors of dTMPK  
 
Another goal of this project was to synthesise sulfamides of thymidine as potential 
inhibitors of thymidine monophosphate kinase (TMPKmt). The recently discovered 
enzyme Mycobacterium tuberculosis TMPKmt is indispensable for the growth and 
survival of M. tuberculosis, as it plays an essential role in DNA synthesis.
75
 Therefore 
the enzyme TMPKmt, which is involved in the de novo and salvage pathways (see 
below), might be an attractive target for the design of novel anti-tuberculosis agents. 
1.4.1  De novo and salvage pathways 
 
Enzymes involved in  pyrimidine biosynthesis have a vital role in cellular 
metabolism, as they provide nucleosides that are essential components of many 
biomolecules.
76
 De novo and salvage are the two major pathways for pyrimidine 
nucleotide synthesis. Since the de novo synthesis requires more energy, cells use the 
salvage pathway to re-use nucleosides derived from waste nucleotides.
77
 The de novo 
and salvage pathways are essential for all bacterial cells and differ among species.
78
 A 
number of enzymes are involved in the pyrimidine salvage pathway, including 
deoxycytidine triphosphate (dCTP) deaminase, deoxyuridine triphosphatase 
(dUTPase), thymidylate synthase, dTMP kinase, and several other enzymes (Figure 
1.13).  
Nucleoside monophosphate kinases are key enzymes for the synthesis of nucleoside 
triphosphates, which are the precursors of a number of major biological molecules 
such as DNA, RNA, and phospholipids.  





1.4.2  Deoxythymidine monophosphate kinase (TMPK) 
 
TMPK, or thymidylate kinase, catalyses for the phosphorylation of thymidine 
monophosphate (dTMP) to give thymidine diphosphate (dTDP) using ATP as a 
phosphoryl donor. It also uses deoxyuridine monophosphate (dUMP) as a substrate, 
which has lower affinity for TMPK than dTMP (Figure 1.14).
79
 TMPK is involved in 
both the de novo and salvage pathway for the synthesis of thymidine triphosphate 
(dTTP).
80,81 
 Maintenance of the DTTP pools is essential for DNA synthesis and 
cellular growth.
82,83
 The kinase from M. tuberculosis, TMPKmt, has low (22%) 
sequence identity with the human enzyme, and therefore represents a promising target 
for the development of selective inhibito 
 













Figure 1.14 Biosynthesis of dTDP from dTMP 
 
TMPKmt is inhibited by azidothymidine monophosphate (AZT-MP), but the AZT-
MP does not inhibit any mammalian TMPKs, which suggests that inhibitors of 
TMPKmt could selectively block bacterial DNA synthesis.
85,86
 Therefore, the enzyme 
TMPKmt is an attractive target for the design of novel anti-tuberculosis agents. 
1.4.3  The dTMP binding site of TMPKmt 
 
The X-ray structure of TMPKmt reveals the following main binding interactions 
between dTMP and the enzyme active site (Figure 1.15).  
(i) The active site contains Mg2+, H2O, and an Arg95 (R95) residue. Non-
bridging oxygens of the phosphate moiety form H-bond with Y39, P36 and 
an ionic interaction with R95 and Mg
2+
. 
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(ii) A stacking interaction between the pyrimidine ring of thymine and Phe70 
(F70). 
(iii) H-bonds between the carbonyl (4-O) and amino groups (3-N) of dTMP 
and the side chains of residues Arg74 (R74) and Asn100 (N100) 
respectively.   
(iv) Another H-bond is formed between the 3'-OH of the deoxyribose and the 
carboxylate of Asp9 (D9), which also makes polar contacts with the water 
molecule (w1009) involved in Mg
2+
 coordination and two other contacts 
with Asp9.  
 
 
Figure 1.15 Schematic diagram of the dTMP binding site of TMPKmt. Adapted from 




These enzyme-substrate interactions suggest that substrate-based competitive 
inhibitors could be designed by replacement of the 5'-phosphoryl group with a 
suitable isostere.  
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1.4.4  Previous work on the design and synthesis of 
inhibitors of TMPKmt 
 
Various approaches have been reported for the modification of either the sugar or 
base moiety of thymidine in order to synthesise TMPKmt inhibitors; the positions 
modified so far include 2‟, 3‟, 5‟ and 5. Munier-Lehmann et al.
85,86
 reported that 
AZT-MP behaves as an inhibitor of TMPKmt with a Ki value of 10 µM, whereas AZT 
has a Ki of 28 µM. Thymidine and other 5‟-modified analogues (5‟-azido or 5‟-
amino-5‟-deoxy thymidine) were also discovered to be competitive inhibitors of 






 synthesized 5‟-thiourea substituted thymidine derivatives 1.67-
1.69, and evaluated their inhibition of TMPKmt. The synthesis of thiourea analogue 






Figure 1.16 Analogues of dTMP reported by Calenbergh et al.
80
 












Scheme 1.8 Synthetic production of 5‟-thiourea substituted thymidine derivatives 
1.67 reported by Calenbergh et al.
80
; (i) 4-chloro-3-(trifluoromethyl)phenyl 
isothiocyanate, DMF, 0 °C to rt; (ii) 1 M TBAF in THF, THF, rt. 
 
For the synthesis of compound 1.67, amine 1.70 was first coupled with 4-chloro-3-
(trifluoromethyl)phenyl isothiocyanate, and the TBDMS group was subsequently 
removed using TBAF in THF. The α-anomer 1.68 was synthesized by the same route 
as the β-anomer.  





Scheme 1.9 Synthetic production of 5‟-thiourea substituted thymidine derivative 1.69 
reported by Calenbergh et al.
80
; (i) Lawesson‟s reagent, 1,4-dioxane, reflux; (ii) 7N 
NH3 in MeOH, rt; (iii) MsCl, py, -78 °C to 0 °C; (iv) NaN3, DMF, 60 °C; (v) PPh3, 
H2O, THF, rt; (vi) 4-chloro-3-(trifluoromethyl)phenyl isothiocyanate, DMF, 0 °C to 
rt.  
For the preparation of 4-thio derivative 1.69, 5‟-O-acetylated derivative 1.72 was first 
treated with Lawesson‟s reagent to give 4-thio pyrimidine 1.73. Subsequent 
hydrolysis of the acetate protecting groups afforded 1.74. The primary hydroxyl was 
selectively mesylated, followed by azide substitution to yield azido derivative 1.75, 
which was then reduced under Staudinger reaction conditions. The coupling of amine 
1.76 with 4-chloro-3-(trifluoromethyl)phenyl isothiocyanate affored 4-thio-AZT 1.69 
(Scheme 1.9).  
The inhibitory activity of thiourea derivatives 1.67-1.69 were evaluated against 
TMPKmt. The 5‟-phenylthiourea-substituted β-thymidine derivative 1.67 showed 
moderate inhibitory activity, with a Ki of 14.5 µM, however, the α-anomer 1.68 was 
24-fold more active (Ki of 0.6 µM) than the β-anomer. The replacement of oxygen at 
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position 4 with sulphur (1.69) increased the activity by a factor of 3 (Ki 0.17 µM), the 
synthesis of compound 1.69 analogue is shown in Scheme 1.9. 
Recently, the following series of 5‟-modified thymidine derivatives 1.79, 1.82, 1.84 
and 1.86 were prepared as shown in Scheme 1.10 by Calenbergh et al.
81
  




Scheme 1.10 Synthesis of  dTMP analogues reported by Calenbergh et al.
81
; (i) X, n-
BuLi, THF, -78 °C to rt; (ii) H2, Pd/C, MeOH, rt; (iii) TBAF, THF, 40 °C; (iv) 
ClPPh3CH2CN, n-BuLi, THF, 0 °C to rt; (v) py-MeOH (3:1), NaBH4, 120 °C; (vi) 
TBAF, THF, rt; (vii) Y, n-BuLi, THF, -78 °C to rt; (viii) MeOH-THF (5:1), NiCl2, 
NaBH4, 0 °C; (ix) TBAF, THF, 40 °C; (x) TMSN3, Bu2SnO, toluene, 110 °C; (xi) 
TBAF, THF, rt. 




To synthesise 5‟-modified derivatives, the 5‟-OH of 3‟-silylated thymidine was 
oxidized using Dess-Martin periodinane, and the resulting aldehyde 1.77 was treated 
with Wittig-Horner reagents to give compounds 1.78, 1.80 and 1.83. Methylsulfone 
1.79 was obtained by catalytic hydrogenation followed by removal of the TBS group. 
The alkenes in 1.80 and 1.83 were reduced using NaBH4 and NaBH4/NiCl2 
respectively, and subsequent TBS deprotection using TBAF afforded 1.82 and 1.84. A 
cycloaddition of nitrile 1.81 and TMSN3 using dibutyltin oxide yielded tetrazole 1.85, 
which was then desilylated using TBAF to afford the target tetrazole 1.86.  
The inhibitory activity of compounds 1.79, 1.82, 1.84 and 1.86 against TMPKmt was 
assessed by a spectrophotometric binding assay. Compounds 1.82 and 1.86 showed 
moderate activities, with Kis of 48 µM and 70 µM respectively. However, the other 
compounds were less active. 
These previous studies have demonstrated that the suitable isosteric replacement of 
phosphate can produce sub-micromolar inhibitors of TMPKmt. There are only a few 
reports on the use of sulfamides as a phosphate isostere in the search for anti-
mycobacterial agents. For example, Aldrich et al.
 72,73,74 
recently reported the synthesis 
of salicyl sulfamoyl adenosine 1.87 and derivatives, which displayed promising 
inhibitory activity with MICs ranging from 0.19-6.25 µg/mL against M. tuberculosis.  
These adenosine analogues disturb siderophore biosynthesis by inhibition of an 













Based on these previous reports, we believed that sulfamide could be a good isostere 
for the replacement of the labile phosphate of dTMP.  
1.5  Project objectives  
 
The objective of this research project was to synthesise a series of sulfamide 
analogues of DPA and dTMP, where sulfamide is an isostere of the labile phosphate 
group, for use in anti-TB drug development.  
This thesis describes the synthesis of sulfamides as analogues of DPA and dTMP, and 
evaluation of their anti-mycobacterial activity against M. smegmatis using an Alamar 
Blue assay. An additional Chapter includes the expeditious discovery and subsequent 
development of a highly practical new method for the reduction of organic azides to 
primary amines.  
Chapter 2 describes the synthesis of sulfamides as analogues of DPA, and evaluation 
of their anti-mycobacterial activity. The effect of the alkyl chain length and the effect 
of insertion of oxygen atoms into the linear alkyl chain were investigated.  
Chapter 3 describes docking studies and the synthesis of sulfamide derivatives of 
thymidine as dTMP analogues. Investigations of the anti-mycobacterial activity of 
sulfamide analogues of dTMP are also reported. 
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Chapter 4 details the discovery and development of a new method for the 
chemoselective reduction of primary amines from azides. 
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Chapter 2 The synthesis of DPA analogues as anti-TB 
agents. 
 2.1  Introduction 
 
The mycobacterial cell wall contains two polysaccharides, lipoarabinomanan (LAM) 
and arabinogalactan (AG), which are crucial to mycobacterial growth and survival.
88
 
Biosynthesis of the mycobacterial cell wall requires several different sugar-processing 
enzymes. Glycosyltransferases, for example galactofuranosyl transferases and 
arabinofuranosyltransferases (AraT's), are responsible for the assembly of the 
glycans.
30
 AraT's are responsible for assembling the arabinan portion of the two 
oligosaccharides, and use decaprenyl phosphoarabinose DPA as the donor of the 
arabinofuranose residues.
13, 89
 Oligosaccharides containing arabinofuranose residues 
are not found in mammals, and the enzymes involved in the biosynthesis of these 
glycans are therefore excellent targets for drug development.
22, 90
 Therefore, 
analogues of DPA would be expected to block cell wall biosynthesis by inhibiting 





Ethambutol, a widely used anti-mycobacterial agent, was found to inhibit 
arabinofuranosyltransferase activity in the DPA assay described by Lee et al.
67
 to a 
residual activity of 40% at 50 µg/mL, coincubation with a variety of enzymic 
cofactors was not affected the residual activity.  The results suggests that 
metabolically stable analogues of DPA are a substrate for more than one AraT, and 
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would therefore be expected to block a number of biosynthetic steps and, in turn, be 
expected to compromise mycobacterial viability. In order to design mimics of DPA, 
replacement of the labile and highly polar glycosyl phosphate with a suitable 
isostere
59
, and an alkyl chain is required to mimic the large hydrophobic side chain.    
As mentioned in the previous chapter, analogues of DPA have previously been 
synthesized by the Fairbanks group
63,64
 and several others.
25-26, 42, 65, 91
 Amongst the 
synthetic analogues synthesised by Fairbanks et al., compounds 1.53e and 1.45d 
displayed the most promising inhibitory activity against M. bovis; exhibiting 
minimum inhibitory concentration (MICs) of 62 µg/mL and 31 µg/mL respectively. 
These values should be compared with those of currently used anti-TB drugs: the 
activity of compounds 1.53e and 1.45d is approximately one order of magnitude 
lower than the anti-TB drugs isoniazid (0.1 µg/mL) and ethambutol (4 µg/mL). It may 
appear, therefore, that a large increase in activity is required for this type of 




Previously, a series of C-phosphonate analogues of DPA had been synthesized by 
Lowary et al.
42
 One of these C-phosphonates 1.25f displayed promising inhibitory 
potency against M. tuberculosis, with a MIC of 3.13 µg/mL. Based on this success, a 
series of sulfone and phosphonic acid analogues bearing different length hydrophobic 
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chains were synthesized. However, screening of these compounds revealed that in fact 








However, such increases in activity have already been demonstrated by Von Itzstein 
et al.
65
 for galactofuranose compounds; a series of galactofuranosyl N,N-dialkylated 
sulfonamides 2.1 and sulfonamides 2.2 were synthesized and number of these 
displayed strong anti-mycobacterial activity with MIC values below 5 µg/mL against 
M. smegmatis.
65
. Notably the shorter alkyl chain N,N-dihexyl sulfonamides had lower 
potency than N,N-dioctyl and N,N-didecyl derivatives; this simple structural variation 
caused more than a 64-fold decrease in the MIC value. In addition, the N,N-dioctyl 
sulfonamide had 2 fold higher activity than the corresponding sulfenamide.
65
 
Furthermore, Von Itzstein et al.
70
 also synthesized galactofuranosyl alkyl 
thioglycosides as possible analogues of uridine diphosphate galactofuranose (UDP-
Galf), which use as the donor of the galactan biosynthesis. The 9-heptadecyl 
thioglycoside 1.59c and sulfone 1.61c displayed significant inhibitory potency against 
M. smegmatis with the MIC of 1 µg/mL and 2 µg/mL respectively, which is 
comparable that of N,N-dioctyl sulfonamide and N,N-dioctyl sulfenamide.  











More recently, Legentil et al.
66
 synthesized a series of 1,2-trans alkyl 
galactofuranosides; from these a mixed alkyl/aryl β-D-galactofuranoside 2.8 had the 







 have reported the use of sulfamide as an isosteric replacement for 
phosphate in a search for anti-mycobacterial agents. The sulfamide functional group 
has previously found use in the design of many other pharmacological agents in a 




has led us to believe that a sulfamide-
based unit may be a good isostere for the replacement of the phosphate part of DPA. 
In addition, Lowary et al.
42
, Fairbanks et al.
63
 and von Itzstein et al.
65
 have 
demonstrated that the hydrophobicity of the side chain is essential for biological 
activity. 
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Based on an assessment of these previous studies, the polarity, the availability of 
heteroatoms for hydrogen bonding and the tetrahedral nature of the central sulfur 
atom reinforced the idea that glycosyl sulfamides with varying hydrophobic side 
chains may be useful mimics of DPA. In this project a four series of β-
arabinofuranosyl sulfamides, namely: mono-substituted, di-substituted, oxygenated 
and prenylated series, were selected as potential inhibitors (Figure 2.1).  
 
  
Figure 2.1 N-Glycosyl sulfamide targets as DPA analogues.   
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2.2  The synthesis of glycosyl sulfamides and anti-mycobacterial 
activities 
2.2.1  Retrosynthetic analysis 
 
A retrosynthetic analysis of glycosyl sulfamides 2.4 is shown in Scheme 2.1. 
Commercially available D-arabinose 2.9 exists as an equilibrium mixture of 
pyranose, furanose, and acyclic forms in solution, with the pyranose form 
predominating. It was envisaged that D-arabinose could be converted to methyl 
furanoside 2.7, and the C-2, C-3, and C-5 alcohols could then be protected with 
benzyl groups. Donor 2.6, readily synthesised from 2.7, could then be glycosylated 
with sulfamide acceptors.  The final product could be obtained by de-protection of 
the benzyl groups followed by isolation of β-anomer of the furanoside using HPLC. 
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2.2.2  Synthesis of the arabinose donor 2.6 
 
 
Scheme 2.2 (i) AcCl, MeOH, 3 h; (ii) NaH, BnBr, DMF, 16 h, 54 %; (iii) AcOH:H2O 
(4:1, v/v), 115 °C, 24 h, 64 %.  
 
The tri-benzylated D-arabinofuranoside glycosyl donor was synthesized following 
methods published by Vanderklein et al.,
92
 as shown in Scheme 2.2. D-Arabinose was 
suspended in methanol and acid-catalysed (AcCl, 3 equiv.) Fischer glycosylation was 
carried out to afford the kinetic product, furanoside as a mixture of anomers 2.8 









Figure 2.2  Mechanism of Fischer glycosylation of D-arabinose 
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The reaction was quenched after three hours to avoid the formation of the undesired 
pyranose form, which is the thermodynamic product. Methyl α,β-D-arabinofuranoside 
2.8 was then benzylated with sodium hydride and benzyl bromide in DMF to afford 
tri-benzylated derivative 2.7, which was then hydrolysed by treatment with  80 % 
acetic acid to give the target glycosyl donor 2.6. Donor 2.6 was confirmed to be in the 
furanose form by X-ray crystallography (Figure 2.3). 
 
Figure 2.3 X-Ray structure of arabinofuranose hemiacetal 2.6 
 
2.2.3  Synthesis of sulfamide acceptors 
 
A series of polyethylene glycol (PEG) derivatives were synthesised (Scheme 2.3) to 
systematically investigate if there was any effect of incorporating more polar groups 
into the side chains of the DPA mimics. One of the hydroxyl groups of 
triethyleneglycol 2.10b was protected as a benzyl ether by using NaH (0.5 equiv.) and 
BnBr (0.5 equiv.) to afford the monobenzylated derivative as the major product, 
together with a small amount of the dibenzylated compound. Purification by flash 
chromatography afforded the pure mono benzylated compound 2.11b. Similar 
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monobenzylation of di- and tetra-ethyleneglycol (2.11a and 2.11c) was performed by 
a previous Postdoc in the Fairbanks group (Andrew Watson). The free hydroxyl 
groups of the mono-benzylated di-, tri- and tetra-ethyleneglycol derivatives 2.11a-c 
were converted into a good leaving group (mesylate) by treatment with 
methanesulfonyl chloride (1.5 equiv.) in the presence of Et3N (1.5 equiv.). The 
mesylates were then directly treated with sodium azide to afford azides 2.12a-c, 











Scheme 2.3 (i) NaH, BnBr, DMF, 0 °C to rt, 16 h, 2.11b – 36 %; (ii) MsCl, Et3N, 
DCM, 0 °C, 2 h; NaN3, DMF, 60 °C, 16 h, 2.12a – 94 %: 2.12b – 97 %: 2.12c – 91 
%; (iii) PPh3, H2O, THF, rt, 16 h, 2.13a – 71 %: 2.13b – 80 %: 2.13c – 67 %. 
 
In order to better mimic the polyprenol chain of DPA, a series of glycosyl sulfamides 
bearing methyl branched side chains were synthesized (Scheme 2.4). Amine 
terminated methyl branch alkyl chains were made from commercially available 
alcohols 2.14a-c, by an analogous sequence of mesylation and azide displacement to 
yield azides 2.15a-b, and then Staudinger reduction to yield amines 2.16a-b.  











Scheme 2.4 (i) MsCl, Et3N, DCM, 0 °C, 2 h; NaN3, DMF, 60 °C, 16 h, 2.15a – 75 %: 
2.15b – 56 %; (ii) PPh3, H2O, THF, rt, 16 h, 2.16a – 63 %: 2.16b – 71 %; (iii) MsCl, 
Et3N, DCM, 0 °C, 2 h; potassium pththalimide, 70 °C, 16 h, 2.15c – 60 %; (iv) 
N2H4.H2O, reflux, 16 h, 2.16c – 43 %. 
However an attempt to convert geraniol 2.14c to the corresponding azide by this 
method as mentioned above was unsuccessful, as allylic azides undergo a rapid [3,3] 
sigmatropic rearrangement (Figure 2.4), resulting in a dynamic equilibrium of several 
isomers. An alternative route was devised using a Gabriel synthesis, wherein the 
hydroxyl group of geraniol was first converted to a mesylate, and this was then treated 
with potassium phthalimide to give compound 2.15c, which was finally converted to 
geranyl-amine 2.16c by treatment with hydrazine hydrate.  
 
 
Figure 2.4 Allylic azide rearrangement 
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It is difficult to achieve chemoselective removal of the benzyl ethers under standard 
condition using catalytic hydrogenation in the presence of the side chain alkenes. 
However, the target citronellyl and geranyl sulfamides derivatives could be achieved 
using suitable protecting groups, such as benzoyl or acetate for the synthesis of 
arabinose donor. As described later in this chapter, all the target deprotected 
sulfamide analogues underwent isomerization from the desired furanose to 
thermodynamically more stable pyranose form. Thus, it will be insignificant in 
synthesizing the undesired pyranose form of citronellyl and geranyl sulfamides using 
a different route. Therefore, only glycosyl sulfamides that possessed a fully saturated 
side chain were synthesised.  
A series of sulfamide acceptors bearing linear alkyl side chains of varying length were 
synthesized (Scheme 2.5) by the treatment of a variety of amines with different alkyl 
chains 2.13a-c and 2.16a using commercially available chlorosulfonyl isocyanate (1.0 
equiv.) 2.17. In the first step of this process, a sulfonyl chloride intermediate A is 
synthesized by using t-BuOH and chlorosufonyl isocyanate, which is then directly 
reacted with the primary amines incorporating different side chains to produce the 
corresponding Boc-protected sulfamides 2.18j-m. Likewise, the mono- and di-
substituted Boc-protected sulfamides 2.18a-i were synthesised by a previous postdoc 
in the Fairbanks group (Andrew Watson) using primary and secondary amines 
respectively. Finally, in all cases the Boc protecting group was removed by treatment 
with trifluoroacetic acid (5.0 equiv.) to give the desired sulfamides 2.19a-m in 
excellent yields (60-90%).  




Scheme 2.5 (i) t-BuOH, 2.17, DCM, 0 °C, 30 minutes; RNH2, Et3N, DCM, 0 °C to rt, 
16 h, 2.18j – 73 %; 2.18k – 93 %; 2.18l – 39 %; 2.18m – 91 %; (ii) TFA, DCM, rt, 16 
h, 2.19a – 86 %; 2.19b – 69 %; 2.19c – 76 %; 2.19d – 68 %; 2.19e – 75 %; 2.19f – 92 
%; 2.19g – 76 %; 2.19h – 66 %; 2.19i – 78 %; 2.19j – 98 %; 2.19k – 88 %; 2.19l – 76 
%; 2.19m – 65 %. 
 
2.2.4  Synthesis of sulfamidoglycosides 
 
A previous Postdoc in the Fairbanks group (Brendan Wilkinson) had performed 
extensive investigations into trying to improve the stereoselectivity of the 
sulfamidoglycosylation, which gave poor β-stereoselectivity under a variety of 
activation conditions. Therefore, sulfamidoglycosylation was performed using the 
standard condition
93
 as mentioned below. Condensation of the furanose hemiacetal 
2.6 and the various sulfamide acceptors 2.19a-m in the presence of stoichiometric 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) afforded the corresponding 
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glycosyl sulfamides 2.20a-m as inseparable mixtures of anomers (α:β 1:1). 
Compounds 2.20a-m were then deprotected by catalytic hydrogenation in the 
presence of 10% Pd on carbon in MeOH under an atmosphere of hydrogen, to yield a 
mixture of compounds (Scheme 2.6), which were partially separated by HPLC.   
 
Scheme 2.6 (i) TMSOTf, RR‟NHSO2NH2, DCM, 0 °C to rt, 16 h, 2.20a – 52 %; 
2.20b – 54 %; 2.20c – 77 %; 2.20d – 71 %; 2.20e – 54 %; 2.20f – 78 %; 2.20g – 68 
%; 2.20h – 59 %; 2.20i – 47 %; 2.20j – 80 %; 2.20k – 74 %; 2.20l – 83 %; 2.20m – 
62 %.  (ii) Pd/C, H2, MeOH, rt, 16 h, 2.21a – 42%; 2.21b – 36 %; 2.21c – 45 %; 
2.21d – 40 %; 2.21e – 47 %; 2.21f - 41 % 2.21g – 45 %; 2.21h – 41%; 2.21i – 39 %; 
2.21j – 43 %; 2.21k – 46 %; 2.21l – 42 %; 2.21m – 46%. 
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The three components, labelled A, B, and C from the deprotection of compound 2.21c 
were separated by RP-HPLC (Figure 2.5) using a Luna C18 semi-preparative column 
(Phenomenex); eluent:A (0.05% TFA in H2O) and B MeCN; gradient: the sample was 
run at 1 mLmin
-1
 with a gradient of 50-85% B and analysed by NMR. Structural 
analysis of the each purified component by HMBC was unclear, and so the structure 
of the major component A (2.21c) was confirmed by X-ray crystallography (Figure 
2.6), which is only one example chosen to study the isomerization and determination 
of the structure by X-ray crystallography. 
 
 
Figure 2.5 RP-HPLC trace of N-(decyl)-N’-(α,β-D-arabinopyranosyl)sulfamide 
2.21c/2.22a and N-(decyl)-N’-(α,β-D-arabinofuranosyl)sulfamides 2.22b/2.22c 












Figure 2.6 X-Ray structure of a α-pyranose sulfamide 2.21c. 
 
Unexpectedly, these crystallographic studies revealed 2.21c to be the α-pyranose 
isomer, in a 
1
C4 conformation. The other components of the mixture were then 









Figure 2.7 Equilibration of N-Glycosylsulfamides in aqueous solution. 
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In order to investigate the isomerization and stability of the various isomers of 
sulfamide 2.21c (Figure 2.7), each component was isolated and then stirred in water 
at pH 7; the quantity of each isomer present was then evaluated at different time 
intervals. The pure α-pyranose anomer 2.21c gave only a minimal amount of the other 
















Figure 2.8 RP-HPLC traces and time-dependence of equilibration of N-(decyl)-N’-(α-
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However, the aqueous solution of other isomers, the α-furanose/β-pyranose mixture 
(Figure 2.9) and the pure β-furanose form (Figure 2.10) all underwent isomerization 
and produced mixtures in which 70 % of the α-pyranose isomer 2.21c was present as 
the major product after 48 hours at rt. The isomerization studies revealed that 
mutarotation and interconversion of the deprotected α-, β-furanose and β-pyranose 
sulfamides were rapid (less than one hour) in neutral aqueous solution.  
  
































Figure 2.9 RP-HPLC traces and time-dependence of equilibration of N-(decyl)-N’-(β-
D-arabinopyranosyl)sulfamide 2.22a and N-(decyl)-N’-(α-D-
arabinofuranosyl)sulfamide 2.22b in water. 
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Figure 2.10 RP-HPLC traces and time-dependence of equilibration of N-(decyl)-N‟-
(β-D-arabinofuranosyl)sulfamide 2.22c  in water. 
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X-ray crystallographic studies revealed that sulfamide 2.21c adopted 
1
C4 
conformation with the anomeric nitrogen in an equatorial position; which should be 
favoured by an nN10→σ
⁎
C2-O1 (Figure 2.6) orbital interaction (an exo-anomeric effect). 
Furanose/pyranose equilibration involves the ring opening of the furanose form to 
give acyclic N-sulfonyl imine/iminium ion intermediates (Figure 2.11). Kiessling et 
al.
94
 provided evidence for this type of iminium ion intermediate in the isomerization 
of UDP-galactopyranose and UDP-galactofuranose catalyzed by the UDP-
galactopyranose mutase (UGM) enzymes that are essential for many pathogenic 
species of bacteria.   
 
 
Figure 2.11 Putative mechanisms for pyranose-furanose isomerization of methyl 
sulfonamide.  
 
The above mutarotation/isomerisation studies demonstrated that α-pyranose N-
glycosyl sulfamides are thermodynamically the more stable isomers in aqueous 
solution. A similar result was observed upon de-protection of all compounds 2.20a-m; 
in each case a mixture of anomers was produced, and the α-pyranose isomer 2.21a-m 
was isolated by RP-HPLC as the major product.  
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2.3   Synthesis of arabinose N-glycosyl sulfonamides and 
sulfamates  
 
In order to synthesize and also investigate the potential isomerization of N-glycosyl 
sulfonamides and sulfamates, TMS triflate-mediated glycosylations were performed 
with furanose hemiacetal 2.6 and trifluoromethane sulfonamide, methane 
sulfonamide, and n-decylsulfamate 2.24 (Scheme 2.7) to afford the furanose glycosyl 
sulfonamides 2.25a and 2.25b and the furanose glycosyl sulfamate 2.25c respectively 
(Scheme 2.8).  
Scheme 2.7 (i) NH2SO2Cl, DMA, 0 °C to rt, 3 h, 85 %. 
Scheme 2.8 (i) TMSOTf, CF3SO2NH2, DCM, 0 °C to rt, 16 h, 2.25a – 44 % (ii) 
TMSOTf, CH3SO2NH2, DCM, 0 °C to rt, 16 h, 2.25b – 53 % (iii) TMSOTf, 
C10H21OSO2NH2, DCM, 0 °C to rt, 16 h, 2.25c – 56 % (iv) Pd/C, H2, MeOH, rt, 16 h, 
2.26a – 65 %; 2.26b – 33 %; 2.26c – 45 %. 
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Compounds 2.25a-c were deprotected by catalytic hydrogenation in the presence of 
10% Pd on carbon in MeOH under an atmosphere of hydrogen. Once again upon 
deprotection of both the methyl sulfonamide 2.26b and the sulfamate 2.26c a mixture 
of anomers was produced, with the major product of these reactions being the α-
pyranose isomer. The structure of methyl sulfonamide 2.26b was confirmed by X-ray 






Figure 2.12 X-Ray structure of α-pyranose methyl sulfonamide 2.26b 
 
As discussed in Figure 2.11, the lone pair on the anomeric nitrogen is involved in the 
facile ring opening of the furanose form. Therefore reasoned that perhaps 
sulfonamides bearing a strong electron withdrawing group may show a reduced 
tendency to isomerise. The corresponding N-glycosyl trifluoromethanesulfonamide 
was therefore synthesized by catalytic hydrogenation of 2.25a, which yielded a single 
compound, which was identified as the β-furanose isomer 2.26a and which was found 
to be configurationally stable in aqueous solution.  
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2.4  Screening of final compounds as anti-tuberculosis agents 
 
The purified α-pyranose anomers 2.21a-m were screened as inhibitors of M. 
smegmatis (mc
2
4517) using the Alamar Blue microplate assay
95,96
 to obtain their 
minimum inhibitory concentration (MIC) values. This assay makes use of Alamar 
Blue dye, which changes from the oxidized indigo blue non-fluorescent state to the 
reduced fluorescent pink state in the presence of the growing bacteria (Figure 2.13). 
Compounds that inhibit the growth of the bacteria thus result in a decrease in 
fluorescence.  
 
Figure 2.13 Resazurin reduction to resorufin.  
 
The purified test compounds and isoniazid were prepared in DMSO at a concentration 
of 40 mg/mL, and subsequent 2 fold serial dilutions were performed in 100 µl LB/T 
media in 96 well microplates, producing compound concentrations of 1000, 500, 250, 
125, 62, 31, 15, 7.5, 3.75 µg/mL. Approximately 4.5 x 10
6
 CFU/mL of M. smegmatis 
was added to each well to give a total volume of 200 µl. Control wells were also made 
up that contained only bacteria with 2.5% DMSO in LB/T media. The plates were 
then incubated at 37 °C for 18 hours. After this time, 10 µl of Alamar Blue dye was 
added to all wells and the plate was then incubated for another 5 hours. The wells 
were then observed for a colour change (blue to pink), and the MIC value was 
determined by visual observation. The results are shown in (Table 2.1, Figure 2.14). 























Figure 2.14 Alamar Blue assay of compounds 2.21a-m plus controls 







2.21a -(CH2)5CH3 > 1000 
2.21b -(CH2)7CH3 500 
2.21c -(CH2)9CH3 62 
2.21d -(CH2)11CH3 250 
2.21e -(CH2)13CH3 > 1000 
2.21f -[(CH2)5CH3]2 125 
2.21g -[(CH2)7CH3]2 500 
2.21h -[(CH2)9CH3]2 > 1000 
2.21i -[(CH2)11CH3]2 > 1000 
2.21j -(CH2)2CH(CH3)(CH2)3CH(CH3)2 125 
2.21k -CH2CH2OCH2CH2OH >1000 
2.21l -(CH2CH2O)2CH2CH2OH >1000 
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From the results presented in Table 2.1, none of the compounds were very potent 
inhibitors of mycobacterial growth. Compound 2.21c, which contains a single alkyl 
chain of 10 carbon atoms, did show moderate activity (MIC 62 µg/mL). The 
biological activity increased with the side chain length, and therefore hydrophobicity, 
was increased from C6 to C10. Activity then decreased as the number of carbons was 
further increased from 12 to 14. The results reveal that a correlation exists between 
the activity of a series of glycosyl sulfones (Figure 2.15), previously reported by the 
Fairbanks group,
64
 and these glycosyl sulfamides. The n-butyl sulfone showed only 
very low activity (MIC 2 mg/mL), but the potency increased with alkyl chain length 
and reached a maximum for the n-dodecyl sulfone (MIC 62 µg/mL).  This sulfone has 
a total chain length of 13 atoms from the anomeric centre, as is the case for 2.21c. 
Subsequently, the activity decreased for sulfones which possessed more extended 
alkyl chains (Figure 2.15). The results demonstrate that a clear correlation exists 












Figure 2.15 Inhibitory effects of glycosyl sulfones against M. bovis.
64
 




-(CH2)9CH3 125 > X > 62 
-(CH2)11CH3 62 
-(CH2)13CH3 250 > X > 125 
-(CH2)15CH3 125 




The N-Glycosyl sulfamide possessing dialkylated side chains with 6 carbon atoms 
(2.21f) gave an MIC of 125 µg/mL.  However, for the dialkyl chain containing 
sulfamides the activity decreased with increasing chain length from 8 carbon atoms 
(MIC 500 µg/mL for 2.21g), to 10 and 12 carbon atoms (MIC > 1000 µg/mL for 
2.21h and 2.21i). However, in related studies, Von Itzstein had previously reported
65
 
that N,N-dihexyl galactofuranosyl sulfonamides, and sulfenamides had lower potency 
than the N,N-dioctyl galactofuranosyl sulfonamides, and in the sulfenamides series 
the N,N-didecyl derivatives; the reverse of the situation observed here. In that work 
the N,N-dioctyl, N,N-didecyl galactofuranosyl sulfenamides and N,N-dioctyl 
galactofuranosyl sulfonamides displayed strong inhibition of mycobacterial growth, 
with MIC values below 5 µg/mL.  
With respect to the other compounds tested, the branched side chain 3,7-
dimethyloctyl sulfamide 2.21j (125 µg/mL) was more active than the straight chain n-
octyl sulfamide 2.21b (500 µg/mL). None of the compounds bearing polyethylene 
glycol side chains displayed any biological activity at the levels tested (MIC > 1000 
µg/mL), possibly due to the increased hydrophilic nature of the side chains. In order 
to investigate the importance of the carbohydrate moiety, n-decyl sulfamide 2.21c was 
also tested against M. smegmatis. The activity of the alkyl sulfamide (500 µg/mL) 
was approximately 8-fold lower than the corresponding glycosyl sulfamide 2.21c (62 
µg/mL) showing that the sugar was important. 
As described above, the N-glycosyl sulfamides, sulfamates and sulfonamides all 
undergo mutarotation and furanose/pyranose equilibration in aqueous solution. These 
AB assays were performed with pure α-pyranose sulfamides. However, other isomers 
would probably be formed during the assay (> 20 h in duration). HPLC analyses were 
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performed on compounds 2.21b and 2.21c under the AB assay conditions and the 
amount of isomerisation quantified. The results revealed that only ~ 7% of the α-
pyranose sulfamide had converted into a mixture of the β-pyranose and α-furanose 
forms, and that both isomers are inseparable by HPLC (Figure 2.16). Approximately 
93% of the material was still in the thermodynamically preferred α-pyranose form. 
Therefore, it is important to realize that the biological activities reported in (Table 
2.1) refer to assays of purified α-pyranose compounds, but a minor amount of other 
isomers was also present at the end of the assay.  
  
 Chapter 2 
66 
 

















Peak  Ret.Time  Height       Area          Rel.Area         Identity 
 /min pA                 pA*min % 
1   18.83       64.732    19.020  93.00     
2   19.79       5.509   1.432   7.00     
Total:   70.240  20.452  100.00     
Figure 2.16  HPLC trace of compound 2.21b for the study of isomerization under the 















Peak  Ret.Time  Height       Area          Rel.Area         Identity 
 /min pA            pA*min % 
1   24.74       18.136    5.215   92.75     
2   26.04       2.062   0.408   7.25     
Total:   20.198  5.622   100.00     
Figure 2.17 HPLC trace of compound 2.21c for the study of isomerization under the 
AB assay conditions.  
 
The activity of sulfonamides 2.26a-b and sulfamate 2.26c were also evaluated as 
inhibitors of M. smegmatis (mc
2




























Figure 2.18 Alamar Blue assay of compounds 2.26a-c plus control 
 
The MIC for the sulfonamides 2.26a and 2.26b was greater than 1 mM. The weak 
activity of the N-glycosyl furanose sulfonamide 2.26a indicates the importance of 
hydrophobic side chain for anti-mycobacterial activity. The sulfamate 2.26c, bearing a 
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C10 alkyl chain, showed moderate activity (125 µg/mL) against M. smegmatis. The 
activity of the sulfamate was a factor of 2 lower than the corresponding N-
glycosylsulfamide bearing a C10 alkyl chain 2.21c (62 µg/mL).  
2.5  Synthesis of N-glycosyl sulfamides lacking a 5-hydroxyl 
group  
 
As discussed earlier in this chapter, the attempted synthesis of a variety of glycosyl 
sulfamides, sulfamates and sulfonamides of arabinofuranose as DPA analogues led to 
compounds that underwent both mutarotation and furanose to pyranose 
interconversion. In all cases the major α-pyranose form had shown low to moderate 
anti-mycobacterial activity. We reason that this may be due to the major component 
being in the pyranose rather than desired furanose form,.
97
  
More positively the crystallographic studies had confirmed that sulfamides had 
tetrahedral geometry. This interesting motif may therefore be of great value for the 
design of pharmacological agents using sulfamides as phosphate isosteres of DPA. In 
order to stop isomerization of the furanose compounds to the thermodynamically 
more able pyranose form upon de-protection, we undertook the synthesis of a series of 
N-glycosyl sulfamides lacking a hydroxyl group at position-5 of arabinose and 
evaluated their anti-mycobacterial activity.  
2.5.1  Synthetic strategy  
 
The synthesis of an arabinofuranose donor substrate with modifications at position-5 
was to be performed by the same methodology as developed previously by the 
Fairbanks group.
15
 A series of arabinofuranosyl sulfamides were synthesized with a 
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hydrophobic side chain, wherein the 5-hydroxyl of arabinofuranose was replaced with 
fluoro, azido, deoxy and methoxy substituents.  
Selective modification at position-5 required selective access to position-5. As 
reported in the literature,
15
 commercially available D-arabinose 2.9 was treated with 
trityl chloride in pyridine at room temperature for 48 h to give the 5-O-trityl 
derivative. The free hydroxyl groups were acetylated using acetic anhydride in 
pyridine to produce ester 2.27. Removal of the trityl group was performed without 
loss of the anomeric acetate by using 80% aqueous acetic acid at 100 °C for 25 
minutes, to afford the alcohol 2.28 (Scheme 2.9).  
Methylation of free hydroxyl groups at position-5 was achieved by using methyl 
triflate in the presence of excess di-tert-butylmethyl pyridine (DTBMP) and catalytic 
Hg(CN)2 in dichloromethane to afford the methyl ether 2.29. Introduction of azide at 
position-5 was achieved by tosylation of the free hydroxyl group, using tosyl chloride 
and pyridine at room temperature for 48 hours, to give 2.31 (58 % yield), which was 
then converted to the azido acetate 2.32 by reaction with sodium azide at 80 °C in 
DMF. Introduction of fluorine at position-5 was performed by the treatment of 
alcohol 2.28 with diethylamino sulfur trifluoride (DAST) in diglyme at -40 °C to 
afford the 5-fluoride 2.30. 5-Deoxy arabinofuranose was synthesized by de-
halogenation. Iodide 2.33 was synthesised by reaction of alcohol 2.28 with 
triphenylphosphine and iodine in the presence of imidazole using an Appel reaction to 
give iodide  2.33 which was then reduced by catalytic hydrogenation with Pd/C in the 
presence of triethylamine to afford the required deoxy arabinofuranose 2.34 (Scheme 
2.9).  




Scheme 2.9 (i) TrCl, pyridine, rt, 48 h, 41 %; (ii) Ac2O, pyridine, rt, 84 %; (iii) 80% 
aqueous AcOH, 100 °C, 25 min, 74 %; (iv) MeOTf, DTBMP, Hg(CN)2, DCM, 40 °C, 
24 h, 63 %; (v) DAST, diglyme, -40 °C to rt, 16 h, 62 %; (vi) TsCl, pyridine, 48 h, 58 
%; (vii) NaN3, DMSO, 80 °C, 24 h, 56 %; (viii) PPh3, I2, imidazole, rt, 2.5 h, 100 °C, 
89 %; (ix) 10 % Pd/C, H2, Et3N, EtOH, rt, 16 h, 74 %. 
 
As discussed in the previous section, the C10 alkyl chain-bearing pyranose glycosyl 
sulfamides had revealed optimal anti-mycobacterial activity against M. smegmatis.
98
 
Therefore glycosyl sulfamides bearing a C10 chain were synthesized (Scheme 2.10) by 
reaction of glycosyl acetates 2.29, 2.32 and 2.34 with n-decyl sulfamide in the 
presence of BF3.OEt2 at room temperature in DCM, which led to the formation of 
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corresponding glycosyl sulfamides 2.35a-c, in each case as an inseparable mixture of 
anomers (α:β 1:1). Cleavage of the acetates under Zemplen conditions yielded the 
then corresponding diols 2.36a-c. The structure of the final compounds was 
confirmed by coupling constant data of the anomeric position NOE experiment. The 
α-arabinofuranosides are characterized by 
3
J1,2 = 0-3 Hz and an NOE between H-1 
and H-3. Whereas β-arabinofuranosides are characterized by 
3
J1,2 = 4-5 Hz and NOE 
was observed between H-1 and H-2, H-4, no NOE was observed between  H-1 and H-
3. 
 
Scheme 2.10 (i) BF3.OEt2, C10H21NHSO2NH2, DCM, rt, 16 h, 2.35a – 75 %; 2.35b – 
57 %; 2.35c – 56 %; (ii) Na/MeOH, rt, 16 h, 2.36a – 82 %; 2.36b – 81%; 2.36c – 62 
%. 
 
In order to assess any effects of alkyl chain lengths on the biological activity of these 
compounds three different 5-fluoro glycosyl sulfamides were synthesized (Scheme 
2.11). Thus, fluoride 2.30 was treated with n-octyl, n-decyl and n-dodecyl sulfamides 
in the presence of BF3.OEt2 at room temperature in DCM to give corresponding 
glycosyl sulfamides 2.37a-c, again as inseparable mixtures of anomers (α:β 1:1). 
Cleavage of the acetates under Zemplen conditions yielded the corresponding diols 
2.38a-c.  




Scheme 2.11 (i) BF3.OEt2, RNHSO2NH2, DCM, rt, 16 h, 2.37a – 53 %; 2.37b – 61 
%; 2.37c – 52 % (ii) Na/MeOH, rt, 16 h, 2.38a – 75 %; 2.38b – 72 %; 2.38c – 78 %.   
 
2.5.2  Biological activity  
 
The biological activity of all of the N-glycosyl sulfamides with functionalization at 
position-5 was tested against M. smegmatis by using an Alamar Blue assay.
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Isoniazid (4 µg/mL), ethambutol (0.5 µg/mL) and n-decyl sulfamide 2.19c were 
assayed as controls. The n-decyl glycosyl sulfamides 2.36a-c and 2.38b with different 
functional groups at position-5 displayed significant anti-mycobacterial activity, with 
all four displaying MIC values of 31 µg/mL. The activity did not appear to depend on 
the modification at position-5. Furthermore, n-decyl sulfamide (NH2SO2NHC10H21) 
2.19c gave a MIC value of 500 µg/mL. These results demonstrate that the 
arabinofuranose ring plays a significant role in the biological activity; the activity was 
enhanced by more than two orders of magnitude as compared to the sulfamide 
without the sugar. Interestingly, the previously reported pyranose n-
decylsulfamidoglycoside 2.21c, possessing an unmodified hydroxyl group at position-
5 (MIC 62 µg/mL) was two times less activity than all of these furanose n-
decylsulfamidoglycosides.   
 

























NH2SO2NHC10H21 2.19c 500 2117 
2.36a 31 81 
2.36b 31 88 
2.36c 31 79 
2.38a 250 731 
2.38b 31 84 
2.38c 1000 2511 
a
 MIC = minimum inhibitory concentration; the lowest concentration of the compound 
which inhibited the growth of M. smegmatis >90% in the Alamar Blue assay. 
Isoniazid (INH, MIC 4 µg/mL) and decylsulfamide 2.19c were used as controls. 
  
Table 2.3 Anti-mycobacterial activity of glycosyl sulfamides. 
 
As reported earlier in this chapter, the alkyl chain lengths influence the anti-
mycobacterial activity of these compounds. The activity of the 5-fluoro 
arabinofuranose glycosyl sulfamides with varying alkyl chain lengths (C8, C10 and 
C12) was investigated. Sulfamide 2.38a, with a C8 alkyl chain, gave a MIC of 250 
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31 µg/mL). Interestingly, these results showed correlation with the previously 
reported results for the pyranose glycosyl sulfamides and the glycosyl sulfones,
64
 in 
which maximal activity was observed with a total chain length of 13 atoms from the 
anomeric centre, as is the case for 2.36a-c and 2.38b. The activity was significantly 
reduced by increasing the side chain length to 12 carbon atoms as in compound 2.38c 
(1000 µg/mL). Interestingly the pyranose n-dodecylsulfamidoglycoside 2.21d (250 
µg/mL) was 4 times more active than the corresponding 5-fluoro furanose form 2.38c.  
2.6  Conclusions 
 
A wide variety of N-glycosyl sulfamides, sulfonamides, and sulfamates of arabinose 
were synthesized. Unexpectedly, the de-protected materials isomerized from the 
furanose to the pyranose form in an aqueous solution, to produce mixtures in which α-
pyranose form was thermodynamically preferred. In contrast, deprotected N-glycosyl 
trifluoromethane sulfonamide was shown to be configurationally stable in aqueous 
solution. All compounds were tested for anti-mycobacterial activity using the Alamar 
Blue microplate assay. Biological testing of the purified α-pyranose sulfamides, 
methanesulfonamide and sulfamate revealed low to moderate activity against M. 
smegmatis. To remedy the problem of furanose/pyranose equilibration, a series of 
glycosyl sulfamides which lacked the 5-hydroxyl group were synthesized in order to 
fix these compounds in the furanose form. These furanose sulfamides were then tested 
for anti-mycobacterial activity and displayed moderate activity, with a MIC of 31 
µg/mL for the C10 hydrophobic side chain.




Chapter 3 Synthesis of thymidine monophosphate 
analogues as potential inhibitors of 
mycobacterial cell wall biosynthesis 
 3.1  Introduction 
 
As discussed in previous chapters, the need for long duration treatment and the 
emergence of multi- (MDR-TB) and extensively drug resistant (XDR-TB) forms of 
M. tuberculosis present significant challenges for the treatment of tuberculosis. 
88, 90
 
The discovery of new mycobacterial targets, and the shortening of current treatment 
durations are essential for treating MDR-TB and XDR-TB. The recently discovered 
enzyme Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) is 
indispensable for growth and survival of M. tuberculosis, as it plays an essential role 
in DNA synthesis.
75
 Therefore, it is an attractive target for the design of novel anti-
tuberculosis agents. 
TMPKmt catalyses the phosphorylation of thymidine monophosphate (dTMP) to give 
thymidine diphosphate (dTDP) using ATP as phosphoryl donor, and is essential for 
maintaining the thymidine triphosphate pool, which is required for DNA synthesis 
and replication of bacteria. This phosphorylation step is situated at the junction of the 
de novo and salvage pathways for the synthesis of thymidine triphosphate (dTTP).
80,81 
 
TMPKmt has low (22%) sequence identity with the human isozyme, and therefore 
represents a promising target for the development of selective inhibitors.
79
  
Inhibitors of TMPKmt have previously been reported by Calenbergh et al.
79-81, 87, 100 
and several others.
101  
5‟-Thiourea-substituted α-thymidine derivatives 3.1 were 
synthesised by Calenbergh et al.
102
 The analogous 3-trifluoromethyl-4-
chlorophenylthiourea 3.2 moiety displayed promising inhibitory activity, with a Ki of 
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0.6 µM, and an MIC99 value of 20 µg/mL against M. bovis. In addition, 5‟-
arylthiourea 4-thio-α-thymidine 3.3 revealed significant inhibition of TMPKmt (Ki = 







The synthesis and biological activity of sulfonamides and sulfamates has been widely 
reported, but there are only a few reports on the use of sulfamides as a phosphate 
isostere. For example Aldrich et al.
74,73
 reported the use of sulfamide as an isosteric 
replacement for phosphate in the search for anti-mycobacterial agents as inhibitors of 
siderophore biosynthesis; salicyl sulfamoyl adenosine and its derivatives displayed 
promising inhibitory activity, with MICs ranging from 0.19-6.25 µg/mL against M. 
tuberculosis.  These adenosine analogues disturb siderophore biosynthesis by 
inhibition of an adenylate-forming enzyme MbtA, which is involved in biosynthesis 
of the mycobactins.  
As mentioned in the previous chapter, our crystallographic studies confirmed that 
sulfamides adopt a tetrahedral geometry. This interesting motif could therefore be of 
great value for the design of pharmacological agents using sulfamides as phosphate 
isosteres. It was therefore thought worthwhile to investigate the design and synthesis 
of sulfamides as analogues of thymidine monophosphate. Possible sulfamide 
structures were screened in silico using induced-fit docking methods.
103
 From the 
docking results, a selection of compounds was synthesized and evaluated for any anti-
mycobacterial activity against M. smegmatis.   
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3.2   Molecular docking and structure-based drug design of 
thymidine monophosphate analogues  
 
Molecular modeling has been of great value in the fields of drug design, 
computational biology and material science.
104
 Molecular docking methods explore 
ligand conformation and binding affinities, and also estimate the ligand-receptor 
binding free energy using scoring functions.
103,105
 There are two types of docking 
methods which are widely used in drug design:  
a) Lock and key\rigid docking 
b) Induced fit\flexible docking 
In rigid docking, the conformation of the receptor is fixed, and docking of the 
molecule of interest is then performed. In contrast, induced-fit docking performs 
docking calculations with multiple receptor conformations. A small library of 
sulfamide analogues of TMP was designed and screened with the published three-
dimensional structure of TMPKmt (PDB accession code: 1N5K)
106
, using an induced 
fit docking method with Schrödinger Suite 2006
107,108 
 by Dr. Wanting Jiao as detailed 
below.  
3.2.1  Docking preparation and settings 
 
The three-dimensional crystal structure of TMPKmt in complex with dTMP substrate 
was imported from the PDB (accession code: 1N5K).
106
 TMPKmt is a homodimer and 
each monomer has 214 amino acids.
109
 The receptor structure was prepared in the 
semi-closed state, which is more representative of the active site conformation when 
substrate is bound. Protein preparation wizard (most frequently used tools and 
techniques in structure preparation)
110
 was used to add hydrogens, assign bond orders, 
create zero-order bonds to metals, and fill in missing side chains. Only two water 
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molecules that coordinate to the metal ion were kept in the structure; all other water 
molecules were removed.  The receptor structure was refined by sampling water 
orientations and assigning hydrogen bonds. Protonation states were also assigned 
using PROPKA.
111
 Then the structure was minimized with a convergence of heavy 
atoms set to a root-mean-square deviation (RMSD) of 0.30 angstroms, which is a 
measure of average atomic distance between the atoms. The receptor grid was 
generated in glide using co-crystallized ligand (dTMP) to define the centre of the grid 
box.
110
 All other settings were kept as default.  
The target compounds were built in Maestro,
112
 and prepared using LigPrep.
113
 The 
ligands were then docked into the receptor grid file using glide with the XP (extra 
precision) mode,
105
 The predicted binding poses for each compound were then 
examined. 
The substrate dTMP adopting a C2‟-endo confirmation in the active site, which was 
docked back in the active site to validate the docking procedure and confirmed that 





Figure 3.1 Docking of dTMP in the active site of TMPKmt (PDB: 1N5K). 
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The active site of TMPKmt contains a Mg
2+
, a water molecule, and residue Arg95, 
which interact with the non-bridging oxygen of the phosphate moiety of dTMP. 
Docking studies revealed that the main interactions between dTMP and the enzyme 
include a stacking interaction between the pyrimidine ring of thymine and Phe70, as 
well as H-bonds formed between the carbonyl and amino groups of dTMP and the 
side chains of Arg74 and Asn100 respectively. Another H-bond is formed between 
the 3'-OH of the 2-deoxyribose and the terminal carboxyl of Asp9 (Figure 3.1). These 
enzyme-substrate interactions therefore suggested that substrate-based competitive 
inhibitors could be designed by replacement of the 5'-phosphoryl group with a 
suitable isostere, for example a sulfamide.  
3.2.2  Induced fit docking of the target sulfamide 
derivatives  
 
In order to investigate the binding affinity of the sulfamide derivatives, the following 
target compounds were docked into the TMPKmt active site using the induced fit 
docking method, and the docking scores (glide score) were listed in Table 3.1. 
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Table 3.1 Docking results of the dTMP analogues on TMPKmt.  
 
The empirical scoring function includes a lipophilic-lipophilic term, a hydrogen bond 
term, a rotatable bond penalty, and a contribution from protein-ligand coulomb-van 




XP GlideScore = Ecoul + EvdW + Ebind + Epenalty  
Compounds 
 
Glide gscore  
(kcal/mol) 























The above 18 compounds in which phosphate group was replaced by a sulfamide that 
was modified with attached groups, were all docked to TMPKmt.  
The docking scores of the compounds ranged from -10.9 to -12.6 kcal/mol. 
Compound 3.10 gave a docking score of -12.153 kcal/mol. This result implied that the 
binding affinity of the compound 3.10 would be less than that of the substrate dTMP 
(-14.611 kcal/mol). As shown in Figure 3.2, the sulfamide group of compound 3.10 
was placed in close proximity to the phosphate binding site. However, due to the lack 
of negative charge the sulfamide group did not form strong interactions with Arg95.  
The results suggested that adding extra functional groups to the sulfamide would in 
fact not improve compound binding. However, a few extra interactions were picked 
up by the some of the additional functional groups. This is because these additional 
groups are mostly solvent exposed, as there is not enough space to accommodate the 








Figure 3.2 Docking of the substrate dTMP (green carbons) and compound 3.10 (grey 
carbons) in the active site of TMPKmt.  
 
All the compounds, except 3.9, showed similar binding affinities ranging from -11 to -
12 kcal/mol. In order to investigate possible anti-mycobacterial activity of these 
materials, compounds 3.10, 3.11, 3.12, 3.13 and 3.14 were synthesised and their anti-
mycobacterial activity was evaluated against M. smegmatis.  
3.3   Synthesis of sulfamide derivatives as dTMP analogues 
3.3.1  Retrosynthetic analysis 
 
A retrosynthetic analysis of the target compound 3.22 is shown Scheme 3.1. 
Commercially available thymidine 3.26 could be selectively iodinated at position-5, to 
give an iodide which could then be converted to azide 3.24. 5-Amino thymidine 3.23 
could be synthesised by reduction of azide 3.24. A selection of target compounds 3.22 
could be obtained by the reaction of primary amine 3.23 with the commercially 
available sulfamoyl chloride and the corresponding aryl sulfamoyl chlorides 3.27a-
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3.27d. The aryl sulfamoyl chlorides 3.27a-3.27d could be synthesized from the 
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Scheme 3.3 (i) HNO3, H2SO4, 50-60 °C, 1h, 72 %; (ii) Pd/C, H2, MeOH, rt, 2 h, 69 
%; (iii) NaN3, CuI, proline, NaOH, EtOH, H2O, 75 °C, 3h, 48 %. 
 
In order to obtain the required sulfamoyl chlorides, the corresponding aniline 
derivatives were synthesized (Scheme 3.3). Nitration of commercially available 4-
chlorobenzotrifluoride 3.29 was carried out using a 1:1 mixture of conc. HNO3 and 
H2SO4 to afford the nitrobenzene 3.30 by electrophilic aromatic substitution.
114
 The 
nitro compound 3.30 was then reduced by catalytic hydrogenation in the presence of 
10% Pd on carbon in MeOH under an atmosphere of hydrogen to yield aniline 3.28a. 
Alternatively, the aryl azide 3.28d was synthesized from commercially available 4-








Scheme 3.4 (i) HSO3Cl, Et3N, DCM, -9 °C to rt, 1 h; PCl5, toluene, 80 °C, 2 h.  
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Sulfamoyl chlorides 3.27a-d were synthesized from the commercially available 
amines 3.28b and 3.28c, and other amine derivatives 3.28a-3.28d, by first convertsion 
into the N-sulfonic acid, and then chlorination using PCl5 to afford the sulfamoyl 
chlorides 3.27a-d (Scheme 3.4).  
3.3.3 The synthesis of target sulfamide derivatives. 
 
 
Scheme 3.5 (i) PPh3, I2, imidazole, THF, 60 °C, 41 % ; (ii) NaN3, DMF, 50 °C, 70 %; 
(iii) PPh3, H2O, rt, 16 h, 60 %; (iv) NH2SO2Cl, Et3N, DMA, 0 °C to rt, 2 h, 74 %; (v) 
Et3N, 3.27a-d, CH3CN, 0 °C to rt, 2 h, 3.11 – 65 %; 3.12 – 49 %; 3.13 – 41 %; 3.14 – 
34 %. 
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 As shown in Scheme 3.5, thymidine 3.26 was used as a starting material. The iodide 
3.25 was synthesized via selective iodination of the primary alcohol with PPh3, I2, and 
imidazole using an Appel reaction
116
. Azide 3.24 was then made by nucleophilic 
substitution of 3.25 using NaN3. This was followed by catalytic hydrogenation in the 
presence of 10% Pd on carbon in MeOH under an atmosphere of hydrogen to yield 
amine 3.23. Amine 3.23 was then sulfamoylated using sulfamoyl chloride and Et3N to 
provide sulfamide 3.10.  
Additionally, analogues 3.11-3.14 were synthesized by reaction of amine 3.23 with 
sulfamoyl chlorides 3.27a-3.27d and purified by RP-HPLC.  
3.4  Biological activity of the sulfamide analogues of dTMP  
 
The biological activity of sulfamide analogues 3.10-3.14 were tested against M. 
smegmatis by using an Alamar Blue assay, using techniques described previously. 
99
 
Ethambutol (MIC 0.5 µg/mL) was also assayed as a control. The visual observation of 
the AB assay and the MIC values for the inhibitors are shown in Figure 3.3 and 




































 MIC = minimum inhibitory concentration; the lowest concentration of the compound 
which inhibited the growth of M. smegmatis >90% in the Alamar Blue assay. 
Ethambutol (EB, MIC 0.5 µg/mL) was used as a control. 
Table 3.2 Anti-mycobacterial activity of sulfamide analogues.  
From the results presented in Table 3.2, none of the compounds displayed potent 
inhibitory activity against M. smegmatis. The sulfamide analogue 3.10 displayed no 
growth inhibition at concentrations up to 1000 µg/mL, possibly due to the hydrophilic 
nature of the sulfamide moiety, which may limit membrane permeability. Analogues 
3.11-3.13, which contain a halogenated phenyl ring sulfamide substituent, displayed 
low activity, with MICs of 250 µg/mL.  The activity did not appear to depend on the 
identity of the halogen substituents on the phenyl ring; namely p-chloro, p-bromo, or 
 Chapter 3 
90 
 
3-CF3-4-Cl-phenyl sulfamide. However, the presence of azide functionality on the 
ring (3.14) led to a greater than 4-fold loss in activity against M. smegmatis (MIC > 
1000 µg/mL).  The halogenated phenyl analogues 3.11-3.13 were more than 4 times 
more active than sulfamide 3.10. In this series of sulfamide analogues of dTMP, anti-
mycobacterial activity was clearly influenced by the nature of the substituent attached 
to the sulfamide.  
As discussed in this chapter, the 5 compounds 3.10-3.14 were docked into the 
substrate binding site of the TMPKmt enzyme. However, the in vitro assays 
demonstrate that no clear correlation exists between anti-mycobacterial activity and in 
silico docking studies.  
 3.5  Conclusions 
 
A wide variety of sulfamide analogues were designed and docked into the active site 
of the enzyme TMPKmt. All the compounds, except 3.9, gave similar docking scores, 
ranging from -11 to -12 kcal/mol. In order to investigate the anti-mycobacterial 
activity of these compounds, five compounds, 3.10, 3.11, 3.12, 3.13, and 3.14, were 
then synthesised and their anti-mycobacterial activity evaluated against M. smegmatis. 
Aryl sulfamides with halogen substituents at position 5‟ gave MICs of 250 µg/mL. 
However, none of the compounds showed inhibitory activity against M. smegmatis 
that was promising enough to merit further investigation.  
3.6  Future work 
 
In order to investigate the effects of other functionalities attached to the sulfamide, 
analogues 3.20 and 3.4-3.6 should be synthesised, and their inhibitory activity 
evaluated for. Additionally, as Calenberg et al.
80
 has previously shown that the α-
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anomers displayed more promising activity than the β-anomers against TMPKmt, the 
-thymidine analogues could also be synthesised and evaluated for their anti-
mycobacterial activity. Finally a TMPKmt inhibitory assay could be developed to 
determine the binding affinities of these sulfamides to the active site, and in particular 
to investigate if there is any correlation between binding affinity and the results of the 




 Chapter 4 
92 
 
Chapter 4 Efficient reduction of organic azides by sodium 
iodide in the presence of acidic ion exchange 
resin 
 4.1  Introduction 
 
Amines play an important role in the organic synthesis and find wide-reaching 
applications in many fields. They are widely used in the treatment of diseases, the 
development of crop protection chemicals, and the production of care products.
117
 





 and in nucleoside chemistry. Among amines, primary amines are 
central in organic synthesis. One of the existing methods for the preparation of 
primary amine starts from the corresponding alcohol, which is then transformed into a 
good leaving group, followed by nucleophilic substitution with azide. The azide is 
then reduced and to obtain a primary amine. Thus, the azide moiety plays a vital role 
as a primary amine precursor in organic synthesis. 
A wide variety of reduction methods of azides to primary amines have previously 
been reported.
120
 The most prominent method of reduction is the catalytic 
hydrogenation. However, the reduction method has drawbacks related to its lack of 
selectivity. The Staudinger reaction using PPh3
121,122,123
 and H2O also widely used for 
the azide reduction, however, the drawback of this reaction is the removal of the 
byproduct O=PPh3. In addition, LiAlH4, borohydrides,
124,125,126





 and radical initiators
120f
 have all been widely used for this 
transformation. The majority of these reductions have some drawbacks related to their 
functional group tolerance and selectivity, long reaction times and sometimes harsh 
reaction conditions.  
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This chapter details the discovery of a new reduction method which was accidentally 
discovered during the synthesis of 6-amino-D-mannose pyranose, using iodide and 
Amberlite IR 120 ion exchange resin (H
+
 form) (Scheme 4.1). During this process, D-
mannose was first selectively iodinated at position-6 with I2, PPh3 and imidazole 
using an Appel reaction. The reaction mixture was concentrated in vacuo, and then re-
dissolved in water. The aqueous layer was then washed with DCM to remove excess 
PPh3 and triphenylphosphine oxide (which is a byproduct of the Appel reaction).  
Then without further purification, the crude 6-iodo-D-mannose pyranoside from the 
aqueous layer was then reacted with NaN3. Following that reaction, in order to 
remove the imidazole, the reaction mixture was filtered through Amberlite IR 120 ion 
exchange resin (H
+
 form), and then concentrated in vacuo. Interestingly, the final 
product was identified as the amine 4.1, and was purified by RP-HPLC. It was 
thought that the reduction of azide at position-6 must have occurred in the presence of 
both the acid and iodide; the latter was formed either during the Appel reaction or by 





Scheme 4.1 One-step synthesis of 6-amino-D-mannose pyranoside 4.1. 
 
From a search of the literature, a few reports were found on the use of Lewis Acids in 







the transformation of azides to amines. Furthermore, Kamal et al. have reported the 
chemoselective reduction of aromatic azides catalysed by Al/Gd triflates/NaI.
132
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 have also been reported as reducing agents for 
azides.   
The major disadvantage associated with the use of Lewis Acids is the difficulty in 
removing the Lewis Acid from the reaction mixture and low functional group 
tolerance. As a result, there is always considerable interest in the development of a 
simple and efficient protocol for this organic transformation.  
In order to investigate the reduction reaction that had occurred using NaI/Amberlite 
IR 120 (H
+
 form), the reaction conditions were first optimized. The reduction was 
performed in the presence of different functional groups.  
 4.2  Optimization of the reduction conditions 
 
As summarized in Table 4.1, the reduction was performed at different temperatures 
and in different solvents.  Additionally, the amount of NaI used was systematically 
increased. Azide 4.2a was used as a substrate for the optimization of the reduction 
procedure. Studies commenced with the use of two equivalents of both iodide and 
acid. Acidic ion exchange resin (Amberlite IR 120, H
+
 form) was used as the source 
of acid. CD3OD and CD3CN were used as solvents to enable monitoring of reaction 
progress by 
1









Equivalents were calculated using an exchange capacity for Amberlite IR 120 of 1.8 
mequiv./mL wetted bed volume (MeOH). 
b 
Performed at 200 mbar on a rotary 
evaporator.  
 
Table 4.1 Conversion of azide 4.2a into primary amine 4.2b using NaI and Amberlite 
IR 120 (H
+
 form) under different experimental conditions. 
 
The use of 2 equivalents of NaI and 2 equivalents of acids did not reduce the azide 
after 1 h at room temperature (Entry 1). A two-fold increase in the equivalents of 
iodide (Entry 2) produced amine 4.2b with 20% conversion. The azide was not 
reduced at all in the absence of acid (Entry 3). When the reaction mixture was stirred 
at 40 °C for 1 h, product formation was increased by 25% (Entry 4) as compared with 
the reduction at room temperature (Entry 2). The efficiency of the reduction was 
accelerated by increasing the amount of iodide from 8 to 12 equivalents, and also by 
increasing the reaction time (Entry 5-9). Complete conversion to product was 






a Solvent Time 
Temp/ 
°C 
% of 1H-NMR 
conversion 
1 2 2 CD3OD 1 h rt 0 
2 4 2 CD3OD 1 h rt 20 
3 4 0 CD3OD 1 h rt 0 
4 4 2 CD3OD 1 h 40 45 
5 8 2 CD3OD 1 h rt 46 
6 8 2 CD3OD 16 h rt 82 
7 8 2 CD3OD 1 h 40  50 
8 10 2 CD3OD 1 h rt 65 
9 10 2 CD3OD 16 h rt 94 
10 12 2 CD3OD 1 h rt 100 
11 12 2 CD3CN 1 h rt 90 
12
b 
4 2 CD3OD 0.25 h 40  100 
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equivalents of acid (Entry 10). In addition, changing the solvent from CD3OD to 
CD3CN reduced the reaction efficiency by only 10% (90% conversion, Entry 11).  
Nine equivalents of NaI had been used in previously reported reduction methods.
129,130
 
The use of such a large excess of iodide was undesirable for large scale synthesis. 
Additionally it is difficult to remove the salts from the highly polar amine products. 
However, during the accidental discovery of the reduction method (Scheme 4.1), 
complete conversion was observed after the concentration of the crude mixture on a 
rotary evaporator. In order to investigate the reaction under reduced pressure, the 
reaction was then performed on a rotary evaporator with 4 equivalents of iodide, 2 
equivalents of acid and at a pressure of 200 mbar at 40 °C. This resulted in complete 
conversion to amine 4.3 after approximately only 15 minutes (i.e. after the solvent had 
been evaporated to dryness, Entry 12).  
In order to explore the reason for the increase in reduction efficiency on the rotary 
evaporator, the reaction was performed with varying iodide concentrations at 
atmospheric pressure. As shown in Table 4.2, the reaction was accelerated by 
increasing the concentration of iodide from 1 M to 4 M. The use of 4 M iodide and 2 
equivalents of acid resulted in the complete conversion of azide to amine in 15 minutes 












Table 4.2 Study of the effects of iodide concentration on reaction efficiency 
 
To examine any inhibitory effect of iodine (a by-product of the reaction) on the 
reduction process, Entry 10 (Table 4.1) was repeated with 6 equivalents of iodine 
also present. This reaction also resulted in 100% conversion to amine after 1 h. This 
result demonstrates that the formation of iodine during the reaction does not influence 
the transformation.  
The possibility of carrying out the reduction using different acids of varying strengths 





















5 1 M 8 2 CD3OD rt 
0.25 h 15 
0.5 h 38 
1 h 59 
5 2 M 8 2 CD3OD rt 
0.25 h 50 
0.5 h 90 
1 h 96 
5 4 M 8 2 CD3OD rt 0.25 h 100 






Table 4.3 Variation of acid used for the azide reduction 
 
The use of the strong acid HCl also caused complete conversion to the desired amine. 
However, weak acids such as trifluoroacetic acid and acetic acid diminished the 
conversion; trifluoroacetic acid gave only 54% conversion and no reaction was 
observed when AcOH was used as the proton source. These results demonstrate that 
the pKa of the acid plays an important role in the transformation of the azide to the 
amine; the efficiency of the reduction was significantly reduced using acids with 
higher pKa (e.g. AcOH, pKa 4.76), which suggests protonation of the nitrogen is 











pKa of acid 
Amberlite (IR-120 H
+
 form) 100  - 
HCl 100  -8.0 
TFA 54  -0.25 
AcOH - 4.76 









Scheme 4.2 Proposed mechanism for the reduction of azides to amines. 
 
Amberlite IR 120 (H
+
 form) was used as the source of acid in all subsequent 
reactions. As Amberlite can be recycled, the reaction efficiency was also tested with 
recycled Amberlite. In this process, Entry 12 (Table 4.1) was repeated three times 
using the same Amberlite resin, which was regenerated after each reaction using the 
standard method (i.e. using 1 M aqueous HCl). As can be seen in the Table 4.4, 80% 














1 4 2 CH3OH 40 0.25 h 100 
2 4 2 CH3OH 40 0.25 h 80 
3 4 2 CH3OH 40 0.25 h 80 
 





Having optimized the reaction conditions, the procedure was then applied to a variety 
of organoazides bearing different function groups. The azides were synthesised either 
from the corresponding alcohols or halides.  
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 4.3  Synthesis of azides for reduction.  
 
The substrates 4.2a, 4.19a and 4.20a (Table 4.5) were synthesised as described in 
Chapters 2 and 3. The other substrates were synthesised as shown in Scheme 4.3 and 
Scheme 4.4. 
Scheme 4.3 (i) PPh3, I2, Imidazole, THF, 50 °C, 16 h, 74 %; (ii) NaN3, DMF, 50 °C, 
16 h, 4.5a – 74 %; 4.8a – 95 % (iii) MsCl, Et3N, DCM, 2 h. 
 
The azides 4.5a and 4.8a were synthesised in two steps; firstly, primary alcohols 4.3 
was iodinated with PPh3, I2, and imidazole using the Appel reaction, to afford iodides 
4.4. Primary alcohol of 4.6 was mesylated using methanesulfonyl chloride and 
triethylamine yielded mesylate 4.7. The compound 4.4 and 4.7 were then converted to 
azides 4.5a and 4.8a using nucleophilic substitution with NaN3.  Similarly, azides 
4.13a-4.16a and 4.18a were also synthesized by nucleophilic substitution using NaN3 
and the commercially available halides 4.9-4.12 and 4.17 (Scheme 4.4).  




Scheme 4.4 (i) NaN3, DMF, 50 °C, 16 h, 4.13a – 68 %; 4.14a – 70 %; 4.15a – 67 %; 
4.16a – 71 %; 4.18a – 80 %. 
  
 4.4  Reduction of azides to primary amines with different 
functional groups 
 
From the optimization of the reaction discussed above, the NaI/Amberlite IR 120 (H
+
 
form) procedure on a rotary evaporator was the most efficient method for the selective 
transformation of azides to primary amines. With these conditions, the scope of the 
reduction was studied with several azides comprising other functional groups, such as 
benzyl ethers, alkenes, glycosides and nucleoside glycosidic linkages.  
As can be seen from Table 4.5, ten azides with different functionality underwent 
smooth reduction using 4 equivalents of iodide and 2 equivalents of acid at 40 °C at a 
pressure of 200 mbar. MeOH was used as a solvent for the polar azides, and a mixture 
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of MeOH/CHCl3 was used for less polar compounds due to poor solubility of these 
azides in MeOH.  
The reaction products were purified by ion exchange chromatography. For the 
purification method, an excess of Amberlite was added after the reaction was 
completed, then the Amberlite was washed with water to remove all other salts and 
impurities. Finally, a 2.5 M ammonia solution in MeOH was used to elute the desired 
product, which in all cases was isolated in excellent yield. The products could also be 
purified by silica-gel flash column chromatography following the removal of resin by 
filtration. 
The scope of the reduction was only studied for monosaccharides. This reduction 
required strong acidic conditions, and therefore this method could be problematic for 
oligosaccharides, particularly with glycans containing furanosidic, fucosidic, or 
rhamnosidic bonds, which could be hydrolysed under acidic conditions. 
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 4.5  Conclusions 
 
A simple, efficient, and mild reduction method for the conversion of azides into 
amines was developed, which is low cost, is easily removed from the reaction by 
filtration, and displays high chemoselectivity. The reduction is highly efficient when 
performed at 40 °C, 200 mbar with four equivalents of iodide and two equivalents of 
acid. In addition, optimization of the iodide concentration revealed that the efficiency 
of the reaction depends on the iodide concentration. Complete conversion to product 
was observed when the reaction was performed with an iodide concentration of 4 M 
and two equivalents of Amberlite IR120 (H
+
 form).  Other strong acids could also be 
used for the reduction. However, the process is simple, rapid and clean when 
Amberlite ion exchange resin is used as a proton source. The resin can be recycled 
effectively, and also used for the purification of the polar amine products. This new 
reduction method has good functional group tolerance; for example alkenes, benzyl 
ethers, glycosides, sulfonyl groups, and nitro groups are all unaffected by the process. 
 




Chapter 5 Experimental section 
 
5.1  General chemical experimental 
 
Melting points were recorded on an Electrothermal
®
 melting point apparatus. Proton 
and carbon nuclear magnetic resonance (H, C) spectra were recorded on Bruker AV 
400 (400 MHz), or Bruker AV 500 (500 MHz) spectrometers. All chemical shifts are 
quoted on the -scale in ppm using residual solvent as an internal standard. High-
resolution mass spectra were recorded on a Bruker FT-ICR electrospray ionisation 
mass spectrometer, using either electrospray ionisation techniques as stated. M/z 
values are reported in Daltons and are followed by their percentage abundance in 





) were measured on a Perkin-
Elmer 241 polarimeter with a path length of 1 dm. Concentrations are given in g / 
100 mL. Thin Layer Chromatography (t.l.c.) was carried out on Merck Silica gel 
60F254 aluminium-backed plates. Visualisation of the plates was achieved using a u.v. 
lamp (max = 254 or 365 nm), and/or ammonium molybdate (5% in 2 M sulfuric 
acid), or sulfuric acid (5% in ethanol). Infrared spectra were recorded on a Bruker 
FTIR spectrometer with Alpha‟s Platinum ATR single reflection diamond where the 
neat samples were recorded. Flash column chromatography was carried out using 
Sorbsil C60 40/60 silica. Reverse phase high performance liquid chromatography 
(RP-HPLC) was performed on a Dionex P680 HPLC instrument with a Phenomenex 
Luna C 18(2) 100 A column (5 µm, 10 x 250 mm) at 15 °C. The column was eluted 
with a gradient of MeCN/H2O at a flow rate of 1 mLmin
-1
. Alcohol-free 
dichloromethane was dried on an alumina column. Anhydrous DMF, pyridine, 
methanol and toluene were purchased from Sigma Aldrich. „Petrol‟ refers to the 
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fraction of light petrol ether boiling in the range of 40-60 °C. Elemental analysis was 
performed by Campbell microanalytical laboratory, University of Otago. 
 
5.2  Experimental for chapter 2 
 
General Procedures 
General Procedure A 
Tert-butyl alcohol (1.5 equiv) was added dropwise to a stirred solution of 
chlorosulfonyl isocyanate (1 equiv) in dry DCM (15 mL) at 0 ˚C under nitrogen. The 
solution was stirred for a further 30 minutes at 0 ˚C before a solution of the amine (1 
equiv) and dry triethylamine (1.5 equiv) in dry DCM (15 mL) was added dropwise. 
The reaction mixture was allowed to warm to room temperature, and then stirred for 
16 hours. The reaction mixture was then diluted with DCM (20 mL), washed with 
saturated aqueous NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered, and concentrated in vacuo to 
give a residue that was then purified by flash chromatography. 
 
General Procedure B: 
Trifluoroacetic acid (4.5 equiv) was added to a solution of sulfamide (1 equiv) in 
DCM (25 mL). The solution was stirred at room temperature for 16 hours. The 
reaction mixture was concentrated in vacuo, and the residue then purified by flash 
chromatography. 
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General Procedure C: 
2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 2.7 (1 equiv), and the sulfamide (1.2 
equiv), and crushed activated 3Å molecular sieves (~ 400 mg) were stirred at room 
temperature in dry DCM (15 mL) under nitrogen. TMSOTf (1 equiv) was added 
dropwise, and the mixture was then stirred for 16 hours. The reaction was neutralized 
by the dropwise addition of excess triethylamine (0.3 mL). The reaction mixture was 
then filtered through Celite
®
, eluting with ethyl acetate, and concentrated in vacuo to 
give a residue which was purified by flash chromatography. 
 
General Procedure D: 
Methanesulfonyl chloride (1.5 equiv) was added dropwise to a stirred solution of 
alcohol (1 equiv) and Et3N (1.5 equiv) in anhydrous DCM (30 mL) at 0 ˚C under 
nitrogen. The reaction was allowed to warm to room temperature, and stirred for 2 
hours. The reaction mixture was poured into methanol (10 mL), and concentrated in 
vacuo. The reaction mixture was then diluted with diethyl ether (20 mL), washed with 
water (3 x 20 mL) and brine (3 x 20 mL). The combined organic extracts were then 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
dissolved in DMF (25 mL), sodium azide (3 equiv.) was added, and the mixture was 
stirred at 60 ˚C for 16 hours. The reaction mixture was concentrated in vacuo, and 
The reaction mixture was then diluted with diethyl ether (50 mL), washed with water 
(3 x 20 mL) and brine (3 x 30 mL), dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo, which was purified by flash chromatography. 
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General Procedure E: 
Triphenylphosphine (2 equiv) and water (1.5 equiv) were added to a stirred solution 
of azide (1 equiv) in THF (25 mL) under nitrogen. The reaction was stirred under 
nitrogen for 16 hours. The reaction mixture was concentrated in vacuo, which was 
then purified by flash chromatography. 
 
General Procedure F: 
10 % Activated Pd-C (20 mg) was added to a solution of the protected glycosyl 
sulfamide (0.1 mmol) in methanol (5 mL). The flask was evacuated and purged with 
nitrogen five times, before it was placed under an atmosphere of hydrogen. The 
solution was stirred for 16 hours at room temperature. The reaction mixture was 
filtered through Celite
®
 (eluting with methanol 20 mL), and concentrated in vacuo to 
give a residue which was purified by flash column chromatography. 
 
General Procedure G: 
Sodium hydride (60 % dispersion in mineral oil, 0.5 equiv) was added portionwise to 
a solution of triethyleneglycol (1 equiv) in THF (50 mL) under nitrogen. The reaction 
was stirred for 1 hour and then cooled to 0 ˚C. Benzyl bromide (0.5 equiv) was then 
added dropwise, and the reaction mixture was warmed to room temperature and then 
stirred for 16 hours. The reaction mixture was cooled in an ice bath quenched by the 
addition of methanol (20 mL), and then concentrated in vacuo. The residue was 
dissolved in DCM (30 mL), and washed with water (30 mL). The combined organic 
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extracts were dried over anhydrous MgSO4, filtered, and concentrated in vacuo, which 







Acetyl chloride (3.08 mL, 43 mmol) was added dropwise to a solution of D-arabinose 
(5.0 g, 33 mmol) in methanol (100 mL) under nitrogen. The reaction was stirred for 3 
hours at room temperature. After this time, t.l.c. (DCM: MeOH, 4:1) indicated the 
formation of two products, a major product (methyl α,β-D-arabinofuranoside, Rf 0.5) 
and the complete consumption of starting material (Rf 0.2). The reaction mixture was 
neutralized by adding solid K2CO3 (~7 g), filtered, concentrated in vacuo, and the 
residue was co-evaporated with toluene (3 x 50 mL) to afford a crude mixture of 
methyl α,β-D-arabinofuranoside and methyl α,β-D-arabinopyranoside as a brown oil 
which was used in the next step without further purification. Sodium hydride (60 % 
dispersion in mineral oil, 8.2 g, 205 mmol) was added dropwise to a solution of the 
mixture produced above (5.6 g, 34 mmol) in DMF (60 mL) under nitrogen. The 
reaction was stirred for 1 hour and then cooled to 0 °C. Benzyl bromide (24.3 mL, 
205 mmol) was then added dropwise. The reaction mixture was warmed to room 
temperature and then stirred for 16 hours. After this time, t.l.c. (petrol: ethyl acetate, 
7:1) indicated the formation of a major product (Rf 0.2), and the complete 
consumption of starting material (Rf 0.0). The reaction was cooled in an ice bath, 
quenched by the addition of methanol (90 mL), and then concentrated in vacuo. The 
residue was dissolved in diethyl ether (50 mL), and washed with brine (3 x 50 mL). 
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The combined organic extracts were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo to afford a yellow oil, which was purified by flash 
chromatography (petrol: ethyl acetate, 7:1) to afford methyl 2,3,5-tri-O-benzyl-α,β-D-
arabinofuranoside  2.7 (7.7 g, 54 %, α:β, 3:1) as a clear oil. δH (500 Hz, CDCl3) α-
anomer: 3.42 (3H, s, OCH3), 3.64 (2H, at, J 4.8 Hz, H-5, H-5‟), 3.94 (1H, dd, J3,4 6.2 
Hz, J2,3 2.8 Hz, H-3), 4.03 (1H, m, H-2), 4.25 (1H, td, J4,5 5.4 Hz, J4,5‟ 5.4 Hz, J3,4 4.8 
Hz, H-4), 4.56-4.59 (6H, m, PhCH2), 4.98 (1H, s, H-1), 7.26-7.39 (15H, m, Ar-H); β 
anomer: 3.35 (3H, s, OCH3), 3.56 (1H, dd, J5,5‟ 8.9 Hz, J 4,5 6.0 Hz, H-5), 3.61 (1H, d, 
J4,5‟ 5.4 Hz, H-5‟), 4.08-4.12 (1H, m, H-4), 4.13-4.14 (1H, m, H-2), 4.15-4.17 (1H, m, 
H-3), 4.51 (5H, ABq, J 9.8 Hz, PhCH2) 4.62-4.66 (1H, m, PhCH2), 4.76 (1H, d, J 4.2 
Hz, H-1), 7.26-7.39 (15H, m, Ar-H); HRMS (ESI) calculated for C27H30NaO5: 










Methyl 2,3,5-tri-O-benzyl-α,β-D-arabinofuranoside  2.7 (7.7 g, 18 mmol) was 
dissolved in a mixture of water and acetic acid (100 mL, 1:4, v/v), and then stirred at 
115 ˚ C for 2 days. After this time, t.l.c. (petrol: ethyl acetate 3:1) indicated the 
formation of a single product (Rf 0.2), and the complete consumption of starting 
material (Rf 0.6). The reaction was quenched by the addition of ice water (100 mL), 
and extracted with diethyl ether (3 x 50 mL). The combined organic extracts were 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo to afford a yellow 
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oil, which was purified by flash chromatography (petrol: ethyl acetate, 3:1) to afford 
2,3,5-tri-O-benzyl-α,β-D-arabinofuranose 2.6 (4.8 g, 64 %, α:β, 1:1) as a white 
crystalline solid. δH (500 MHz, CDCl3) α anomer: 3.52-3.62 (2H, m, H-5, H-5‟), 3.93-
3.95 (1H, m, H-3), 3.98-3.99 (1H, m, H-2), 4.46-4.48 (1H, m, H-4), 4.51-4.67 (6H, m, 
PhCH2), 5.40 (1H, s, H-1), 7.26-7.37 (15H, m, Ar-H); β anomer: 3.52-3.62 (2H, m, H-
5, H-5‟), 4.02 (1H, d, J 4.5 Hz, H-2), 4.09 (1H, aq, J 4.3 Hz, H-4), 4.17 (1H, t, J 4.5 
Hz, H-3), 5.33 (1H, d, J1,2 3.2 Hz, H-1), 4.51-4.67 (6H, m, PhCH2), 7.26-7.37 (15H, 










General procedure G, using triethyleneglycol 2.10b, and purification by flash 
chromatography (petrol: ethyl acetate, 2:1, Rf 0.2), afforded benzyl ether 2.11b (6.56 
g, 36 %) as a pale yellow oil. δH (400 MHz, CDCl3)
137
 2.75 (1H, s, OH), 3.58-3.71 
(12H, m, 6 x OCH2), 4.55 (2H, s, PhCH2), 7.26-7.33 (5H, m, Ar-H); HRMS (ESI) 













General procedure D, using alcohol 2.11a, and purification by flash chromatography 
(petrol: ethyl acetate, 1:1, Rf 0.8), afforded azide 2.12a (0.45 g, 94 %) as a clear oil. 
υmax (neat) 2099 (s, N3) cm
-1
; δH (500 MHz, CDCl3) 3.39 (2H, t, J 5.0 Hz, CH2N3), 
3.64-3.69 (6H, m, 3 x CH2), 4.58 (2H, s, PhCH2), 7.27-7.35 (5H, m, Ar-H); δC (125 
MHz, CDCl3) 50.7 (t, CH2N3), 69.4, 70.0, 70.7 (3 x t, 3 x CH2), 73.3 (t, PhCH2), 
127.6, 127.7, 128.4 (3 x d, 5 x Ar(C)H), 138.1 (s, Ar-C); HRMS (ESI) calculated for 








General procedure D, using alcohol 2.11b, and purification by flash chromatography 
(petrol: ethyl acetate, 1:1, Rf 0.4), afforded azide 2.12b (4.38 g, 98 %) as a clear oil. 
υmax (neat) 2097 (s, N3) cm
-1
; δH (400 MHz, CDCl3) 3.36 (2H, t, J 4.0 Hz, CH2N3), 
3.63-3.68 (10H, m, 5 x CH2), 4.56 (2H, s, PhCH2), 7.26-7.34 (5H, m, Ar-H); δC (125 
MHz, CDCl3) 50.6 (t, CH2N3), 69.4, 70.0, 70.6, (3 x t, 5 x CH2), 73.2 (t, PhCH2), 
127.5, 127.7, 128.3 (3 x d, 5 x Ar(C)H), 138.2 (s, Ar-C); HRMS (ESI) calculated for 










General procedure D, using alcohol 2.11c, and purification by flash chromatography 
(petrol: ethyl acetate, 1:1, Rf 0.5), afforded azide 2.12c (0.54 g, 91 %) as a clear oil. 
υmax (neat) 2097 (s, N3) cm-1; δH (500 MHz, CDCl3) 3.37 (2H, t, J 5.0 Hz, CH2N3), 
3.63-3.66 (14H, m, 7 x CH2), 4.56 (2H, s, PhCH2), 7.26-7.33 (5H, m, Ar-H); δC (125 
MHz, CDCl3) 50.7 (t, CH2N3), 69.5, 70.1, 70.5, 70.6, 70.7, 70.8, 70.9 (7 x t, 7 x CH2), 
73.3 (t, Ph-CH2), 127.9, 128.3, 128.6 (3 x d, 3 x Ar(C)H), 138.3 (s, Ar-C); HRMS 







General procedure E, using azide 2.12a, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.1), afforded amine 2.13a (0.25 g, 71 %) as a clear oil. υmax 
(neat) 3260 (w, NH2) cm
-1
 ; δH (500 MHz, CDCl3) 2.09 (2H, s, NH2), 2.85 (2H, t, J 
5.0 Hz, CH2N), 3.50 (2H, t, J  5.0 Hz, OCH2), 3.62-3.64 (4H, m, 2 x CH2) 4.56 (2H, s, 
PhCH2), 7.25-7.34 (5H, m, Ar-H); δC (125 MHz, CDCl3) 41.3 (t, CH2N), 69.4, 70.3 (2 
x t, 2 x CH2), 72.3 (t, OCH2), 73.3 (t, Ph-CH2), 127.7, 127.8, 128.3, 128.3, 128.4 (5 x 











General procedure E, using azide 2.12b, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.1), afforded amine 2.13b (3.10 g, 80 %) as a clear oil. υmax 
(neat) 3260 (w, NH2) cm
-1
 ; δH (400 MHz, CDCl3)
41
 1.81 (2H, s, NH2), 2.84 (2H, t, J 
6.0 Hz, CH2N), 3.41 (2H, t, J 8.0 Hz, OCH2), 3.61-3.67 (8H, m, 4 x CH2) 4.55 (2H, s, 
PhCH2), 7.24-7.32 (5H, m, Ar-H); δC (125 MHz, CDCl3) 41.7 (t, CH2N), 69.4, 70.3, 
70.6 (3 x t, 5 x CH2), 73.2 (t, PhCH2), 127.6, 127.7, 128.3 (3 x d, 5 x Ar(C)H), 138.2 








General procedure E, using azide 2.12c, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.1), afforded amine 2.13c (0.23 g, 67 %) as a clear oil. υmax 
(neat) 3264 (w, NH2) cm
-1
; δH (500 MHz, CDCl3) 2.23 (2H, s, NH2), 2.79 (2H, t, J 5.0 
Hz, CH2N), 3.52 (2H, t, J 5.0 Hz, OCH2), 3.62-3.68 (12H, m, 6 x CH2) 4.56 (2H, s, 
PhCH2), 7.25-7.34 (5H, m, Ar-H); δC (125 MHz, CDCl3) 40.9 (t, CH2N), 69.4, 69.6, 
70.3, 70.4, 70.4, 70.6, 71.0 (7 x t, 7 x CH2), 73.2 (t, PhCH2), 127.8, 128.0, 128.3 (3 x 










General procedure D, using alcohol 2.14a, and purification by flash chromatography 
(petrol, Rf 0.9), afforded azide 2.15a (4.26 g, 75 %) as a clear oil. υmax (KBr) 2096 (s, 
N3) cm
-1
; δH (500 MHz, CDCl3) 0.85-0.89 (9H, m, 3 x CH3), 1.11-1.15 (2H, m, CH2), 
1.21-1.31 (2H, m, CH2), 1.35-1.41 (2H, m, CH2), 1.48-1.50 (2H, m, CH2), 1.51-1.64 
(2H, m, 2 x CH), 3.23-3.29 (2H, m, CH2N3); δC (125 MHz, CDCl3) 19.3, 22.6, 22.7 (3 
x q, 3 x CH3), 24.6 (t, CH2), 27.9, 30.3 (2 x d, 2 x CH), 35.7, 37.0, 39.2 (3 x t, 3 x 
CH2), 49.5 (t, CH2N3); Micro elemental analysis requires for C10H21N3: C 65.53 %, H 





General procedure D, using 3,7-dimethyloct-6-en-1-ol 2.14b, and purification by flash 
chromatography (petrol; Rf 0.5), afforded azide 2.15b (1.1 g, 56 %) as a clear oil. υmax 
(neat) 2089 (s, C-N3) cm
-1
 ; δH (400 MHz, CDCl3) 0.91 (3H, d, J 8.0 Hz, CHCH3), 
1.18-1.43 (4H, m, 2 x CH2), 1.55-1.69 (8H, m, CH2, 2 x CH3), 1.96- 2.01 (2H, m, 
=CHCH2), 3.28 (2H, m, CH2N3), 5.09 (1H, t, J 8.0 Hz, =CH); δC (125 MHz, CDCl3) 
17.6, 19.1, 25.3 (3 x q, 3 x CH3), 25.6 (t, =CHCH2), 29.9, 35.6, 36.8 (3 x t, 3 x CH2), 
49.5 (t, CH2N3), 124.4 (d, =CH), 131.4 (s, C(CH3)2). Micro elemental analysis 
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requires for C10H19N3 C 66.26 %, H 10.56 %, 23.18 %; found C 65.59 %, H 10.43 %, 








Methanesulfonylchloride (1.31 mL, 17 mmol) was added dropwise to a stirred 
solution of (E)-3,7-dimethylocta-2,6-dien-1-ol 2.14c (2 mL, 11 mmol) and Et3N (2.35 
mL, 17 mmol) in anhydrous DCM (30 mL) at 0 ˚C under nitrogen. The reaction was 
allowed to warm n to room temperature and stirred for 2 hours. After this time, t.l.c 
(Petrol: Ethyl acetate, 1:1) indicated the formation of a single product (Rf 0.9), and 
complete consumption of starting material (Rf 0.6). The reaction mixture was poured 
into methanol (20 mL), and extracted with diethyl ether (3 x 50 mL). The combined 
organic extracts were then dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo. The residue was dissolved in DMF (30 mL) and potassium phthalimide (4.2 g, 
34 mmol, 2 equiv.) was added. The resulting solution was stirred at 70 °C for 16 
hours. After this time, t.l.c (Petrol: Ethyl acetate, 3:1) indicated the formation of a 
single product (Rf 0.6), and complete consumption of starting material (Rf 0.4). The 
reaction mixture was cooled, poured into water (30 mL), and extracted with diethyl 
ether (3 x 50 mL). The combined organic extracts were dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo to afford a yellow solid, which was purified by 
flash chromatography (Petrol: Ethyl acetate, 3:1) to afford phthalimide 2.15c (1.94 g, 
60 %) as pale yellow solid. m.p 62-65 °C (EtOAc/petrol); δH (400 MHz, CDCl3) 1.47, 
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1.53, 1.75 (9H, 3 x s, 3 x CH3), 1.93-1.99 (4H, m, 2 x CH2), 4.17 (2H, d, J 8 Hz, 
CH2N), 4.95, 5.20 (2H, 2 x t, J  8 Hz, C=CH), 7.60,7.72 (4H, 2 x d, J1,2 4 Hz, J1,3 8 
Hz, Ar-H); HRMS (ESI) calculated for C18H21NNaO2 (M+Na
+






General procedure E, using azide 2.15a, and purification by flash chromatography 
(petrol: EtOAc, 2:1, Rf 0.2), afforded amine 2.16a (1.6 g, 63 %) as a clear oil. υmax 
(neat) 3260 (w, C-NH2) cm
-1
; δH (500 MHz, CDCl3) 0.81-0.83 (9H, m, 3 x CH3), 
1.10-1.27 (8H, m, 4 x CH2), 1.40-1.49 (2H, m, 2 x CH), 1.89 (s,NH2), 2.69 (2H, m, 
CH2N);  δC (125 MHz, CDCl3) 19.6, 22.6, 22.7 (3 x q, 3 x CH3), 24.6 (t, CH2), 27.9, 
30.4 (2 x d, 2 x CH), 37.3, 39.2, 39.9 (3 x t, 3 x CH2), 40.7 (t, CH2N); HRMS (ESI) 








General procedure E, using azide 2.15b, and purification by the flash chromatography 
(DCM: MeOH, 19:1; Rf 0.0), afforded amine 2.16b (0.66 g, 71 %) as a yellow oil. 
υmax (neat) 3260 (w, C-NH2) cm
-1
; δH (400 MHz, CDCl3) 0.89 (3H, d, J 4.0 Hz, CH3), 
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1.15, 1.30, 1.50 (6H, m, 3 x CH2), 1.60, 1.68 (6H, 2 x s, 2 x CH3), 1.79 (2H, s, NH2), 
1.97 (2H, m, =CHCH2), 2.72 (2H, m, CH2N3), 5.09 (1H, t, J 8.0 Hz, =CH); δC (125 
MHz, CDCl3) 17.6, 19.5, 25.4 (3 X q, 3 X CH3), 25.6 (t, =CHCH2), 30.1, 37.1, 39.8 (3 
x t, 3 x CH2), 40.7 (t, CH2N3), 124.7 (d, =CH), 131.1 (s, C(CH3)2). HRMS (ESI) 
calculated for C10H22N (M+H
+









N2H4.H2O (0.7 mL, 14 mmol, 2 equiv.) was added to phthalimide 2.15c (1.9 g , 7 
mmol) in ethanol (60 mL) and then the mixture was refluxed for 16 hours. After this 
time, t.l.c (DCM: MeOH 19:1) indicated the formation of a single product (Rf 0.2), 
and complete consumption of starting material (Rf 0.9). The reaction mixture was 
cooled, and was extracted with diethyl ether (3 x 50 mL). The combined organic 
extracts were then dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
The residue was then purified by flash chromatography (DCM: MeOH, 19:1) to 
afford amine 2.16c (0.45 g, 43 %) as yellow oil. δH (400 MHz, CDCl3)
138
 1.58, 1.61, 
1.66 (9H, 3 x s, 3 x CH3), 2.03-2.07 (4H, m, 2 x CH2), 3.26 (2H, m, CH2N), 5.07, 5.24 
(2H, 2 x t, J 8.0 Hz, 2 x =CH). HRMS (ESI) calculated for C10H20N (M+H
+
) 
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tert-Butyl N-3,7-dimethyloctylsulfamoylcarbamate 2.18j 
 
 
General procedure A, using amine 2.16a, and purification by flash chromatography 
(DCM, Rf 0.4), afforded sulfamoylcarbamate 2.18j (646 mg, 73 %) as a colourless 
solid; υmax (neat) 3250 (N-H), 1697 (s, C=O), 1345 (s, S=O), 1137 (s, S=O) cm
-1
; δH 
(500 MHz, CDCl3) 0.85-0.88 (9H, m, 3 x CH3), 1.11-1.15 (2H, m, CH2), 1.21-1.31 
(2H, m, CH2), 1.35-1.41 (2H, m, CH2), 1.49 (9H, s, 3 x CH3), 1.51-1.64 (4H, m, 2 x 
CH, CH2), 3.04-3.11 (2H, m, CH2NHSO2), 5.19 (1H, br. s, CH2NHSO2); δC (125 
MHz, CDCl3) 19.2, 22.6, 22.7 (3 x q, 3 x CH3), 24.5 (t, CH2), 27.9 (d, CH), 28.0 (q, 
(C(CH3)3), 30.2 (d, CH), 36.1, 37.0, 39.2 (3 x t, 3 x CH2), 42.0 (t, NHCH2), 83.7 (s, 









General procedure A, using amine 2.13a, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.5), afforded sulfamoylcarbamate 2.18k (0.36 g, 93 %) as a 
white solid. m.p. 68-70 °C (petrol/ EtOAc);  υmax (neat) 1708 (s, C=O), 1351 (s, S=O), 
1139 (s, S=O) cm
-1
; δH (500 MHz, CDCl3) 1.46-1.48 (9H, s, C(CH3)3), 3.29 (2H, q, J 
5.5 Hz, CH2NH), 3.61-3.64 (6H, m, 3 x CH2), 4.57 (2H, s, PhCH2), 5.63(1H, t, J 10 
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Hz, CH2NH), 7.26-7.35 (5H, m, Ar-H); δC (125 MHz, CDCl3) 27.9 (q, C(CH3)3), 43.6 
(t, CH2NH), 69.3, 70.2 (2 x t, 3 x CH2), 73.3 (t, PhCH2), 83.5 (s, C(CH3)3), 127.7, 
127.9, 128.4 (3 x d, 3 x Ar(C)H), 138.0 (s, Ar-C), 150.4 (s, C=O); HRMS (ESI) 








General procedure A, using amine 2.13b, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.4), afforded sulfamoylcarbamate 2.18l (1.35 g, 39 %) as a 
clear oil. υmax (neat) 1715 (s, C=O), 1350 (s, S=O), 1150 (s, S=O) cm
-1
; δH (500 MHz, 
CDCl3)
41
 1.44-1.47 (9H, s, C(CH3)3), 3.27-3.30 (2H, m, CH2NH), 3.61-3.67 (10H, m, 
5 x CH2), 4.57 (2H, s, Ph-CH2), 7.26-7.34 (5H, m, Ar-H); δC (125 MHz, CDCl3) 28.0 
(q, C(CH3)3), 43.6 (t, CH2NH), 69.3, 70.1, 70.6 (3 x t, 5 x CH2), 73.2 (t, PhCH2), 83.2 
(s, C(CH3)3), 127.6, 127.8, 128.3 (3 x d, 5 x Ar(C)H), 138.1 (s, Ar-C), 150.4 (s, 















General procedure A, using amine 2.13c, and purification by flash chromatography 
(DCM: MeOH, 19:1, Rf 0.3), afforded sulfamoylcarbamate 2.18m (0.33 g, 91 %) as a 
clear oil. υmax (neat) 1729 (s, C=O), 1350 (s, S=O), 1090 (s, S=O) cm
-1
; δH (400 MHz, 
CDCl3) 1.47 (9H, s, C(CH3)3), 3.29 (2H, m, CH2NH), 3.59-3.68 (14H, m, 7 x CH2), 
4.57 (2H, s, PhCH2), 7.25-7.34 (5H, m, Ar-H); δC (125 MHz, CDCl3) 28.1 (q, 
C(CH3)3), 43.7 (t, CH2NH), 69.4, 70.1, 70.6 (3 x t, 7 x CH2), 73.2 (t, PhCH2), 83.2 (s, 
C(CH3)3), 127.6, 127.8, 128.3 (3 x d, 3 x Ar(C)H, 138.2 (s, Ar-C), 150.5 (s, C=O); 








General Procedure B, using sulfamoylcarbamate 2.18a, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.3), afforded sulfamide 2.19a (280 mg, 86 
%) as a white solid; m.p. 67-70 °C (DCM); υmax (neat) 3331 (N-H), 3289 (N-H), 1357 
(s, S=O), 1130 (s, S=O); δH (400 MHz, CDCl3) 0.89 (3H, t, J 6.4 Hz, CH3), 1.28-1.37 
 Chapter 5 
122 
 
(6H, m, 3 x CH2), 1.53-1.61 (2H, m, NHCH2CH2), 3.13 (2H, t, J 7.2 Hz, CH2NHSO2), 
4.52 (2H, br s, NH2); δC (100.5 MHz, CDCl3) 13.9 (q, CH3), 22.5, 26.3, 29.4, 31.3, (4 
x t, 4 x CH2), 43.7 (t, CH2NH); HRMS (ESI) calculated for C6H16N2NaO2S: 








General Procedure B, with sulfamoylcarbamate 2.18b, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.3), afforded sulfamide 2.19b (472 mg, 69 
%) as a white solid; m.p. 82-85 °C (DCM); υmax (neat) 3330 (N-H), 3283 (N-H), 1345 
(s, S=O), 1135 (s, S=O); δH (400 MHz, DMSO) 0.85 (3H, t, J 6.8 Hz, CH3), 1.18-1.30 
(10H, m, 5 x CH2), 1.41-1.46 (2H, m, NHCH2CH2), 2.82 (2H, aq, J 6.7 Hz, 
CH2NHSO2), 6.37 (1H, t, J 5.5 Hz, SO2NH), 6.40 (2H, s, NH2); δC (100.5 MHz, 
DMSO) 14.4 (q, CH3), 22.5, 26.8, 29.1, 29.1, 29.4, 31.7 (6 x t, 6 x CH2), 43.0 (t, 















General Procedure B, using sulfamoylcarbamate 2.18c, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.3), afforded sulfamide 2.19c (536 mg, 76 
%) as a white solid; m.p. 83-86 °C (DCM); υmax (neat) 3330 (N-H), 3270 (N-H), 1342 
(s, S=O), 1135 (s, S=O); δH (400 MHz, DMSO) 0.84 (3H, t, J 6.4 Hz, CH3), 1.18-1.30 
(14H, m, 7 x CH2), 1.39-1.44 (2H, m, NHCH2CH2), 2.82 (2H, aq, J 6.7 Hz, CH2NH), 
6.36 (1H, t, J 5.5 Hz, NH), 6.40 (2H, s, NH2); δC (100.5 MHz, DMSO) 14.4 (q, CH3), 
22.6, 26.8, 29.2, 29.4, 29.5, 31.8 (6 x t, 8 x CH2), 43.0 (t, CH2NH); HRMS (ESI) 








General Procedure B, using sulfamoylcarbamate 2.18d and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.3), sulfamide 2.19d (493 mg, 68 %) as a 
white solid; m.p. 95-96 °C (DCM); υmax (neat) 3338 (N-H), 3278 (N-H), 1345 (s, 
S=O), 1136 (s, S=O); δH (400 MHz, DMSO) 0.84 (3H, t, J 6.4 Hz, CH3), 1.18-1.30 
(18H, m, 9 x CH2), 1.39-1.44 (2H, m, NHCH2CH2), 2.82 (2H, aq, J 6.7 Hz, CH2NH), 
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6.37 (1H, t, J 5.5 Hz, NH), 6.40 (2H, s, NH2); δC (100.5 MHz, DMSO) 14.4 (q, CH3), 
22.5, 26.8, 29.2, 29.5, 29.5, 31.8 (6 x t, 10 x CH2), 43.0 (t, CH2NH); HRMS (ESI) 








General Procedure B, using sulfamoylcarbamate 2.18e, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.4), afforded sulfamide 2.19e (562 mg, 75 
%) as a white solid; m.p. 99-101 °C (DCM); υmax (neat) 3338 (N-H), 3276 (N-H), 
1340 (s, S=O), 1134 (s, S=O); δH (400 MHz, DMSO) 0.84 (3H, t, J 6.4 Hz, CH3), 
1.18-1.32 (22H, m, 11 x CH2), 1.37-1.44 (2H, m, NHCH2CH2), 2.82 (2H, aq, J 6.7 
Hz, CH2NH), 6.36 (1H, t, J 5.5 Hz, NH), 6.40 (2H, s, NH2); δC (100.5 MHz, DMSO) 
14.4 (q, CH3), 22.5, 26.8, 29.2, 29.2, 29.5, 29.5, 31.7 (7 x t, 12 x CH2), 43.0 (t, 
















General Procedure B, using sulfamoylcarbamate 2.18f, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.5), afforded sulfamide 2.19f (667 mg, 92 
%) as a pale yellow solid; m.p. 55-58 °C (DCM); υmax (neat) 3381 (N-H), 3264 (N-H), 
1350 (s, S=O), 1137 (s, S=O); δH (400 MHz, CDCl3) 0.89 (6H, t, J 6.4 Hz, 2 x CH3), 
1.25-1.32 (12H, m, 6 x CH2), 1.54-1.63 (4H, m, 2 x NCH2CH2), 3.15 (4H, t, J 7.8 Hz, 
2 x CH2N); δC (100.5 MHz, CDCl3) 14.0 (q, 2 x CH3), 22.6, 26.4, 28.1, 31.5 (4 x t, 8 x 









General Procedure B, using sulfamoylcarbamate 2.18g, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.5), afforded sulfamide 2.19g (537 mg, 76 
%) as a pale yellow solid; m.p. 48-50 °C (DCM); υmax (neat) 3381 (N-H), 3264 (N-H), 
1350 (s, S=O), 1137 (s, S=O); δH (400 MHz, CDCl3) 0.88 (6H, t, J 6.4 Hz, 2 x CH3), 
1.27-1.29 (20H, m, 10 x CH2), 1.55-1.63 (4H, m, 2 x NCH2CH2), 3.15 (4H, t, J 7.8 
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Hz, 2 x CH2N); δC (100.5 MHz, CDCl3) 14.1 (q, 2 x CH3), 22.6, 26.8, 28.2, 29.2, 31.8 
(5 x t, 12 x CH2), 48.4 (t, 2 x CH2N); HRMS (ESI) calculated for C16H37N2O2S: 








General Procedure B, using sulfamoylcarbamate 2.18h, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.6), afforded sulfamide 2.19h (521 mg, 66 
%) as a pale yellow solid; m.p. 53-55 °C (DCM); υmax (neat) 3392 (N-H), 3285 (N-H), 
1350 (s, S=O), 1137 (s, S=O); δH (400 MHz, CDCl3) 0.88 (6H, t, J 6.6 Hz, 2 x CH3), 
1.26-1.29 (28H, m, 14 x CH2), 1.54-1.63 (4H, m, 2 x NCH2CH2), 3.15 (4H, t, J 7.8 
Hz, 2 x CH2N); δC (100.5 MHz, CDCl3) 14.1 (q, 2 x CH3), 22.7, 26.8, 28.2, 29.3, 29.6, 
31.9 (6 x t, 16 x CH2), 48.4 (t, 2 x CH2N); HRMS (ESI) calculated for C20H45N2O2S: 




N,N-(Didodecyl)sulfamide  2.19i 
 
 
General Procedure B, using sulfamoylcarbamate 2.18i, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.6), afforded sulfamide 2.19i (632 mg, 78 
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%) as a pale yellow solid; m.p. 58-60 °C (DCM); υmax (neat) 3392 (N-H), 3285 (N-H), 
1350 (s, S=O), 1137 (s, S=O); δH (400 MHz, CDCl3) 0.88 (6H, t, J 6.6 Hz, 2 x CH3), 
1.25-1.29 (36H, m, 18 x CH2), 1.54-1.62 (4H, m, 2 x NCH2CH2), 3.15 (4H, t, J 7.2 
Hz, 2 x CH2N); δC (100.5 MHz, CDCl3) 14.1 (q, 2 x CH3), 22.7, 26.8, 28.2, 29.3, 
29.6, 29.6, 31.9 (7 x t, 20 x CH2), 48.4 (t, 2 x CH2N); HRMS (ESI) calculated for 








General Procedure B, using sulfamoylcarbamate 2.18j, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.4), afforded sulfamide 2.19j (0.8 g, 98 %) 
as a yellowish brown waxy solid; υmax (neat) 3275 (N-H), 1324 (w, S=O), 1137 (s, 
S=O); δH (500 MHz, CDCl3) 0.85-0.91 (9H, m, 3 x CH3), 1.11-1.15 (2H, m, CH2), 
1.21-1.31 (2H, m, CH2), 1.35-1.41 (2H, m, CH2), 1.48-1.50 (2H, m, CH2), 1.51-1.64 
(2H, m, 2 x CH), 3.10-3.16 (2H, m, CH2NHSO2), 4.40 (1H, s, NH), 4.67 (2H, s, 
NH2); δC (125 MHz, CDCl3) 19.3, 22.6, 22.7 (3 x q, 3 x (CH3)2), 24.6 (t, CH2), 27.9, 
30.4 (2 x d, 2 x CH), 36.5, 37.1 (2 x t, 2 x CH2), 39.2 (t, CH2), 41.8 (t, NHCH2); 













General procedure B, using sulfamoylcarbamate 2.18k, and purification by flash 
chromatography (DCM: MeOH, 19:1, Rf 0.2), afforded sulfamide 2.19k (1.1 g, 88 %) 
as a yellowish brown waxy solid. υmax (neat) 3253 (N-H), 1333 (s, S=O), 1127 (s, 
S=O); δH (400 MHz, CDCl3) 3.34 (2H, t, J 4.0 Hz, CH2NH), 3.61-3.65 (6H, m, 3 x 
CH2), 4.54 (2H, s, PhCH2), 7.26-7.38 (5H, m, Ar-H); δC (125 MHz, CDCl3) 43.1 (t, 
CH2NH), 68.6, 69.7 (2 x t, 3 x CH2), 72.8 (t, Ph-CH2), 127.8, 127.9, 128.4 (3 x d, 5 x 









General procedure B, using sulfamoylcarbamate 2.18l, and purification by flash 
chromatography (petrol: EtOAc, 1:2, Rf 0.3), afforded sulfamide 2.19l (0.76 g, 76 %) 
as a yellow waxy solid. υmax (neat) 3277 (N-H), 1335 (s, S=O), 1132 (s, S=O) cm
-1
; δH 
(400 MHz, CDCl3) 3.32 (2H, t, J 4.7 Hz, CH2NH), 3.62-3.68 (10H, m, 5 x CH2), 4.57 
(2H, s, Ph-CH2), 7.26-7.36 (5H, m, Ar-H); δC (125 MHz, CDCl3) 43.4 (t, CH2NH), 
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69.1, 69.7, 70.2, 70.3 (4 x t, 5 x CH2), 73.1 (t, PhCH2), 127.8, 128.0, 128.4 (3 x d, 5 x 









General procedure B, using sulfamoylcarbamate 2.18m, and purification by flash 
chromatography (petrol: ethyl acetate, 1:2, Rf 0.2), afforded sulfamide 2.19m (0.15 g, 
65 %) as a yellow waxy solid. υmax (neat) 3251 (N-H), 1332 (s, S=O), 1082 (s, S=O) 
cm
-1
; δH (400 MHz, CDCl3) 3.29 (2H, t, J 4.0 Hz, CH2NH), 3.59-3.65 (14H, m, 7 x 
CH2), 4.58 (2H, s, PhCH2), 7.26-7.35 (5H, m, Ar-H); δC (100.5 MHz, CDCl3) 43.6 (t, 
CH2NH), 69.2, 69.6, 69.9, 70.2 (4 x t, 7 x CH2), 73.2 (t, PhCH2), 127.7, 128.1, 128.4 
(3 x d, 3 x Ar(C)H), 137.9 (s, Ar-C); HRMS (ESI) calculated for C15H26N2NaO6S 







General Procedure C, using sulfamide 2.19a, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.4), afforded glycosylsulfamide 2.20a (280 
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mg, 52 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) 3285 (NH), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.89 (3H, t, J 6.8 Hz,  CH3), 
1.24-1.36 (6H, m, 3 x CH2), 1.48-1.55 (2H, m, NHCH2CH2), 3.00-3.04 (2H, m, 
CH2NH), 3.48 (1H, d, J 7.0 Hz, H-5), 3.55 (1H, d, J 5.8 Hz, H-5‟), 3.94-4.03 (2H, m, 
H-2, H-3), 4.34 (1H, d, J 7.0 Hz, H-4), 4.47-4.59 (6H, m, Ph-CH2), 5.44 (1H, d, JNH,1 
11.8 Hz, H-1), 5.52-5.64 (1H, m, NH), 7.16-7.42 (15H, m, Ar-H); β anomer: 0.89 
(3H, m, CH3), 1.24-1.36 (6H, m, 3 x CH2), 1.48-1.55 (2H, m, NHCH2CH2), 3.00-3.03 
(2H, m, CH2NH), 3.53 (2H, dd, J5,5‟ 7.0 Hz, J4,5  5.5 Hz, H-5, H-5‟), 3.94-4.04 (3H, 
m, H-2, H-3, H-4), 4.47-4.59 (6H, m, Ph-CH2), 5.37 (1H, dd, J1,NH 6.8 Hz, J1,2 4.5 Hz, 
H-1), 5.52-5.64 (1H, m, NH), 7.16-7.42 (15H, m, Ar-H); δC (100.5 MHz, CDCl3) 14.0 
(q, CH3), 22.5, 26.3, 29.4, 31.4 (4 x t, 4 x CH2), 43.4, 43.5 (2 x t, NHCH2α, NHCH2β 
), 70.0, 70.1(2 x t, C-5α, C-5β), 71.8, 71.8, 72.0, 72.3, 73.4, 73.4 (6 x t, PhCH2), 80.8 
(d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.4 (C-3β), 83.3 (d, C-4α), 84.3 (d, C-1β), 
84.8 (d, C-3α), 88.2 (d, C-1α), 127.7, 127.7, 127.8, 127.8, 127.9, 127.9, 128.0, 128.0, 
128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.6 (15 x d, 15 x Ar(C)H), 136.7, 136.8, 
136.9, 137.4, 137.6, 137.9 (6 x s, 6 x Ar-C); HRMS (ESI) calculated for 








General Procedure C, using sulfamide 2.19b, and purification by flash 
chromatography (petrol: EtOAc , 2:1, Rf 0.4), afforded glycosylsulfamide sulfamide 
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2.20b (230 mg, 54 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) 3280 (N-H), 1350 
(s, S=O), 1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.88 (3H, t, J 6.6 Hz, 
CH3), 1.19-1.36 (10H, m, 5 x CH2), 1.48-1.55 (2H, m, NHCH2CH2), 2.98-3.03 (2H, 
m, CH2NH), 3.48 (1H, dd, J5,5‟ 9.6 Hz, J4,5‟ 7.6 Hz, H-5), 3.58 (1H, dd, J5,5‟ 9.8 Hz, 
J4,5‟ 5.9 Hz, H-5‟), 3.94-3.97 (1H, m, H-3), 3.98 (1H, at, J 3.1 Hz, H-2), 4.34 (1H, at, J 
6.7 Hz, H-4), 4.40-4.61 (6H, m, Ph-CH2), 5.41 (1H, d, JNH,1 10.6 Hz, H-1), 5.52-5.61 
(1H, m, NH), 7.19-7.44 (15H, m, Ar-H); β anomer: 0.88 (3H, m, CH3), 1.19-1.36 
(10H, m, 5 x CH2), 1.48-1.55 (2H, m, NHCH2CH2), 2.98-3.03 (2H, m, CH2NH), 3.52 
(2H, d, J 5.1 Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 4.01 (1H, at, J1,2 4.3 Hz, H-2), 
4.05 (1H, dd, J4,5 5.1 Hz,J3,4 3.5 Hz, H-4), 4.40-4.61 (6H, m, Ph-CH2), 5.37 (1H, dd, 
JNH,1 10.2 Hz, J1,2 4.3Hz, H-1), 5.52-5.61 (1H, m, NH), 7.19-7.44 (15H, m, Ar-H); δC 
(100.5 MHz, CDCl3) 14.1 (q, CH3), 22.6, 26.7, 29.2, 29.4, 31.8 (5 x t, 6 x CH2), 43.4, 
43.5 (2 x t, NHCH2α, NHCH2β), 70.0, 70.1 (2 x t, C-5α, C-5β), 71.7, 71.8, 72.0, 72.3, 
73.3, 73.4 (6 x t, PhCH2), 80.8 (d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.4 (C-3β), 
83.3 (d, C-4α), 84.2 (d, C-1β), 84.8 (d, C-3α), 88.2 (d, C-1α), 127.7, 127.7, 127.8, 
127.9,127.9, 127.9, 127.9, 128.1, 128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.6 (15 x 
d, 15 x Ar-C), 136.7, 136.7, 136.8, 137.4, 137.7, 137.9 (6 x s, 6 x Ar-C); HRMS (ESI) 







General Procedure C, using sulfamide 2.19c, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.4), afforded glycosylsulfamide 2.20c (470 
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mg, 77 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) ) 3280 (N-H), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.89 (3H, t, J 6.7 Hz, CH3), 
1.24-1.29 (14H, m, 7 x CH2), 1.48-1.53 (2H, m, NHCH2CH2), 2.98-3.03 (2H, m, 
CH2NH), 3.46-3.50 (1H, m, H-5), 3.58 (1H, dd, J5,5‟ 8.6 Hz, J4,5‟ 6.7 Hz, H-5‟), 3.95-
3.97 (1H, m, H-3), 3.98-4.02 (1H, m, H-2), 4.34 (1H, at, J 6.6 Hz, H-4), 4.38-4.63 
(6H, m, Ph-CH2), 5.42 (1H, d, JNH,1 10.5 Hz, H-1), 5.54 (1H, d, JNH,1 11.0 Hz NH), 
7.15-7.40 (15H, m, Ar-H); β anomer: 0.89 (3H, t, J 6.7 Hz, CH3), 1.24-1.29 (14H, m, 
7 x CH2), 1.48-1.53 (2H, m, NHCH2CH2), 2.98-3.03 (2H, m, CH2NH), 3.52-3.54 (1H, 
m, H-5, H-5‟), 3.95-3.97 (1H, m, H-3), 3.98-4.02 (1H, m, H-2), 4.05-4.06 (1H, m, H-
4), 4.38-4.63 (6H, m, Ph-CH2), 5.37 (1H, dd, JNH,1 10.2 Hz, J1,2 4.3 Hz, H-1), 5.52 
(1H, d, JNH,1 10.8 Hz NH), 7.15-7.40 (15H, m, Ar-H); δC (100.5 MHz, CDCl3) 14.1 (q, 
CH3), 22.7, 26.7, 29.2, 29.3, 29.4, 29.5, 29.5, 31.8, (8 x t, 8 x CH2), 43.4, 43.5 (2 x t, 
NHCH2α, NHCH2β), 70.1 (t, C-5α, C-5β), 71.8, 71.8, 72.0, 72.3, 73.3, 73.4 (6 x t, Ph-
CH2), 80.8 (d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.4 (d, C-3β), 83.3 (d, C-4α), 
84.3 (d, C-1β), 84.8 (d, C-3α), 88.2 (d, C-1α), 127.7, 127.7, 127.7, 127.8, 127.9, 
127.9, 128.1, 128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.5, 128.6 (15 x d, 15 x Ar-
C), 136.7, 136.8, 136.9, 137.4, 137.7, 137.9 (6 x s, 6 x Ar-C); HRMS (ESI) calculated 







General Procedure C, using sulfamide 2.19d, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.4), afforded glycosylsulfamide 2.20d (450 
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mg, 71 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) 3286 (N-H), 1344 (s, S=O), 
1151 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.89 (3H, t, J 6.9 Hz, CH3), 
1.20-1.38 (18H, m, 9 x CH2), 1.44-1.65 (2H, m, CH2), 3.00 (2H, t, J 6.7 Hz, CH2NH), 
3.47 (1H, dd, J5,5‟ 9.8 Hz, J4,5‟ 7.4 Hz, H-5), 3.58 (1H, dd, J5,5‟ 9.6 Hz, J4,5‟ 6.1 Hz, H-
5‟), 3.94-3.97 (1H, m, H-3), 3.98 (1H, at, J 3.1 Hz, H-2), 4.34 (1H, at, J 5.9 Hz, H-4), 
4.40-4.67 (6H, m, Ph-CH2), 5.42 (1H, d, JNH,1 10.5 Hz, H-1), 5.57 (1H, at, J 11.3 Hz, 
NH), 7.18-7.41 (15H, m, Ar-H); β anomer: 0.89 (3H, t, J 6.9 Hz, CH3), 1.20-1.38 
(18H, m, 9 x CH2), 1.44-1.65 (2H, m, CH2), 3.00 (2H, t, J 6.7 Hz, CH2NH), 3.52 (2H, 
d, J 5.1 Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 4.01 (1H, at, J1,2 4.3 Hz, H-2), 4.05 
(1H, dd, J4,5 5.1 Hz,J3,4 3.5 Hz, H-4), 4.40-4.67 (6H, m, Ph-CH2),  5.37 (1H, dd, JNH,1 
10.2 Hz, J1,2 4.3Hz, H-1), 5.57 (1H, t, J 11.3 Hz, NH), 7.18-7.41 (15H, m, Ar-H); δC 
(100.5 MHz, CDCl3) 14.1 (q, CH3), 22.7, 26.7, 26.7, 29.2, 29.3, 29.4, 29.6, 29.6, 29.7, 
31.9 (10 x t, 10 x CH2), 43.4, 43.5 (2 x t, NHCH2α, NHCH2β), 70.0, 70.1(2 x t, C-5α, 
C-5β), 71.7, 71.8, 72.0, 72.3, 73.3, 73.4 (6 x t, Ph-CH2), 80.8 (d, C-4β), 81.2, 81.8 (2 
x d, C-2α, C-2β), 82.4 (d, C-3β), 83.3 (d, C-4α), 84.3 (d, C-1β), 84.8 (d, C-3α), 88.2 
(d, C-1α), 127.7, 127.7, 127.8, 127.9, 127.9, 127.9, 128.0, 128.1, 128.2, 128.2, 128.4, 
128.5, 128.5, 128.5, 128.6 (15 x d, 15 x Ar-C), 136.7, 136.7, 136.9, 137.4, 137.7, 
















General Procedure C, sulfamide 2.19e, and purification by flash chromatography 
(petrol: EtOAc, 2:1, Rf 0.4), afforded glycosylsulfamide 2.20e (360 mg, 54 %, α:β, 
1:1) as a yellow waxy solid; υmax (neat) 3280 (N-H), 1350 (s, S=O), 1158 (s, S=O) 
cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.90 (3H, t, J 6.6 Hz, CH3), 1.21-1.38 (22H, m, 
11 x CH2), 1.44-1.74 (2H, m, CH2), 3.01 (2H, t, J 7.2 Hz, CH2NH), 3.49 (1H, dd, J5,5‟ 
9.8 Hz, J4,5‟ 7.4 Hz, H-5), 3.59 (1H, dd, J5,5‟ 9.8 Hz, J4,5‟ 5.9 Hz, H-5‟), 3.94-3.97 (1H, 
m, H-3), 4.00 (1H, at, J 3.1 Hz, H-2), 4.35 (1H, at, J 6.6 Hz, H-4), 4.43-4.65 (6H, m, 
Ph-CH2), 5.43 (1H, d, JNH,1 10.6 Hz, H-1), 5.62 (1H, d, JNH,1 10.9, NH), 7.20-7.46 
(15H, m, Ar-H); β anomer: 0.90 (3H, t, J 6.6 Hz, CH3), 1.21-1.38 (22H, m, 11 x CH2), 
1.44-1.74 (2H, m, CH2), 2.98-3.01 (2H, t, J 7.2 Hz, CH2NH), 3.54 (2H, d, J 5.1 Hz, 
H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 4.03 (1H, at, J1,2 4.3 Hz, H-2), 4.06 (1H, dd, J4,5 
5.1 Hz,J3,4 3.5 Hz, H-4),  4.43-4.65 (6H, m, Ph-CH2), 5.38 (1H, dd, JNH,1 10.4 Hz, J1,2 
4.5Hz, H-1), 5.58 (1H, d, JNH,110.4 Hz NH), 7.20-7.46 (15H, m, Ar-H); δC (100.5 
MHz, CDCl3) 14.1 (q, CH3), 22.7, 26.7, 26.7, 29.2, 29.4, 29.5, 29.5, 29.6, 29.7, 29.7, 
29.7, 31.9 (12 x t, 12 x CH2), 43.4, 43.5 (2 x t, NHCH2α, NHCH2β), 70.1 (t, C-5α, C-
5β), 71.8, 72.0, 72.2, 72.3, 73.4, 73.5 (6 x t, Ph-CH2), 80.8 (d, C-4β), 81.2, 81.8 (2 x 
d, C-2α, C-2β), 82.4 (d, C-3β), 83.2 (d, C-4α), 84.3 (d, C-1β), 84.9 (d, C-3α), 88.2 (d, 
C-1α), 127.7, 127.7, 127.8, 127.8, 127.9, 128.0, 128.2, 128.2, 128.3, 128.4, 128.4, 
128.5, 128.5,128.5, 128.6 (15 x d, 15 x Ar-C), 136.7, 136.8, 136.9, 137.9, 137.9, 
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General Procedure C, using sulfamide 2.19f, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.6), afforded glycosylsulfamide 2.20f (250 
mg, 78 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) 3288 (N-H), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.89 (6H, t, J 6.7 Hz, 2 x CH3), 
1.17-1.37 (12H, m, 6 x CH2), 1.51-1.63 (4H, m, 2 x NCH2CH2), 2.97-3.25 (4H, m, 2 x 
CH2NH), 3.50 (1H, dd, J5,5‟ 9.8 Hz, J4,5‟ 7.8 Hz, H-5), 3.60 (1H, dd, J5,5‟ 9.8 Hz, J4,5‟ 
5.9 Hz, H-5‟), 3.95-3.97 (1H, m, H-3), 3.99-4.02 (1H, m, H-2), 4.35 (1H, at, J 6.7 Hz, 
H-4), 4.42-4.64 (6H, m, Ph-CH2), 5.36 (1H, d, JNH,1 10.5 Hz, H-1), 5.47 (1H, d, JNH,1 
8.0 Hz, NH), 7.18-7.44 (15H, m, Ar-H); β anomer: 0.89 (6H, t, J 6.7 Hz, 2 x CH3), 
1.17-1.37 (12H, m, 6 x CH2), 1.51-1.63 (4H, m, 2 x NHCH2CH2), 2.97-3.25 (4H, m, 2 
x CH2NH), 3.54 (2H, at, J 5.1 Hz, H-5, H-5‟), 3.95-3.97 (1H, m, H-3), 3.99-4.02 (1H, 
m, H-2), 4.03-4.07 (1H, m, H-4), 4.42-4.64 (6H, m, Ph-CH2), 5.31 (1H, dd, JNH,1 
9.8Hz, J1,2 3.1 Hz, H-1), 5.43 (1H, d, JNH,1 8.5 Hz, NH), 7.18-7.44 (15H, m, Ar-H); δC 
(100.5 MHz, CDCl3) 14.0 (q, 2 x CH3), 22.6, 26.5, 28.7, 31.5, (4 x t, 8 x CH2), 48.8 (t, 
2 x CH2N), 70.2, 70.2 (t, C-5α, C-5β), 71.7, 71.8, 71.8, 72.3, 73.3, 73.4 (6 x t, Ph-
CH2), 80.5 (d, C-4β), 81.5, 81.9 (2 x d, C-2α, C-2β), 82.5 (d, C-3β), 82.8 (d, C-4α), 
84.0 (d, C-1β), 85.1 (d, C-3α), 87.8 (d, C-1α), 127.7, 127.7, 127.7, 127.8, 127.9, 
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128.0, 128.1, 128.1, 128.2, 128.4, 128.4, 128.5, 128.5, 128.6 (14 x d, 14 x Ar-C), 
136.9, 136.9, 137.1, 137.6, 137.8, 138.0 (6 x s, 6 x Ar-C); HRMS (ESI) calculated for 








General Procedure C, using sulfamide 2.19g, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.6), afforded glycosylsulfamide 2.20g (230 
mg, 68 %, α:β, 1:1) as a yellow waxy solid; υmax (neat) 3282 (N-H), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.88 (6H, t, J 6.7 Hz, 2 x CH3), 
1.21-1.33 (20H, m, 10 x CH2), 1.51-1.60 (4H, m, 2 x NHCH2CH2), 2.99-3.25 (4H, m, 
2 x CH2NH), ), 3.48 (1H, dd, J5,5‟ 9.8 Hz, J4,5‟ 8.2 Hz, H-5), 3.59 (1H, dd, J5,5‟ 9.6 Hz, 
J4,5‟ 5.7 Hz, H-5‟), 3.93-3.96 (1H, m, H-3), 3.97-4.00 (1H, m, H-2), 4.32 (1H, at, J 6.5 
Hz, H-4), 4.41-4.62 (6H, m, Ph-CH2), 5.33 (1H, d, JNH-1 11.9 Hz, H-1), 5.42 (1H, d, J 
9.8 Hz, NH), 7.20-7.38 (15H, m, Ar-H); β anomer: 0.88 (6H, m, 2 x CH3), 1.26 (20H, 
m, 10 x CH2), 1.55 (4H, m, 2 x NCH2CH2), 2.99-3.25 (4H, m, 2 x CH2NH), 3.53 (2H, 
at, J 4.3 Hz, H-5, H-5‟), 3.93-3.96 (1H, m, H-3), 3.97-4.00 (1H, m, H-2), 4.01-4.04 
(1H, m, H-4), 4.41-4.62 (6H, m, Ph-CH2), 5.29 (1H, dd, JNH,1 10.2 Hz, J1,2 3.9 Hz, H-
1), 5.42 (1H, d, J 9.8 Hz, NH), 7.20-7.38 (15H, m, Ar-H); δC (100.5 MHz, CDCl3) 
14.1 (q, 2 x CH3), 22.6, 26.8, 28.7, 28.8, 29.2, 29.3, 31.8 (7 x t, 12 x CH2), 48.8, 48.9 
(2 x t, 2 x CH2N), 70.1, 70.2 (t, C-5α, C-5β), 71.7, 71.8, 71.8, 72.3, 73.3, 73.4 (6 x t, 
Ph-CH2), 80.5 (d, C-4β), 81.5, 81.9 (2 x d, C-2α, C-2β), 82.5 (d, C-3β), 82.8 (d, C-
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4α), 84.0 (d, C-1β), 85.1 (d, C-3α), 87.9 (d, C-1α), 127.6, 127.7, 127.7, 127.8, 127.9, 
128.0, 128.1, 128.1, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6 (14 x d, 14 x Ar-C), 
136.8, 136.9, 137.0, 137.5, 137.8, 138.0 (6 x s, 6 x Ar-C); HRMS (ESI) calculated for 








General Procedure C, using sulfamide 2.19h, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.6), afforded glycosylsulfamide 2.20h (320 
mg, 59 %, α:β, 1:1) as a yellow waxy solid. υmax (neat) 3285 (N-H), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; 0.88 (6H, t, J 6.7 Hz, 2 x CH3), 1.18-1.35 (28H, m, 14 x CH2), 
1.50-1.61 (4H, m, 2 x NHCH2CH2), 3.00-3.19 (4H, m, 2 x CH2NH), 3.49 (1H, dd, J5,5‟ 
9.7 Hz, J4,5‟ 7.4 Hz, H-5), 3.58 (1H, dd, J5,5‟ 10.0 Hz, J4,5‟ 5.7 Hz, H-5‟), 3.94-3.97 
(1H, m, H-3), 3.97-4.00 (1H, m, H-2), 4.33 (1H, at, J 6.8 Hz, H-4), 4.42-4.58 (6H, m, 
Ph-CH2), 5.34 (1H, d, JNH,1 10.5 Hz, H-1), 5.43 (1H, d, J 9.7 Hz, NH), 7.22-7.38 
(15H, m, Ar-H); β anomer: 0.88 (6H, t, J 6.7 Hz, 2 x CH3), 1.18-1.35 (28H, m, 14 x 
CH2), 1.50-1.61 (4H, m, 2 x NHCH2CH2), 3.04-3.21 (4H, m, 2 x CH2NH), 3.54 (2H, 
at, J 4.7 Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 3.97-4.00 (1H, m, H-2), 4.02-4.04 
(1H, m, H-4), 4.39-4.61 (6H, m, Ph-CH2), 5.29 (1H, dd, JNH,1 9.8 Hz, J1,2 3.9 Hz, H-
1), 5.43 (1H, d, J 9.7 Hz, NH), 7.22-7.38 (15H, m, Ar-H); δC (100.5 MHz, CDCl3) 
14.1 (q, 2 x CH3), 22.6, 26.8, 26.8, 28.8, 28.8, 29.3, 29.4, 29.6, 29.6, 31.9 (10 x t, 20 x 
CH2), 48.9, 48.9 (2 x t, 2 x CH2N), 70.2, 70.2 (2 x t, C-5α, C-5β), 71.7, 71.8, 71.8, 
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72.3, 73.3, 73.4 (6 x t, Ph-CH2), 80.5 (d, C-4β), 81.5, 81.9 (2 x d, C-2α, C-2β), 82.5 
(d, C-3β), 82.7 (d, C-4α), 84.0 (d, C-1β), 85.1 (d, C-3α), 87.8 (d, C-1α), 127.7, 127.7, 
127.7, 127.8, 127.9, 127.9, 128.1, 128.1, 128.2, 128.3, 128.4, 128.4, 128.5, 128.5, 
128.6 (15 x d, 15 x Ar-C), 136.9, 136.9, 137.1, 137.6, 137.8, 138.0 (6 x s, 6 x Ar-C); 








General Procedure C, using sulfamide 2.19i, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.6), afforded glycosylsulfamide 2.20i (280 
mg, 47 %, α:β, 1:1) as a yellow waxy solid. υmax (neat) 3265 (N-H), 1350 (s, S=O), 
1158 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.89 (6H, t, J 6.5 Hz, 2 x CH3), 
1.12-1.37 (36H, m, 18 x CH2), 1.52-1.61 (4H, m, 2 x NHCH2CH2), 3.04-3.21 (4H, m, 
2 x CH2NH), 3.49 (1H, dd, J5,5‟ 9.7 Hz, J4,5‟ 7.4 Hz, H-5), 3.59 (1H, dd, J5,5‟ 10.0 Hz, 
J4,5‟ 5.7 Hz, H-5‟), 3.94-3.97 (1H, m, H-3), 3.97-4.00 (1H, m, H-2), 4.33 (1H, at, J 6.8 
Hz, H-4), 4.42-4.58 (6H, m, Ph-CH2), 5.35 (1H, d, JNH,1 10.5 Hz, H-1), 5.43 (1H, d, J 
9.7 Hz, NH), 7.22-7.38 (15H, m, Ar-H); β anomer: 0.89 (6H, t, J 6.5 Hz, 2 x CH3), 
1.12-1.37 (36H, m, 18 x CH2), 1.52-1.61 (4H, m, 2 x NHCH2CH2), 3.04-3.21 (4H, m, 
2 x CH2NH), 3.54 (2H, at, J 4.7 Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 3.97-4.00 
(1H, m, H-2), 4.02-4.04 (1H, m, H-4), 4.39-4.61 (6H, m, Ph-CH2), 5.30 (1H, dd, JNH,1 
9.8 Hz, J1,2 3.9 Hz, H-1), 5.43 (1H, d, J 9.7 Hz, NH), 7.22-7.38 (15H, m, Ar-H); δC 
(100.5 MHz, CDCl3) 14.1 (q, 2 x CH3), 22.7, 26.8, 28.8, 28.8, 29.4, 29.6, 29.6, 29.7, 
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29.7, 31.7 (10 x t, 20 x CH2), 48.9, 48.9 (2 x t, 2 x CH2N), 70.2, 70.2 (2 x t, C-5α, C-
5β), 71.7, 71.8, 71.8, 72.3, 73.3, 73.4 (6 x t, Ph-CH2), 80.5 (d, C-4β), 81.5, 81.9 (2 x 
d, C-2α, C-2β), 82.5 (d, C-3β), 82.8 (d, C-4α), 84.0 (d, C-1β), 85.1 (d, C-3α), 87.9 (d, 
C-1α), 127.6, 127.7,127.7, 127.8, 127.8, 127.9, 127.9, 128.1, 128.2, 128.3, 128.4, 
128.4, 128.5, 128.5, 128.6 (15 x d, 15 x Ar-C), 136.8, 136.9, 137.0, 137.8, 137.9, 










General Procedure C, using sulfamide 2.19j, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.6), afforded glycosyl sulfamide 2.20j (250 
mg, 80 %, α:β, 1:1) as a yellow waxy solid. υmax (neat) 3270 (w, NH), 1337 (s, S=O), 
1071 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.88 (9H, d, J 6.7 Hz, 3 x CH3), 
1.10-1.16 (2H, m, CH2), 1.20-1.32 (4H, m, 2 x CH2), 1.48-1.58 (4H, m, 2 x CH, CH2), 
3.02-3.07 (2H, m, CH2NHSO2), 3.48 (1H, dd, J5,5‟ 9.6 Hz, J4,5‟ 7.6 Hz, H-5), 3.58 (1H, 
dd, J5,5‟ 9.6 Hz, J4,5‟ 5.7 Hz, H-5‟), 3.94-3.97 (1H, m, H-3), 3.98-4.00 (1H, at, J 3.1 
Hz, H-2), 4.35 (1H, at, J 6.8 Hz, H-4), 4.45-4.57 (6H, m, Ph-CH2), 5.42 (1H, d, J1,NH 
10.6 Hz, H-1), 5.61 (1H, d, JNH-1 10.6 Hz, NH), 7.22-7.37 (15H, m, Ar-H); β anomer: 
0.88 (9H, d, J 6.7 Hz, 3 x CH3), 1.10-1.16 (2H, m, CH2), 1.20-1.32 (4H, m, 2 x CH2), 
1.48-1.58 (4H, m, 2 x CH, CH2), 3.02-3.07 (2H, m, CH2NHSO2), 3.54 (2H, at, J 5.1 
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Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 4.01-4.02 (1H, at, J 4.7 Hz, H-2), 4.04-4.07 
(1H, dd, J4,5 5.1 Hz, J3,4 3.5 Hz, H-4), 4.45-4.57 (6H, m, Ph-CH2), 5.37 (1H, dd, J1,NH 
10.2 Hz, J1,2 4.3 Hz, H-1), 5.57 (1H, d, J1,NH 10.2 Hz, NH), 7.22-7.37 (15H, m, Ar-H); 
δC (100.5 MHz, CDCl3) 19.3, 22.6, 22.7 (3 x q, 3 x CH3), 24.6 (t, CH2), 27.9, 30.4 (2 x 
d, 2 x CH), 36.6, 36.6 (2 x t, 2 x CH2), 39.2 (t, CH2), 41.5, 41.6 (2 x t, NHCH2α, 
NHCH2 β), 70.0 (t, C-5α, C-5β), 71.8, 71.8, 72.0, 72.3, 73.3, 73.4 (6 x t, PhCH2), 80.8 
(d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.3 (d, C-3β ), 83.3 (d, C-4α,), 84.3 (d, C-
1β), 84.8 (d, C-3α,), 88.2 (d, C-1α), 127.7, 127.7, 127.7, 127.8, 127.9, 127.9, 127.9, 
128.0, 128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.6 (15 x d, 15 x Ar-C), 136.7, 
136.8, 136.9, 137.4, 137.7, 137.9 (6 x s, 6 x Ar-C); HRMS (ESI) calculated for 









General procedure C, using sulfamide 2.19k, and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.2), afforded glycosylsulfamide 2.20k (0.36 
g, 74 %, α:β, 1:1) as a yellow waxy solid. υmax (neat) 3267 (N-H), 1348 (s, S=O), 
1074 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 3.18-3.27 (2H, m, NHCH2), 
3.47-3.49 (1H, m, H-5), 3.55-3.63 ( 7H, m, 3 x CH2, H-5‟), 3.93-3.97 (1H, m, H-3), 
4.01 (1H, at, J 3.5 Hz, H-2), 4.36 (1H, t, J 5.5 Hz, H-4), 4.45-4.56 (8H, m, PhCH2), 
5.40 (1H, d, J1,NH 10.2 Hz, H-1), 5.78 (1H, d, JNH,1 10.6 Hz, NH), 7.22-7.36 (20H, m, 
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Ar-H); β anomer: 3.18-3.27 (2H, m, NHCH2), 3.52 (2H, d, J 5.5 Hz, H-5, H-5‟), 3.55-
3.63 ( 6H, m, 3 x CH2), 3.93-3.97 (1H, m, H-3), 3.99 (1H, at, J 4.3 Hz, H-2), 4.03-
4.05 (1H, m, H-4), 4.45-4.56 (8H, m, PhCH2), 5.36 (1H, dd, J1,2 4.3 Hz, JNH,1 10.2 Hz, 
H-1), 5.62 (1H, d, JNH,1 10.2 Hz, NH), 7.22-7.36 (20H, m, Ar-H); δC (100.5 MHz, 
CDCl3) 43.1, 43.3 (2 x t, NHCH2α, NHCH2β), 69.3, 69.6, 69.7 (3 x t, 3x CH2), 70.1, 
70.2 (2 x t, C-5α, C-5β), 71.7, 71.8, 71.9, 72.3,73.2, 73.2, 73.3, 73.4 (8 x t, 8 x 
PhCH2), 80.7 (d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.4 (d, C-3β), 82.6 (d, C-4α), 
84.2 (d, C-1β), 85.2 (d, C-3α), 88.3 (d, C-1α), 127.7, 127.7, 127.7, 127.8, 127.8, 
127.8, 127.9, 128.0, 128.1, 128.2, 128.2, 128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 
128.6 (18 x d,  Ar-C), 136.8, 136.9, 137.0, 137.5, 137.7, 137.9, 137.9, 138.0 (8 x s, 










General procedure C, sulfamide 2.19l, and purification by flash chromatography 
(petrol: EtOAc, 2:1, Rf 0.2), afforded glycosylsulfamide 2.20l (0.29 g, 83 %, α:β, 1.1) 
as a yellow waxy solid. υmax (neat) 3262 (N-H), 1343 (s, S=O), 1068(s, S=O) cm
-1
δH 
(400 MHz, CDCl3) α anomer: 3.18-3.22 (2H, m, NHCH2), 3.48 (1H, dd, J 9.6 Hz, J 
7.2 Hz, H-5), 3.55-3.65 (11H, m, 5 x CH2, H-5‟), 3.93-3.97 (1H, m, H-3), 4.00 (1H, 
at, J 2.7 Hz, H-2), 4.36 (1H, t, J 6.6 Hz, H-4), 4.41-4.58 (8H, m, PhCH2), 5.41 (1H, d, 
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J1,NH 8.6 Hz, H-1), 5.72 (1H, d, JNH,1 10.2 Hz, NH) , 7.22-7.35 (20H, m, Ar-H); β 
anomer: 3.18-3.22 (2H, m, NHCH2), 3.52 (2H, d, J 5.5 Hz, H-5, H-5‟), 3.55-3.65 
(10H, m, 5 x CH2), 3.93-3.97 (1H, m, H-3), 3.98 (1H, at, J 3.5 Hz, H-2), 4.01-4.05 
(1H, m, H-4), 4.41-4.58 (8H, m, PhCH2), 5.36 (1H, dd, J1,2 4.5 Hz, JNH,1 10.0 Hz, H-
1), 5.62 (1H, d, JNH,1 9.8 Hz, NH), 7.22-7.35 (20H, m, Ar-H); δC (125 MHz, CDCl3) 
43.0, 43.1 (2 x t, NHCH2α, NHCH2β), 69.4, 69.4, 69.5, 70.0, 70.1 (5 x t, 5 x CH2), 
70.5, 70.6 (2 x t, C-5α, C-5β), 71.6, 71.7, 71.8, 71.9, 72.2, 73.1, 73.3, 73.4 (8 x t, 8 x 
PhCH2), 80.6 (d, C-4β), 81.2, 81.8 (2 x d, C-2α, C-2β), 82.4 (d, C-3β), 82.6 (d, C-4α), 
84.2 (d, C-1β), 85.2 (d, C-3α), 88.3 (d, C-1α), 127.6, 127.7, 127.7, 127.8, 127.8, 
127.8, 127.9, 127.9, 128.0, 128.1, 128.2, 128.2, 128.4, 128.4, 128.5, 128.5, 128.6, 
128.6 (18 x d, Ar-C), 136.8, 136.9, 137.0, 137.5, 137.7, 138.0, 138.2, 138.2 (8 x s, Ar-









General procedure C, using sulfamide 2.19m, and purification by flash 
chromatography (petrol: EtOAc, 1:1, Rf 0.2), afforded glycosylsulfamide 2.20m (0.23 
g, 62 %, α:β, 1:1) as a yellow oil. υmax (neat) 3254 (N-H), 1346 (s, S=O), 1089 (s, 
S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 3.19-3.23 (2H, m, NHCH2), 3.48 (1H, 
m, H-5), 3.55-3.65 (15H, m, 7 x CH2, H-5‟), 3.93-3.97 (1H, m, H-3), 3.99 (1H, at, J 
2.0 Hz, H-2), 4.36 (1H, t, J 6.2 Hz, H-4), 4.42-4.59 (8H, m, PhCH2), 5.41 (1H, d, 
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JNH,1 9.8 Hz, H-1), 5.73 (1H, d, JNH,1 10.9 Hz, NH), 7.23-7.35 (20H, m, Ar-H); β 
anomer: 3.19-3.23 (2H, m, NHCH2), 3.52 (2H, d, J 5.1 Hz, H-5, H-5‟), 3.55-3.65 
(14H, m, 7 x CH2), 3.93-3.97 (1H, m, H-3), 4.01 (1H, at, J 3.5 Hz, H-2), 4.03-4.05 
(1H, m, H-4), 4.42-4.59 (8H, m, PhCH2), 5.37 (1H, dd, J1,2 4.5 Hz, JNH,1 10.4 Hz, H-
1), 5.63 (1H, d, JNH,1 10.2 Hz, NH), 7.23-7.35 (20H, m, Ar-H); δC (125 MHz, CDCl3) 
43.0, 43.1 (2 x t, NHCH2α, NHCH2β), 69.4, 69.5, 69.5, 70.0, 70.1, 70.1, 70.2 (7 x t, 
7x CH2), 70.5, 70.6 (2 x t, C-5α, C-5β), 71.7, 71.8, 71.9, 72.3, 73.2, 73.2, 73.3, 73.4 
(8 x t, 8 x PhCH2), 80.6 (d, C-4β), 81.3, 81.8 (2 x d, C-2α, C-2β), 82.5 (d, C-3β), 82.6 
(d, C-4α), 84.2 (d, C-1β), 85.2 (d, C-3α), 88.2 (d, C-1α), 127.6, 127.7, 127.7, 127.8, 
127.8, 127.8, 127.9, 127.9, 128.1, 128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.5, 
128.6, 128.6 (18 x d, Ar-C), 136.8, 136.9, 137.0, 137.5, 137.7, 138.0, 138.2, 138.2 (8 









General Procedure F, using sulfamide 2.20a, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 35-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21a (18 mg, 42 %) as white solid. 
[α]D
20 
-11.6 (c, 0.5 in CH3OH); m.p 125-128 °C (MeOH/Et2O); υmax (neat) 3310 (br, 
OH), 1318 (s, S=O), 1134 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.92 (3H, t, J 7.3 Hz, 
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CH3), 1.28-1.38 (6H, m, 3 x CH2), 1.48-1.54 (2H, m, NHCH2CH2), 2.93-3.01 (2H, m, 
CH2NH), 3.46 (1H, at, J 8.3 Hz, H-2), 3.51-3.56 (2H, m, H-3, H-5), 3.77-3.82 (2H, m, 
H-4, H-5‟), 4.27 (1H, at, J1,2 8.9 Hz, H-1), 5.07-5.13 (1H, m, NHCH2), 6.12 (1H, d, 
J1,NH 9.8 Hz, NHSO2); δC (100.5 MHz, CD3OD) 12.9 (q, CH3), 22.2, 26.2, 29.1, 31.2 
(4 x t, 4 x CH2), 42.6 (t, CH2NH), 66.7 (t, C-5), 68.3 (d, C-4), 70.0 (d, C-2), 73.5 (d, 









General Procedure F, using sulfamide 2.20b, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 35-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21b (16 mg, 36 %) as white solid. 
[α]D
20 
-15.6 (c, 0.5 in MeOH); m.p 115-118 °C (MeOH/Et2O); υmax (neat) 3315 (br, 
OH), 1316 (s, S=O), 1152 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (3H, t, J 6.7 Hz, 
CH3), 1.29-1.36 (10H, m, 5 x CH2), 1.48-1.54 (2H, m, NHCH2CH2), 2.93-3.00 (2H, 
m, CH2NH), 3.45 (1H, at, J 8.3 Hz, H-2), 3.51-3.54 (1H, m, H-3), 3.55-3.56 (1H, m, 
H-5), 3.78-3.80 (1H, m, H-4), 3.81 (1H, d, J 2.9 Hz, H-5‟), 4.27 (1H, at, J1,2 8.1 Hz, 
H-1), 5.07-5.13 (1H, m, NHCH2); δC (100.5 MHz, CD3OD) 13.0 (q, CH3), 22.3, 26.5, 
28.8, 29.0, 29.1, 31.8 (6 x t, 6 x CH2), 42.6 (t, CH2NH), 66.7 (t, C-5), 68.3 (d, C-4), 
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70.0 (d, C-2), 73.5 (d, C-3), 85.1 (d, C-1); HRMS (ESI) calculated for 








General Procedure F, using sulfamide 2.20c and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21c (21 mg, 45 %) as white solid; 
[α]D
20 
-14 (c, 0.5 in CH3OH); m.p. 103-105 °C (MeOH/Et2O); υmax (neat) 3340 (br, 
OH), 1340 (s, S=O), 1157 (s, S=O) cm
-1
; δH (500 MHz, CD3CN) 0.90 (3H, t, J 6.7 Hz, 
CH3), 1.29-1.36 (14H, m, 7 x CH2), 1.49-1.53 (2H, m, NHCH2CH2), 2.95-2.99 (2H, t, 
CH2NH), 3.44 (1H, at, J 7.3 Hz, H-2), 3.53-3.56 (2H, m, H-3, H-5), 3.77-3.80 (1H, m, 
H-4), 3.84 (1H, d, J4,5‟ 4.0 Hz, H-5‟), 4.27 (1H, d, J1,2 7.6 Hz, H-1), 5.03 (1H, t, J 5.8 
Hz, NHCH2); δC (100.5 MHz, CD3OD) 13.0 (q, CH3), 22.3, 26.5, 29.0, 29.3, 31.6 (5 x 
t, 8 x CH2), 42.6 (t, CH2NH), 66.7 (t, C-5), 68.3 (d, C-4), 70.0 (d, C-2), 73.5 (d, C-3), 














δH (400 MHz, CD3CN) 0.91 (3H, t, J 6.7 Hz, CH3), 1.25-1.40 (14H, m, 7 x CH2), 
1.45-1.56 (2H, m, NHCH2CH2), 2.93-3.00 (2H, t, CH2NH), 3.53 (1H, dd, J5,5‟ 11.0 
Hz, J4,5‟ 9.0 Hz, H-5), 3.66 (1H, dd, J 5,5‟ 11.6 Hz, J4,5‟ 4.3 Hz, H-5‟), 3.70 (1H, dd, J2,3 
5.5 Hz, J1,2 2.3 Hz H-2), 3.78-3.80 (1H, m, H-3), 3.86-3.89 (1H, m, H-4), 4.84 (1H, d, 
J1,NH 9.0 Hz, H-1), 5.06 (1H, t, J 4.6 Hz, NHCH2), 5.73 (1H, d, J1,NH 9.8 Hz, NH-1); 
δC (100 MHz, CD3CN) 13.4 (q, CH3), 22.4, 26.5, 28.9, 29.0, 29.3, 31.6 (6 x t, 8 x 







δH (400 MHz, CD3CN) 0.91 (3H, t, J 6.7 Hz, CH3), 1.25-1.40 (14H, m, 7 x CH2), 
1.45-1.56 (2H, m, NHCH2CH2), 2.93-3.00 (2H, t, CH2NH), 3.60-3.65 (2H, m, H-5, H-
5‟), 3.76 (1H, at, J 2.8 Hz, H-3), 3.89-3.95 (1H, m, H-2), 3.97-3.99 (1H, m, H-4), 4.95 
(1H, dd, J1,NH 10.6 Hz, J1,2 2.7 Hz, H-1), 5.00 (1H, t, J 4.6 Hz, NHCH2), 5.98 (1H, d, 
J1,NH 11.2 Hz, NH-1). 







δH (400 MHz, CD3CN) 0.91 (3H, t, J 6.7 Hz, CH3), 1.25-1.40 (14H, m, 7 x CH2), 
1.45-1.56 (2H, m, NHCH2CH2), 2.93-3.00 (2H, t, CH2NH), 3.60-3.65 (2H, m, H-5, H-
5‟), 3.68 (1H, at, J 2.8 Hz, H-3), 3.84 (1H, at, J 2.9 Hz, H-2), 4.02 (1H, aq, J 4,7 Hz, 
H-4), 5.13 (1H, d, J1,2 3.7 Hz, H-1), 5.00 (1H, t, J 4.6 Hz, NHCH2). 
 
Experimental Procedure for time dependent isomerization studies of glycosyl 
sulfamides 2.21c and 2.22a-c  
The debenzylated glycosyl sulfamide (10 mg, 0.03 mmol) was dissolved in methanol 
(1 mL), and purified by RP-HPLC (Luna C-18 column (Phenomenex); eluent: A (0.05 
% TFA in H2O) and B MeCN; gradient: the sample was run at 1 mL/min with a 
gradient of 50-85 % B; column oven: 15 °C; detection: CAD). Each of the three peaks 
(Figure 2.5) were separated and frozen immediately. After freeze drying, the samples 
(1 mg, 0.003 mmol) were then dissolved in a mixture of H2O and MeOH (4:1), and 
the equilibration of the three samples was analysed by RP-HPLC (Luna C-18 column 
(Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: the sample 
was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; detection: 
CAD) over a 48 hour time period. The results are shown in Figure 2.8, 2.9 and 2.10. 
 
 







General Procedure F, using sulfamide 2.20d, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21d (19 mg, 40 %) as white solid. 
[α]D
20 
-12.3 (c, 0.5 in CH3OH); m.p 108-110 °C (MeOH/Et2O); υmax (neat) 3320 (br, 
OH), 1330 (s, S=O), 1154 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (3H, t, J 7.3 Hz, 
CH3), 1.27-1.36 (18H, m, 9 x CH2), 1.47-1.54 (2H, m, NHCH2CH2), 2.94-3.00 (2H, 
m, CH2NH), 3.45 (1H, at, J 8.0 Hz, H-2), 3.52-3.54 (1H, m, H-3), 3.54-3.56 (1H, m, 
H-5), 3.77-3.80 (1H, m, H-4), 3.80-3.82 (1H, m, H-5‟), 4.27 (1H, d, J1,2 7.3 Hz, H-1), 
5.04 (1H, t, J 6.6 Hz, NHCH2); δC (100.5 MHz, CD3OD) 13.0 (q, CH3), 22.3, 26.5, 
29.0, 29.0, 29.1, 29.3, 29.3, 29.3, 29.4, 31.6 (10 x t, 10 x CH2), 42.6 (t, CH2NH), 66.7 
(t, C-5), 68.3 (d, C-4), 70.0 (d, C-2), 73.5 (d, C-3), 85.1 (d, C-1); HRMS (ESI) 







General Procedure F, using sulfamide 2.20e, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
 Chapter 5 
149 
 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21e (23mg, 47 %) as white solid. 
[α]D
20 
-11.4 (c, 0.5 in MeOH); m.p 118-128 °C (MeOH/Et2O); υmax (neat) 3410 (br, 
OH), 1325 (s, S=O), 1149 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (3H, t, J 6.5 Hz, 
CH3), 1.27-1.37 (22H, m, 11 x CH2), 1.49-1.52 (2H, m, NHCH2CH2), 2.94-3.00 (2H, 
m, CH2NH), ), 3.45 (1H, at, J 8.3 Hz, H-2), 3.51-3.54 (1H, m, H-3), 3.54-3.56 (1H, m, 
H-5), 3.77-3.80 (1H, m, H-4), 3.80-3.82 (1H, m, H-5‟), 4.27 (1H, d, J1,2 7.8 Hz, H-1), 
5.02-5.07 (1H, m, NHCH2); δC (100.5 MHz, CD3OD) 13.0 (q, CH3), 22.3, 26.5, 29.0, 
29.0, 29.1, 29.3, 29.3, 29.3, 29.4, 31.6 (10 x t, 12 x CH2), 42.6 (t, CH2NH), 66.7 (t, C-
5), 68.3 (d, C-4), 70.0 (d, C-2), 73.5 (d, C-3), 85.1 (d, C-1); HRMS (ESI) calculated 








General Procedure F, using sulfamide 2.20f, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21f (12 mg, 41 %) as yellow 
waxy solid. [α]D
20 
-12.1 (c, 0.5 in MeOH); υmax (neat) 3366 (br, OH), 1334 (s, S=O), 
1135 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.92 (6H, t, J 6.5 Hz, 2 x CH3), 1.29-1.37 
(12H, m, 6 x CH2), 1.53-1.62 (4H, m, 2 x NHCH2CH2), 3.03-3.15 (4H, t, 2 x 
CH2NH), 3.43 (1H, at, J 8.3 Hz, H-2), 3.50-3.55 (2H, m, H-3, H-5), 3.77-3.79 (1H, m, 
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H-4), 3.80-3.82 (1H, m, H-5‟), 4.24 (1H, d, J1,2 7.8 Hz, H-1); δC (100.5 MHz, CD3OD) 
12.9 (q, 2 x CH3), 22.3, 26.2, 28.8, 31.3 (4 x t, 8 x CH2), 49.1 (t, 2 x CH2NH), 66.4 (t, 
C-5), 68.2 (d, C-4), 70.1 (d, C-2), 73.5 (d, C-3), 85.0 (d, C-1); HRMS (ESI) calculated 








General Procedure F, using sulfamide 2.20g, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21g (14 mg, 45 %) as yellow 
waxy solid. [α]D
20 
-14.8 (c, 0.5 in MeOH); υmax (neat) 3396 (br, OH), 1313 (s, S=O), 
1140 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (6H, t, J 6.2 Hz, 2 x CH3), 1.26-1.37 
(20H, m, 10 x CH2), 1.54-1.61 (4H, m, 2 x NHCH2CH2), 3.02-3.14 (4H, m, 2 x 
CH2NH), 3.43 (1H, at, J 8.1 Hz, H-2), 3.49-3.55 (2H, m, H-3, H-5), 3.75-3.80 (2H, m, 
H-4, H-5‟), 4.24 (1H, d, J1,2 7.6 Hz, H-1); δC (100.5 MHz, CD3OD) 13.0 (q, 2 x CH3), 
22.3, 26.5, 28.8, 28.9, 28.9, 31.5 (6 x t, 12 x CH2), 49.1 (t, 2 x CH2NH), 66.4 (t, C-5), 
68.2 (d, C-4), 70.1 (d, C-2), 73.5 (d, C-3), 85.1 (d, C-1); HRMS (ESI) calculated for 












General Procedure F, using sulfamide 2.20h, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21h (16 mg, 41 %) as yellow 
waxy solid. [α]D
20 
-13.2 (c, 0.5 in MeOH); υmax (neat) 3389 (w, NH), 1337 (s, S=O), 
1137 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (6H, t, J 6.5 Hz, 2 x CH3), 1.27-1.37 
(28H, m, 14 x CH2), 1.54-1.61 (4H, m, 2 x NHCH2CH2), 3.04-3.15 (4H, t, 2 x 
CH2NH), 3.44 (1H, at, J 8.1 Hz, H-2), 3.50-3.57 (2H, m, H-3, H-5), 3.77-3.82 (2H, m, 
H-4, H-5‟), 4.26 (1H, at, J 9.0 Hz, H-1), 5.96 (1H, d, J1,NH 9.8 Hz, NHSO2); δC (100.5 
MHz, CD3OD) 13.0 (q, 2 x CH3), 22.3, 26.4, 28.8, 28.9, 29.0, 29.3, 29.3, 31.6 (8 x t, 
16 x CH2), 49.1 (t, 2 x CH2NH), 66.4 (t, C-5), 68.2 (d, C-4), 70.1 (d, C-2), 73.5 (d, C-








General Procedure F, using sulfamide 2.20i, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
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the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21i (13 mg, 39 %) as yellow 
waxy solid. [α]D
20 
-15.2 (c, 0.5 in MeOH); υmax (neat) 3385 (br, OH), 1315 (s, S=O), 
1132 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (6H, t, J 6.5 Hz, 2 x CH3), 1.27-1.37 
(36H, m, 18 x CH2), 1.54-1.61 (4H, m, 2 x NHCH2CH2), 3.04-3.15 (4H, t, 2 x 
CH2NH), 3.44 (1H, at, J 8.1 Hz, H-2), 3.50-3.57 (2H, m, H-3, H-5), 3.77-3.82 (2H, m, 
H-4, H-5‟), 4.26 (1H, at, J 9.0 Hz, H-1), 5.96 (1H, d, J1,NH 9.8 Hz, NHSO2); δC (100.5 
MHz, CD3OD) 13.0 (q, 2 x CH3), 22.3, 26.4, 28.8, 29.0, 29.1, 29.2, 29.3, 29.3, 29.4, 
31.6 (10 x t, 20 x CH2), 49.1 (t, 2 x CH2NH), 66.4 (t, C-5), 68.2 (d, C-4), 70.1 (d, C-









General Procedure F, using sulfamide 2.20j, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 50-85 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21j (10 mg, 43 %) as yellow 
waxy solid. [α]D
20 
-11.2 (c, 0.5 in MeOH); υmax (neat) 3391 (br, OH), 1314 (s, S=O), 
1134 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.88-0.91 (9H, m, 3 x CH3), 1.16-1.21 
(2H, m, CH2), 1.32-1.36 (6H, m, 3 x CH2), 1.54-1.59 (2H, m, 2 x CH), 2.98-3.05 (2H, 
m, CH2NH), 3.44 (1H, at, J 8.1 Hz, H-2), 3.50-3.57 (2H, m, H-3, H-5), 3.76-3.86 (2H, 
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m, H-4, H-5‟), 4.27 (1H, at, J 9.0 Hz, H-1), 5.00-5.02 (1H, m, NHCH2), 6.11 (1H, d, 
J1,NH 10.2 Hz, NHSO2); δC (100.5 MHz, CD3OD) 18.4, 22.5, 22.6 (3 x q, 3 x CH3), 
24.4 (t, CH2), 27.7, 30.2 (2 x d, 2 x CH), 36.2 (t, CH2), 36.9 (t, CH2), 39.0 (t, 
CH2CH2NH), 40.7 (t, CH2NH), 66.7 (t, C-5), 68.3 (d, C-4), 70.1 (d, C-2), 73.5 (d, C-









 General Procedure F, using sulfamide 2.20k, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 10-35 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21k (6 mg, 46 %) as yellow waxy 
solid. . [α]D
20 
-11.7 (c, 0.5 in MeOH); υmax (neat) 3328 (br, OH), 1324 (s, S=O), 1130 
(s, S=O) cm
-1
; δH (500 MHz, CD3OD) 3.19-3.24 (2H, m, NHCH2), 3.52-3.56 (4H, m, 
CH2, H-2, H-3), 3.58 (1H, m, H-5), 3.60 (2H, m, CH2), 3.67 (2H, t, J 5.0 Hz,  CH2), 
3.82-3.84 (1H, m, H-4), 3.85-3.87 (1H, m, H-5‟), 4.32 (1H, d, J1,2 7.8 Hz, H-1); δC 
(125 MHz, CD3OD) 42.4 (t, CH2NH), 60.8 (t, CH2), 66.8 (t, C-5), 68.3 (d, C-4), 69.4 
(t, CH2), 70.0 (d, C-2), 71.9 (t, CH2), 73.5 (d, C-3), 85.2 (d, C-1); HRMS (ESI) 











General Procedure F, using sulfamide 2.20l, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
the sample was run at 1 mL/min with a gradient of 10-35 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21l (6 mg, 42 %) as yellow waxy 
solid. [α]D
20 
-12.4 (c, 0.5 in MeOH); υmax (neat) 3330 (br, OH), 1322 (s, S=O), 1131 
(s, S=O) cm
-1
; δH (500 MHz, CD3OD) 3.19-3.24 (2H, m, NHCH2), 3.53-3.56 (2H, m, 
H-2, H-3), 3.57-3.59 (3H, m, CH2, H-5), 3.60-3.63 (2H, m, CH2), 3.64-3.68 (4H, m, 2 
x CH2), 3.68- 3.70 (2H, m, CH2), 3.83-3.86 (2H, m, H-4, H-5‟), 4.33 (1H, t, J1,2 7.6 
Hz, H-1); δC (125 MHz, CD3OD) 42.4 (t, CH2NH), 60.7 (t, CH2), 66.8 (t, C-5), 68.3 
(d, C-4), 69.5, 69.7, 69.9 (3 x t, 3 x CH2), 70.1 (d, C-2), 72.3 (t, CH2), 73.5 (d, C-3), 









General Procedure F, using sulfamide 2.20m, and purification by RP-HPLC (Luna C-
18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
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the sample was run at 1 mL/min with a gradient of 10-35 % B; column oven: 15 °C; 
detection: CAD), afforded de-protected sulfamide 2.21m (7 mg, 46 %) as yellow 
waxy solid. [α]D
20 
-10.6 (c, 0.5 in MeOH); υmax (neat) 3324 (br, OH), 1326 (s, S=O), 
1131 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) 3.12-3.24 (2H, m, NHCH2), 3.55-3.68 
(17H, m, 7 x CH2, H-2, H-3, H-5), 3.83-3.86 (2H, m, H-4, H-5‟), 4.32 (1H, d, J1,2 7.0 
Hz, H-1); δC (100.5 MHz, CD3OD) 42.4 (t, CH2NH), 60.8 (t, CH2), 66.8 (t, C-5), 68.3 
(d, C-4), 69.5, 69.6, 69.7, 69.9 (4 x t, 4 x CH2), 70.0 (d, C-2), 72.0, 72.1 (2 x t, 2 x 
CH2), 73.5 (d, C-3), 85.2 (d, C-1); HRMS (ESI) calculated for C13H28N2NaO10S 










n-Decanol 2.23 (250 mg, 1.5 mmol), and sulfamoyl chloride (300 mg, 2 equiv.) were 
added to N,N-dimethylacetamide at 0 °C under nitrogen. The reaction was allowed to 
warm to room temperature and then stirred for 3 hours. After this time, t.l.c. (Petrol: 
EtOAc, 3:1) indicated the formation of a single product (Rf 0.1), and the complete 
consumption of starting material (Rf 0.0). The reaction mixture was then poured into 
cold brine (20 mL), and extracted with ethyl acetate (3 x 20 mL). The combined 
organic extracts were dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo to give a residue which was purified by flash chromatography (petrol: ethyl 
acetate, 3:1) to afford n-decyl sulfamate 2.24 (380 mg, 85 %) as a white crystalline 




C); υmax (neat) 3367 (w, N-H), 3285 
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(m, N-H), 1343 (s, S=O), 1177 (s, S=O) cm
-1
; δH (400 MHz, DMSO) 0.84 (3H, t, J 
6.4 Hz, CH3), 1.23-1.29 (14H, m, 7 x CH2), 1.59 (2H, t, J 6.8 Hz, OCH2CH2), 3.98 
(2H, t, J 6.4 Hz, CH2O), 7.35 (2H, s, NH2); δC (100 MHz, DMSO) 14.4 (q, CH3), 
22.5, 25.5, 28.7, 28.9, 29.1, 29.4, 31.7 (7 x t, 8 x CH2), 69.4 (t, CH2O); HRMS (ESI) 









2,3,5-Tri-O-benzyl-α,β-D-arabinofuranoside 2.6 (100 mg, 0.2 mmol), and 
trifluoromethanesulfonamide (71 mg, 0.3 mmol.) were stirred at room temperature in 
dry diethyl ether (15 mL) under nitrogen. TMSOTf (40 µl) was added dropwise, and 
the mixture stirred for 16 hours. After this time, t.l.c. (petrol:EtOAc, 3:1) indicated the 
formation of a single product (Rf 0.4), and complete consumption of starting material 
(Rf 0.2). The reaction mixture was then neutralized by the dropwise addition of excess 
triethylamine (0.1 mL), filtered through Celite
®
, eluting with ethyl acetate, and 
concentrated in vacuo to give a residue which was purified by flash chromatography 
(petrol: ethyl acetate, 3:1) to afford trifluoromethanesulfonamide 2.25a (58 mg, 44 %) 
as a white solid. m.p. 110-113 °C (DCM/petrol);  [α]D
20 
+9.0 (c, 0.35 in CH3OH);  
υmax (neat) 3386 (w, NH), 1382 (s, S=O), 1188 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) 
3.59-3.62 (2H, m, H-5, H-5‟), 3.90 (1H, dd, J3,4 6.3 Hz, J 2,3 2.3 Hz, H-3), 4.04-4.05 
(1H, m, H-2), 4.14 (1H, aq, J 5.5 Hz, H-4), 4.43-4.58 (6H, m, Ph-CH2), 5.38 (1H, s, 
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H-1), 7.24-7.33 (15H, m, Ar-H); δC (100 MHz, CD3OD) 69.6 (t, C-5), 71.5, 71.7, 72.9 
(3 x t, Ph-CH2), 81.5 (d, C-4), 83.6 (d, C-3), 87.4 (d, C-2), 101.9 (d, C-1), 119.8 (q, J 
C,F 334.1 HZ, CF3), 127.3, 127.5, 127.6, 127.9, 128.0 (5 x d, 5 x Ar-C), 137.4, 137.8, 
137.9 (3 x s, 3 x Ar-C); δF (376.6 MHz, CD3OD) -81.59; HRMS (ESI) calculated for 








2,3,5-Tri-O-benzyl-α,β-D-arabinofuranoside 2.6 (100 mg), and methanesulfonamide 
(34 mg, 0.3 mmol) were stirred at room temperature in dry DCM (15 mL) under 
nitrogen. TMSOTf (40 µl) was added dropwise, and the mixture stirred for 16 hours. 
After this time, t.l.c (petrol: ethyl acetate, 2:1) indicated the formation of a product (Rf 
0.45), and the complete consumption of starting material (Rf 0.3). The reaction was 
then neutralized by the dropwise addition of excess triethylamine (0.1 mL). The 
reaction mixture was filtered through Celite
®
, eluting with ethyl acetate, and 
concentrated in vacuo. Purification by flash chromatography (petrol:ethyl acetate, 2:1) 
afforded methanesulfonamide 2.25b (63 mg, 53 %, α:β, 2:1) as a yellow waxy solid. 
υmax (neat) 3267 (w, NH), 1328 (s, S=O), 1159 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α 
anomer: 3.07 (3H, s, CH3), 3.47 (1H, at, J  9.2 Hz, H-5), 3.58 (1H, dd, J5,5‟ 9.4 Hz, J4,5‟ 
5.9 Hz, H-5‟), 3.94-3.97 (1H, m, H-3), 4.02-4.05 (1H, m, H-2), 4.34 (1H, at, J 4.0 Hz, 
H-4)  4.42-4.46 (1H, m, Ph-CH2), 4.49-4.57 (5H, m, PhCH2), 5.48 (1H, d, JNH,1 11.0 
Hz, H-1), 5.63 (1H, d, J 11.2 Hz, NH), 7.21-7.33 (15H, m, Ar-H); β anomer: 3.07 
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(3H, s, CH3), 3.52 (2H, at, J 4.1 Hz, H-5, H-5‟), 3.94-3.97 (1H, m, H-3), 4.02-4.05 
(2H, m, H-2, H-4), 4.42-4.46 (1H, m, Ph-CH2), 4.49-4.57(5H, m, PhCH2), 5.42 (1H, 
dd, J1,2 4.5 Hz, JNH,1 10.4 Hz, H-1), 5.57 (1H, d, JNH,1 10.2 Hz, NH), 7.21-7.33 (15H, 
m, Ar-H); δC (100 MHz, CDCl3) 42.9 (q, CH3), 69.8, 70.1 (2 x t, C-5α, C-5β), 71.7, 
71.8, 71.9, 72.3, 73.3, 73.4 (6 x t, Ph-CH2), 80.9 (d, C-4β), 81.1 (d, C-2β), 81.9 (C-
3β), 82.3 (d, , C-2α), 83.3 (d, C-4α), 83.9 (d, C-1β), 84.7 (d, C-3α), 87.9 (d, C-1α), 
127.7, 127.9, 128.4, 128.5, 128.7 (5 x d, 5 x Ar-C), 136.6, 136.8, 137.9 (3 x s, 3 x Ar-








2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 2.6 (100 mg, 0.2 mmol), and decyl 
sulfamate  (68 mg, 0.3 mmol) were stirred at room temperature in dry DCM (15 mL) 
under nitrogen. TMSOTf (40 µl) was added dropwise, and the mixture stirred for 16 
hours. After this time, t.l.c. (petrol:ethyl acetate, 3:1) indicated the formation of a 
single product (Rf 0.5), and the complete consumption of starting material (Rf 0.2). 
The reaction mixture was then neutralized by the dropwise addition of excess 
triethylamine (0.3 mL). The reaction mixture was filtered through Celite
®
, eluting 
with ethyl acetate, and concentrated in vacuo to give a residue which was purified by 
flash chromatography (petrol:ethyl acetate, 2:1) to afford sulfamate 2.25c (86 mg, 56 
%, α:β, 1:1) as a waxy yellow solid. υmax (neat) 3280 (w, NH), 1365 (s, S=O), 1181 (s, 
S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.90 (3H, t, J 6.7 Hz, CH3), 1.21-1.43 
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(14H, m, 7 x CH2), 1.64-1.74 (2H, m, OCH2CH2), 3.44-3.46 (1H, m, H-5), 3.54-3.64 
(1H, m, H-5‟), 4.04-4.09 (1H, m, H-3), 4.12 (2H, t, J 6.7 Hz, OCH2), 4.16-4.22 (1H, 
m, H-2), 4.38 (1H, t, J 4.0 Hz, H-4), 4.43-4.48 (2H, m, Ph-CH2), 4.54 (4H, ABq, J 
12.0 Hz, Ph-CH2), 5.44 (1H, d, JNH,1 12.0 Hz, H-1), 5.73 (1H, d, J1,NH 10.6 Hz, NH), 
7.22-7.37 (15H, m, Ar-H); β anomer: 0.90 (3H, t, J 6.7 Hz, CH3), 1.21-1.43 (14H, m, 
CH2), 1.64-1.74 (2H, m, OCH2CH2), 3.49-3.54 (2H, m, H-5, H-5‟), 4.04-4.09 (1H, m, 
H-3), 4.12 (2H, t, J 6.7 Hz, OCH2), 4.16-4.22 (2H, m, H-2, H-4), 4.54 (6H, m, Ph-
CH2), 5.04 (1H, dd, J 1,2 3.9 Hz, J 1,NH 10.4 Hz, H-1), 5.79 (1H, d, J1,NH 10.2 Hz, NH), 
7.22-7.37 (15H, m, Ar-H); δC (100 MHz, CDCl3) 14.1 (q, CH3), 22.7, 25.5, 28.7, 29.1, 
29.3, 29.4, 29.5, 31.8 (8 x t, 8 x CH2), 69.7, 69.9 (2 x t, C-5α, C-5β), 71.2 (t, CH2O), 
71.4, 71.7, 71.9, 72.3, 73.3, 73.6 (6 x t, Ph-CH2), 80.8, 80.8 (2 x d, C-2β, C-4β), 82.0 
(d, C-3β), 82.1 (d, C-2α), 83.3 (d, C-4α), 84.1 (d, C-1β), 84.7 (d, C-3α), 88.1 (d, C-
1α), 127.6, 127.8, 127.9, 128.5, 128.6 (5 x d, 5 x Ar-C), 136.7, 137.4, 137.5 (3 x s, 3 x 









10 % Activated Pd/C (10 mg) was added to a solution of 1,1,1-trifluoro-N-(2,3,5-tri-
O-benzyl-β-D-arabinofuranosyl)methanesulfonamide 2.25a (40 mg, 0.1 mmol) in 
methanol. The flask was evacuated and purged with nitrogen five times, before being 
placed under an atmosphere of hydrogen. The solution was stirred for 16 hours at 
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room temperature. After this time, t.l.c. (ethyl acetate) indicated the formation of a 
single product (Rf 0.0), and the complete consumption of starting material (Rf 0.9). 
The reaction mixture was filtered through Celite
®
 (eluting with methanol, 20 mL), and 
concentrated in vacuo to give a residue which was purified by RP-HPLC (Luna C-18 
column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: the 
sample was run at 1 mL/min with a gradient of 50 -80 % B; column oven 15 °C; 
detection: CAD) to afford de-protected triflurosulfonamide 2.26a (13 mg, 65 %) as 
waxy yellow solid. [α]D
20 
+36.4 (c, 0.5 in CH3OH); υmax (neat) 3288 (br s, OH), 1316 
(s, S=O), 1150 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) 3.64 (1H, dd, J4,5 5.8 Hz, J5,5‟ 
11.7 Hz, H-5), 3.74 (1H, dd, J4,5‟ 4.3 Hz, J5.5‟ 12.5 Hz, H-5‟), 3.84-3.86 (1H, dd, J3,4 
5.7 Hz, J2,3 3.3 Hz, H-3), 3.97-4.00 (1H, aq, J 5.1 Hz, H-4), 4.02 (1H, m, H-2), 5.17 
(1H, s, H-1); δC (100 MHz, CD3OD) 61.7 (t, C-5), 77.4 (d, C-3), 81.9 (d, C-2), 84.8 
(d, C-4), 103.9 (d, C-1), 118.3 (q, J C,F 324.2 HZ, CF3); δF (376.6 MHz, CD3OD) -





Experimental procedure for attempted equilibration of 2.26a. 
The purified β-furanose trifluoromethanesulfonamide 2.26a (1 mg, 0.003 mmol) was 
dissolved in a mixture of H2O and MeOH (4:1), and equilibration was analysed by 
RP-HPLC (Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B 
MeCN; gradient: the sample was run at 1 mL/min with a gradient of 50-85 % B; 
column oven: 15 °C; detection: CAD) over a 48 hour time period. No mutarotation or 
equilibration to the pyranose form was observed. The results are shown in Figure 5.1. 




Figure 5.1 RP-HPLC traces and time-dependence of equilibration of 1,1,1-trifluoro-
N-(β-D-arabinofuranosyl)methanesulfonamide 2.26a in methanol/water. 
  
2 hours 4 hours 
12 hours 48 hours 
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10 % Activated Pd/C (15 mg) was added to a solution of N-(2,3,5-tri-O-benzyl-α,β-D-
arabinofuranosyl)methanesulfonamide 2.25b (60 mg, 0.1 mmol) in methanol. The 
flask was evacuated and purged with nitrogen five times, before being placed under 
an atmosphere of hydrogen. The solution was then stirred for 16 hours at room 
temperature. After this time, t.l.c. (ethyl acetate) indicated the formation of a single 
product (Rf 0.0), and the complete consumption of starting material (Rf 0.9). The 
reaction mixture was filtered through Celite
®
 (eluting with methanol, 20 mL), and 
concentrated in vacuo to give a residue which was purified by RP-HPLC (Luna C-18 
column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: the 
sample was run at 1 mL/min with a isocratic flow of 20 % B; column oven: 15 °C; 
detection: CAD) to afford de-protected methanesulfonamide 2.26b (9 mg, 33 %) as 
white solid. α-anomer: m.p. 178-180 °C (MeOH/diethyl ether);  [α]D
20  
-16 (c, 0.5 in 
CH3OH);  υmax (neat) 3280 (br s, OH), 1328 (s, S=O), 1159 (s, S=O) cm
-1
; δH (400 
MHz, CD3CN) 3.01 (3H, s, CH3), 3.48 (1H, at, J1,2 7.9 Hz, H-2), 3.53-3.59 (2H, m, H-
3, H-5), 3.79-3.84 (1H, m, H-4, H-5‟), 4.36 (1H, d, J1,2 7.6 Hz, H-1); δC (100 MHz, 
CD3OD) 42.0 (q, CH3), 66.9 (d, C-5), 68.3 (d, C-4), 69.8 (d, C-2), 73.4 (d, C-3), 85.2 













10 % Activated Pd/C (20 mg) was added to a solution of decyl-N-(2,3,5-tri-O-benzyl-
α,β-D-arabinofuranosyl)sulfamate 2.25c (80 mg, 0.1 mmol) in methanol. The flask 
was evacuated and purged with nitrogen five times, before being placed under an 
atmosphere of hydrogen. The solution was then stirred for 16 hours at room 
temperature. After this time, t.l.c. (ethyl acetate) indicated the formation of a single 
product (Rf 0.0), and the complete consumption of starting material (Rf 0.9). The 
reaction mixture was filtered through Celite
®
 (eluting with methanol, 20 mL), and 
concentrated in vacuo to give a residue which was purified by RP-HPLC (Luna C-18 
column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: the 
sample was run at 1 mL/min with a gradient of 50-85 % B; column oven 15 °C; 
detection: CAD) to afford de-protected sulfamate 2.26c (21 mg, 45 %) as white solid. 
[α]D
20 
-5.4 (c, 0.5 in CH3OH); 
 
m.p. 138-140 °C (MeOH/diethylether);  υmax (neat) 
3334 (br s, OH), 1344 (s, S=O), 1178 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) 0.91 (3H, 
t, J 6.5 Hz, CH3), 1.27-1.39 (14H, m, CH2), 1.66-1.74 (2H, m, OCH2CH2), 3.47 (1H, 
at, J 7.8 Hz, H-2), 3.52-3.58 (2H, m, H-3, H-5), 3.77-3.80 (1H, m, H-4), 3.83 (1H, d, 
J4,5‟ 2.7 Hz, H-5‟), 4.15 (2H, t, J 6.5 Hz, CH2O), 4.31 (1H, d, J1,2 7.8 Hz, H-1); δC (100 
MHz, CD3OD) 13.0 (q, CH3), 22.3, 25.2, 28.4, 29.2, 31.8 (5 x t, 8 x CH2), 67.1 (t, C-
5), 68.4 (d, C-4), 69.9 (d, C-2), 70.3 (t, CH2O), 73.5 (d, C-3), 85.3 (d, C-1); HRMS 
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General Procedure A: 
Arabinofuranosyl acetates 2.29, 2.30, 2.32 and 2.34 (1 equiv.), and the sulfamide (1 
equiv.) were stirred at room temperature in dry DCM (15 mL) under nitrogen. 
BF3.OEt2 (2 equiv.) was added dropwise, and the mixture was then stirred for 16 h. 
The reaction was then neutralized by the dropwise addition of excess triethylamine 
(~0.3 mL). The reaction mixture was then filtered through Celite
®
, eluting with ethyl 
acetate, and concentrated in vacuo to give a residue which was purified by flash 
chromatography. 
 
General Procedure B: 
Glycosyl sulfamides 2.35a-c and 2.39a-c was dissolved in dry methanol (~5 mL). 





) was added the pH was neutral. The reaction mixture was then 









D-Arabinose (2 g, 13 mmol, 1 equiv.) was dissolved by heating in pyridine (35 mL), 
and solution allowed to cool to room temperature before trityl chloride (3.7 g, 13 
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mmol, 1 equiv.) was added portion-wise. The reaction mixture was then stirred for 48 
h under nitrogen. The reaction was quenched by the addition of with MeOH (10 mL), 
and concentrated in vacuo. The residue was dissolved in ethyl acetate (30 mL) and the 
organic layer was washed with water (3 x 20 mL). The combined organic extracts 
were dried over anhydrous MgSO4, filtered, and concentrated in vacuo to give a 
residue that was then purified by flash chromatography (Petrol: EtOAc 1:1, to Petrol: 
EtOAc 1:8), afforded 5-O-trityl-D-arabinofuranose (2.1 g, 41 %). The product (1.8 g, 
4.5 mmol) was then dissolved pyridine (20 mL) and acetic anhydride (3.5 mL) was 
added dropwise at 0 °C under nitrogen. The reaction mixture was allowed to warm to 
room temperature, and then stirred for 16 h. The solvent was removed in vacuo and 
the residue was dissolved in DCM (20 mL). The solution was washed with saturated 
aqueous NaHCO3 (3 x 20 mL), and brine (3 x 20 mL). The combined organic extracts 
were dried over anhydrous MgSO4, filtered, and concentrated in vacuo to give a 
residue that was then purified by flash chromatography (Petrol: EtOAc 1:1, Rf 0.5), to 
afford 1,2,3-tri-O-acetyl-5-O-trityl-D-arabinofuranose 2.27 (2.0 g, 84 % α:β, 2:1) as a 
colourless oil. δH (400 MHz, CDCl3) α anomer: 2.07, 2.08, 2.11 (9H, 3 x s, 3 x OAc), 
3.29-3.35 (2H, m, H-5, H-5‟), 4.32 (1H, aq, J 4.7 Hz, H-4), 5.25 (1H, d,  J2,3 1.6 Hz, 
H-2), 5.27 (1H, d, J3,4 4.7 Hz, H-3), 6.21 (1H, s, H-1); β anomer: 2.03, 2.05, 2.07 (9H, 
3 x s, 3 x OAc), 3.29-3.35 (2H, m, H-5, H-5‟), 4.17 (1H, aq, J 5.5 Hz, H-4), 5.33 (1H, 














1,2,3-Tri-O-acetyl-5-O-trityl-D-arabinofuranose 2.27 (2 g, 3.8 mmol) was dissolved in 
a mixture of water and acetic acid (20 mL, 1:4, v/v), and then stirred at 100 °C for 25 
min. After this time, t.l.c. (petrol: EtOAc 1:1) indicated the formation of a single 
product (Rf 0.2), and the complete consumption of starting material (Rf 0.5). The 
reaction was cooled in an ice-bath, and the crystallized trityl alcohol was filtered off. 
Brine (40 mL) was added to the filtrate, and the mixture was extracted with DCM (3 x 
30 mL). The combined organic extracts were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to give a residue that was then purified by flash 
chromatography (petrol: EtOAc 5:1 to 2:3) to afford alcohol 2.28 (790 mg, 74 %, α:β, 
2:1) as a colourless oil. δH (400 MHz, CDCl3) α anomer: 2.07, 2.10, 2.11 (9H, 3 x s, 3 
x OAc), 3.72-3.91 (2H, m, H-5, H-5‟), 4.23 (1H, aq, J 4.0 Hz, H-4), 5.12 (1H, dd, J2,3 
1.2 Hz, J3,4 5.1 Hz, H-3), 5.25 (1H, d, J2,3 1.2 Hz, H-2), 6.17 (1H, s, H-1); β anomer: 
2.12, 2.13, 2.13 (9H, 3 x s, 3 x OAc), 3.72-3.91 (2H, m, H-5, H-5‟), 4.08 (1H, aq, J 
















1,2,3-Tri-O-acetyl-D-arabinofuranose 2.28 (300 mg, 1.0 mmol, 1 equiv.), 2,6-di-
tertbutyl-4-methylpyridine (498 mg, 2.6 mmol, 2.4 equiv.) and Hg(CN)2 (2.7 mg, 
0.001 mmol, 0.01 equiv.) were stirred in DCM (25 mL) at room temperature under 
nitrogen. Methyl triflate (0.26 mL, 2.3 mmol, 2.2 equiv.) was added, and the mixture 
stirred for 5 min. The reaction mixture was then heated to 40 
◦
C for 24 h. After this 
time, t.l.c. (petrol: EtOAc 2:1) indicated the formation of a single product (Rf 0.2), 
and the complete consumption of starting material (Rf 0.0).  The reaction mixture was 
washed with 1 M aqueous HCl (2 × 50 mL) and brine (50 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered, and concentrated in vacuo to 
give a residue that was then purified by flash chromatography (petrol: EtOAc 12:1 to 
3:1) to afford methyl ether 2.29 (197 mg, 63 %, α:β, 2:1) as a colourless oil; δH (400 
MHz, CDCl3) α anomer: 2.10, 2.11, 2.12 (9H, 3 x s, 3 x OAc), 3.39 (3H, s, OCH3), 
3.54-3.67 (2H, m, H-5, H-5‟), 4.28-4.31 (1H, m, H-4), 5.11 (1H, dd, J2,3 1.4 Hz, J3,4 
5.3 Hz, H-3), 5.19 (1H, d, J2,3 1.6 Hz, H-2), 6.20 (1H, s, H-1); β anomer: 2.07, 2.09, 
2.09 (9H, 3 x s, 3 x OAc), 3.41 (3H, s, OCH3), 3.54-3.67 (2H, m, H-5, H-5‟), 4.12-
4.16 (1H, m, H-4), 5.33-5.36 (1H, m, H-2), 5.38-5.42 (1H, m, H-3), 6.36 (1H, d, J1,2 














1,2,3-Tri-O-acetyl-D-arabinofuranose 2.28 (340 mg, 1.2 mmol, 1 equiv.), was stirred 
in dry diglyme (5 mL). The mixture was stirred at room temperature for 5 min under 
nitrogen before it was cooled to −40 
◦
C. (Diethylamino)sulfur trifluoride (DAST) 
(0.81 mL, 6.1 mmol, 5 equiv.) was added, and the mixture was then stirred for 30 min. 
The reaction was then allowed to warm to room temperature and stirred for 16 hours. 
After this time, t.l.c. (petrol: EtOAc 2:1) indicated the formation of a single product 
(Rf 0.6), and the complete consumption of starting material (Rf 0.0). The reaction was 
carefully quenched by the addition of saturated aqueous NaHCO3 (50 mL). The 
mixture was extracted with diethyl ether (3 × 25 mL) and the combined organic 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. The residue was 
purified by flash chromatography (petrol: EtOAc1:1) to afford fluoride 2.30 (213 mg, 
62%, α:β, 2:1) as a colourless oil. δH (400 MHz, CDCl3) α anomer: 2.11, 2.12, 2.14 
(9H, 3 x s, 3 x OAc), 4.28-4.37 (1H, m, H-4), 4.48-4.72 (2H, m, H-5, H-5‟), 5.11 (1H, 
d, J3,4 4.7 Hz, H-3), 5.23 (1H, s, H-2), 6.22 (1H, s, H-1); β anomer: 2.07, 2.09, 2.09, 
(9H, 3 x s, 3 x OAc), 4.13-4.22 (1H, m, H-4), 4.48-4.72 (4H, m, H-5, H-5‟), 5.36 (1H, 















1,2,3-Tri-O-acetyl-D-arabinofuranose 2.28 (210 mg, 0.8 mmol, 1 equiv.) was 
dissolved in a mixture of dry DCM (20 mL) and pyridine (5 mL). Tosyl chloride (217 
mg, 1.1 mmol 1.5 equiv.) was then added slowly. The reaction mixture was stirred at 
room temperature for 48 h under nitrogen. After this time, t.l.c. (petrol: EtOAc 1:1) 
indicated the formation of a single product (Rf 0.4), and the complete consumption of 
starting material (Rf 0.2). The reaction mixture was washed with water and the 
aqueous layer was extracted with DCM (3 × 20 mL). The combined organic extracts 
were washed with 1 M aqueous HCl (20 mL), saturated aqueous NaHCO3, and brine 
(30 mL), and then dried over MgSO4, filtered, and concentrated in vacuo. The residue 
was purified by flash chromatography (petrol: EtOAc 1:1) to afford tosylate 2.31 (190 
mg, 58 %, α:β, 2:1), as a colourless oil. δH (400 MHz, CDCl3) α anomer: 2.09, 2.10, 
2.11 (9H, 3 x s, 3 x OAc), 2.45 (3H, s, CH3), 4.15-4.33 (3H, m, H-4, H-5, H-5‟), 4.98-
5.01 (1H, m, H-3), 5.16 (1H, d, J2,3 0.5 Hz, H-2), 6.12 (1H, s, H-1), 7.35 (2H, d, J 8.2 
Hz, Ar-H), 7.80 (2H, d, J 7.4 Hz, Ar-H); β anomer: 2.05, 2.07, 2.08 (9H, 3 x s, 3 x 
OAc), 2.45 (3H, s, CH3), 4.15-4.33 (3H, m, H-4, H-5, H-5‟), 5.29-5.32 (2H, m, H-2, 
















1,2,3-Tri-O-acetyl-5-O-tosyl-D-arabinofuranose 2.31 (230 mg, 0.5 mmol) and sodium 
azide (139 mg, 2.1 mmol, 4 equiv.) were heated to 80 
◦
C in DMSO (15 mL). The 
reaction was stirred for 24 h under nitrogen. After this time, t.l.c. (petrol: EtOAc1:1) 
indicated the formation of a single product (Rf 0.6), and the complete consumption of 
starting material (Rf 0.4).  The reaction was allowed to cool to room temperature and 
then diluted with DCM (40 mL), and washed with water (50 mL). The combined 
organic extracts were dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo to give a residue that was then purified by flash chromatography (petrol:EtOAc 
2 : 1) to afford azide 2.32 as a colourless oil (90 mg, 56 %, α:β, 2:1). δH (400 MHz, 
CDCl3) α anomer: 2.12, 2.13, 2.14 (9H, 3 x s, 3 x OAc),  3.47-3.49 (1H, m, H-5 ), 
3.68 (1H, dd, J4,5 3.1 Hz, J5,5’ 13.3 Hz, H-5‟), 4.30 (1H, aq, J 4.2 Hz, H-4), 5.05 (1H, 
d, J3,4 4.7 Hz, H-3), 5.22 (1H, s, H-2), 6.23 (1H, s, H-1); β anomer: 2.09, 2.10, 2.12 
(9H, 3 x s, 3 x OAc), 3.43-3.46 (1H, m, H-5), 3.60 (1H, dd, J4,5 3.3 Hz, J5,5’13.5 Hz, 
















1,2,3-Tri-O-acetyl-D-arabinofuranose 2.28 (210 mg, 0.8 mmol, 1 equiv.), 
triphenylphosphine (289 mg, 1.1 mmol, 1.45 equiv.), imidazole (155 mg, 2.3 mmol, 3 
equiv.) and iodine (289 mg, 1.1 mmol, 1.5 equiv.) were stirred in dry toluene (20 mL) 
before heating the mixture to 100 
◦
C for 2.5 h. After this time, t.l.c. (petrol: EtOAc 
1:1) indicated the formation of a single product (Rf 0.7), and the complete 
consumption of starting material (Rf 0.2). The reaction was allowed to cool to room 
temperature. The solvent was removed in vacuo and the residue was dissolved in 
DCM (20 mL). The solution was washed with 10 % aqueous Na2S2O3 (30 mL). The 
combined organic extracts were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo to give a residue that was then purified by flash 
chromatography (petrol: EtOAc 2 : 1) to afford iodide 2.33 as a colourless oil (260 
mg, 89 %, α:β, 1.5:1). δH (500 MHz, CDCl3) α anomer: 2.11, 2.12, 2.13 (9H, 3 x s, 3 x 
OAc), 3.35-3.46 (2H, m, H-5, H-5‟), 4.16-4.24 (1H, s, H-4), 4.99 (1H, d, J3,4 4.6 Hz, 
H-3), 5.20 (1H, s, H-2), 6.20 (1H, s, H-1), β anomer: 2.07, 2.07, 2.10 (9H, 3 x s, 3 x 
OAc),  3.35-3.46 (2H, m, H-5, H-5‟), 4.16-4.24 (1H, s, H-4), 5.32-5.37 (2H, m, H-2, 















Iodide 2.37 (380 mg, 1.0 mmol), triethylamine (0.11 mL, 0.8 mmol) and 10% Pd/C 
(78 mg, 25% w/w) were stirred in ethanol (5 mL), and the flask was evacuated and 
purged with nitrogen three times, before it was placed under an atmosphere of 
hydrogen. The solution was then stirred for 16 h at room temperature. After this time, 
t.l.c. (petrol: EtOAc 1:1) indicated the formation of a single product (Rf 0.9), and the 
complete consumption of starting material (Rf 0.7). The reaction mixture was filtered 
through Celite
®
 (eluting with methanol, 20 mL), and concentrated in vacuo to give a 
residue which was purified by flash column chromatography (petrol: EtOAc 2:1) to 
afford 1,2,3-tri-O-acetyl-5-deoxy-D-arabinofuranose 2.34 (190 mg, 74 %, α:β, 1:1) as 
a colourless oil. δH (500 MHz, CDCl3) α anomer:  1.41 (3H, d, J4,5 6.3 Hz, CH3), 2.11, 
2.11, 2.11 (9H, 3 x s, 3 x OAc), 4.26 (1H, quint, J  6.1 Hz, H-4), 4.84 (1H, dd, J2,3 1.2 
Hz, J3,4 5.5 Hz, H-3), 5.17-5.21 (1H, m, H-2), 6.13 (1H, s, H-1); β anomer: 1.45 (3H, 
d, J4,5 6.7 Hz, CH3), 2.08, 2.09, 2.10 (9H, 3 x s, 3 x OAc), 4.11 (1H, quint, J 6.2 Hz, 
H-4), 5.17-5.21 (1H, m, H-3), 5.31 (1H, dd, J1,2 4.7 Hz, J2,3 6.7 Hz, H-2), 6.33 (1H, d, 












General Procedure A, using 1,2,3-tri-O-acetyl-5-O-methyl-D-arabinofuranose 2.29 
(100 mg, 0.3 mmol) and N-(decyl)sulfamide
98
 (81 mg, 0.3 mmol), and purification by 
flash chromatography (petrol: EtOAc, 2:1, Rf 0.2), afforded glycosylsulfamide 2.35a 
(120 mg, 75 %, α:β, 1:1) as a colourless oil;  υmax (neat) 3256 (N-H), 1756 (s, C=O), 
1362 (s, S=O), 1167 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.87 (3H, t, J 6.7 
Hz, CH3), 1.21-1.36 (14H, m, 7 x CH2), 1.50-1.58 (2H, m, NHCH2CH2), 2.10, 2.11 
(6H, 2 x s, 2 x OAc), 2.99-3.08 (2H, m, CH2NH), 3.40 (3H, s, OCH3), 3.55-3.59 (2H, 
m, H-5, H-5‟), 4.21 (1H, aq, J 4.3 Hz, H-4), 5.09-5.15 (2H, m, H-2, H-3), 5.30 (1H, d, 
JNH,1 10.1 Hz, H-1), 5.54 (1H, d, JNH,1 11.0 Hz NH); β anomer: 0.87 (3H, t, J  6.7 Hz, 
CH3), 1.21-1.36 (14H, m, CH2), 1.50-1.58 (2H, m, NHCH2CH2), 2.09, 2.12 (6H, 2 x s, 
2 x OAc), 2.99-3.08 (2H, m, CH2NH), 3.46 (3H, s, OCH3), 3.55-3.59 (1H, m, H-5), 
3.64 (1H, dd, J5,5‟ 10.6 Hz, J4,5‟ 3.1Hz, H-5‟), 3.93-3.97 (1H, m, H-4), 5.20-5.27 (2H, 
m, H-2, H-3), 5.45 (1H, dd, JNH,1 10.8 Hz, J1,2 5.3 Hz, H-1), 5.78 (1H, d, JNH,1 10.6 Hz 
NH); δC (100.5 MHz, CDCl3) 14.1 (q, CH3), 20.7, 20.7, 20.7, 20.8 (4 x q, 2 x OAc-α, 
2 x OAc-β), 22.6, 26.7, 29.2, 29.3, 29.5, 29.5, 29.5, 31.9 (8 x t, 8 x CH2), 43.2, 43.5 (2 
x t, NHCH2α, NHCH2β), 59.4 (q, OCH3), 72.1, 72.1 (t, C-5α, C-5β), 75.8 (d, C-2β), 
75.8 (d, C-3β), 76.8 (d, C-3α), 79.9 (d, C-2α), 80.9 (d, C-4β), 82.1 (d, C-4α), 83.1 (d, 
C-1β), 88.1 (d, C-1α), 169.5, 169.7, 169.8, 170.3 (4 x s, 2 x OAc-α, 2 x OAc-β); 











General Procedure A, using 1,2,3-tri-O-acetyl-5-deoxy-D-arabinofuranose 2.34 (190 
mg, 0.7 mmol) and N-(decyl)sulfamide
98
 (172 mg, 0.7 mmol), and purification by 
flash chromatography (petrol: EtOAc, 1:1, Rf 0.6), afforded glycosylsulfamide 2.35b 
(180 mg, 57 %, α:β, 1:1) as a pale yellow waxy solid; υmax (neat) 3294 (N-H), 1743 (s, 
C=O), 1372 (s, S=O), 1162 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.86 (3H, 
t, J 6.7 Hz, CH3), 1.24-1.40 (17H, m, 7 x CH2, CH3), 1.50-1.57 (2H, m, NHCH2CH2), 
2.11, 2.15 (6H, 2 x s, 2 x OAc), 2.99-3.08 (2H, m, CH2NH), 4.16-4.24 (1H, m, H-4), 
4.81-4.85 (1H, m, H-3), 5.08 (1H, s, H-2), 5.26 (1H, d, JNH,1 8.6 Hz, H-1), 5.59 (1H, d, 
JNH,1 9.0Hz, NH); β anomer: 0.86 (3H, t, J  6.7 Hz, CH3), 1.24-1.40 (17H, m, CH2, 
CH3), 1.50-1.57 (2H, m, NHCH2CH2), 2.08, 2.10 (6H, 2 x s, 2 x OAc), 2.99-3.08 (2H, 
m, CH2NH), 3.81-3.88 (1H, m, H-4), 4.71-4.74 (1H, m, H-3), 5.15-5.19 (1H, m, H-2), 
5.33 (1H, dd, JNH,1 10.8 Hz, J1,2 4.1 Hz, H-1), 5.51 (1H, d, JNH,1 11.0 Hz NH); δC 
(100.5 MHz, CDCl3) 14.1 (q, CH3), 18.9, 19.2 (2 x q, C-5α, C-5β), 20.7, 20.7, 20.8, 
20.8 (4 x q, 2 x OAc-α, 2 x OAc-β), 22.6, 26.7, 29.2, 29.3, 29.3, 29.4, 29.5, 31.8 (8 x 
t, 8 x CH2), 43.4, 43.4 (2 x t, NHCH2α, NHCH2β), 75.9 (d, C-2β), 77.8 (d, C-4β), 79.6 
(d, C-4α), 80.3 (d, C-3β), 80.5 (d, C-2α), 80.6 (d, C-3α), 83.4 (d, C-1β), 88.0 (d, C-
1α), 169.2, 169.7, 169.8, 169.8 (4 x s, 2 x OAc-α, 2 x OAc-β); HRMS (ESI) 












General Procedure A, using 1,2,3-tri-O-acetyl-5-azido-D-arabinofuranose 2.32 (90 
mg, 0.3 mmol)  and N-(decyl)sulfamide
98
 (70 mg, 0.3 mmol), and purification by 
flash chromatography (petrol: EtOAc, 1:1, Rf 0.6), afforded glycosyl sulfamide 2.35c 
(80 mg, 56 %, α:β, 1:1) as a pale yellow waxy solid; υmax (neat) 3273 (N-H), 2098 
(N3), 1743 (s, C=O), 1370 (s, S=O), 1165 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α 
anomer: 0.87 (3H, t, J 6.3 Hz, CH3), 1.22-1.36 (14H, m, 7 x CH2), 1.50-1.61 (2H, m, 
NHCH2CH2), 2.11, 2.19 (6H, 2 x s, 2 x OAc), 3.01-3.14 (2H, m, CH2NH), 3.37-3.48 
(1H, m, H-5), 3.53-3.63 (1H, m, H-5‟), 4.21-4.26 (1H, m, H-4), 4.36-4.49 (1H, m, 
NHCH2), 5.03-5.06 (1H, m, H-3), 5.16 (1H, d, J 1.6 Hz, H-2), 5.35 (1H, d, JNH,1 9.4 
Hz, H-1), 5.49-5.56 (1H, m, NH); β anomer: 0.87 (3H, t, J  6.3 Hz, CH3), 1.22-1.36 
(14H, m, CH2), 1.50-1.61 (2H, m, NHCH2CH2), 2.13, 2.13 (6H, 2 x s, 2 x OAc), 3.01-
3.14 (2H, m, CH2NH), 3.37-3.48 (1H, m, H-5), 3.53-3.63 (1H, m, H-5‟), 3.91-3.95 
(1H, m, H-4), 4.36-4.49 (1H, m, NHCH2), 4.91-4.94 (1H, m, H-3), 5.18-5.21 (1H, m, 
H-2), 5.42 (1H, dd, JNH,1 10.6 Hz, J1,2 3.5 Hz, H-1), 5.49-5.56 (1H, m, NH); δC (100.5 
MHz, CDCl3) 14.1 (q, CH3), 20.6, 20.7 (2 x q, 2 x OAc), 22.6, 26.7, 29.2, 29.3, 29.4, 
29.5, 29.5, 31.9 (8 x t, 8 x CH2), 43.5, 43.6 (2 x t, NHCH2α, NHCH2β), 51.7, 51.7 (t, 
C-5α, C-5β), 75.6 (d, C-2β), 76.5, 77.1 (2 x d, C-3α, C-3β), 79.7 (d, C-2α), 81.3 (d, C-
4β), 82.6 (d, C-4α), 83.8 (d, C-1β), 88.1 (d, C-1α), 169.7, 169.9 (2 x s, 2 x OAc); 











General Procedure B, using glycosyl sulfamide 2.35a (60 mg, 0.1 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-(decyl)-
N‟-(5-O-methyl-α,β-D-arabinofuranosyl)sulfamide 2.36a (40 mg, 82 %, α:β, 1:1) as a 
white solid; m.p. 91-93 °C (MeOH/DCM); υmax (neat) 3280 (N-H), 1347 (s, S=O), 
1141 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) α anomer: 0.91 (3H, t, J 6.7 Hz, CH3), 
1.25-1.39 (14H, m, 7 x CH2), 1.49-1.56 (2H, m, NHCH2CH2), 2.93-3.01 (2H, m, 
CH2NH), 3.37 (3H, s, OCH3), 3.47-3.54 (2H, m, H-5, H-5‟), 3.87-3.92 (2H, m, H-2), 
3.93-3.98 (1H, m, H-3), 4.04 (1H, aq, J 4.2 Hz, H-4), 4.92 (1H, d, JNH,1 10.4 Hz, H-1), 
5.00-5.08 (1H, m, NHCH2), 5.98 (1H, d, JNH,1 10.2 Hz, NH); β anomer: 0.91 (3H, t, J 
6.7 Hz, CH3), 1.25-1.39 (14H, m, 7 x CH2), 1.49-1.56 (2H, m, NHCH2CH2), 2.93-
3.01 (2H, m, CH2NH), 3.38 (3H, s, OCH3), 3.47-3.54 (2H, m, H-5, H-5‟), 3.80 (1H, 
aq, J 3.5 Hz, H-4), 3.82-3.86 (2H, m, H-2), 3.93-3.98 (1H, m, H-3), 5.00-5.08 (1H, m, 
NHCH2), 5.12 (1H, dd, JNH,1 10.2 Hz, J1,2 3.9 Hz, H-1), 5.76 (1H, d, JNH,1 10.6 Hz, 
NH); δC (100.5 MHz, CD3CN) 13.4 (q, CH3), 22.4, 26.5, 29.0, 29.0, 29.0, 29.1, 29.3, 
31.6 (8 x t, 8 x CH2), 43.0, 43.0 (2 x t, NHCH2α, NHCH2β), 58.5, 58.6 (2 x q, OCH3α, 
OCH3β), 72.5, 72.8 (t, C-5α, C-5β), 76.1 (d, C-2β), 76.6 (d, C-3β, C-3α), 79.9 (d, C-
2α), 82.8 (d, C-4β), 84.4 (d, C-4α), 85.3 (d, C-1β), 89.9 (d, C-1α); HRMS (ESI) 












General Procedure B, using glycosyl sulfamide 2.35b (80 mg, 0.2 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-(decyl)-
N‟-(5-deoxy-α,β-D-arabinofuranosyl)sulfamide 2.36b (52 mg, 81 %, α:β, 2:1) as a 
white solid; m.p. 100-102 °C (MeOH/DCM); υmax (neat) 3287 (N-H), 1318 (s, S=O), 
1149 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) α anomer: 0.89 (3H, t, J 7.0 Hz, CH3), 
1.24-1.38 (17H, m, 7 x CH2, CH3), 1.49-1.57 (2H, m, NHCH2CH2), 2.94-3.02 (2H, m, 
CH2NH), 3.66-3.70 (1H, m, H-3), 3.87-3.95 (2H, m, H-2, H-4), 4.91 (1H, d, J1,2 4.3 
Hz, H-1); β anomer: 0.89 (3H, t, J 7.0 Hz, CH3), 1.24-1.38 (17H, m, 7 x CH2, CH3), 
1.49-1.57 (2H, m, NHCH2CH2), 2.94-3.02 (2H, m, CH2NH), 3.57 (1H, at, J 6.7 Hz, 
H-3), 3.66-3.70 (1H, m, H-4), 3.87-3.95 (1H, m, H-2), 5.11 (1H, d, J1,2 4.7 Hz, H-1); 
δC (100.5 MHz, CD3OD) 13.1 (q, CH3), 17.6, 18.4 (2 x q, C-5α, C-5β), 22.3, 26.5, 
29.0, 29.0, 29.1, 29.3, 31.7 (7 x t, 8 x CH2), 42.6, 42.7 (2 x t, NHCH2α, NHCH2β), 
76.5 (d, C-2β), 77.8 (d, C-4β), 78.5 (d, C-4α), 80.8 (d, C-3β), 81.0 (d, C-2α), 81.1 (d, 
C-3α), 84.4 (d, C-1β), 88.4 (d, C-1α); HRMS (ESI) calculated for C15H33N2O5S: 













General Procedure B, using glycosyl sulfamide 2.35c (80 mg, 0.2 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-(decyl)-
N‟-(5-azido-α,β-D-arabinofuranosyl)sulfamide 2.36c (42 mg, 62 %, α:β, 1:1) as a 
white solid; m.p. 99-101 °C (MeOH/DCM); υmax (neat) 3293 (N-H), 2103 (N3), 1340 
(s, S=O), 1141 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) α anomer: 0.90 (3H, t, J 6.7 Hz, 
CH3), 1.25-1.39 (14H, m, 7 x CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.95-3.03 (2H, 
m, CH2NH), 3.34-3.50 (2H, m, H-5, H-5‟), 3.83-3.90 (1H, m, H-3), 3.92-3.98 (1H, m, 
H-2), 4.01 (1H, aq, J 3.9 Hz, H-4), 4.93 (1H, dd, JNH,1 10.2 Hz, J1,2 3.9 Hz, H-1), 4.99-
5.12 (1H, m, NHCH2), 6.07 (1H, d, JNH,1 10.2 Hz, NH); β anomer: 0.90 (3H, t, J 6.7 
Hz, CH3), 1.25-1.39 (14H, m, 7 x CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.95-3.03 
(2H, m, CH2NH), 3.34-3.50 (2H, m, H-5, H-5‟), 3.72-3.80 (1H, m, H-4), 3.83-3.90 
(1H, m, H-3), 3.92-3.98 (1H, m, H-2), 5.17 (1H, dd, JNH,1 10.0 Hz, J1,2 4.1 Hz, H-1), 
4.99-5.12 (1H, m, NHCH2), 5.83 (1H, d, JNH,1 10.2 Hz, NH); δC (100.5 MHz, CD3CN) 
13.4 (q, CH3), 22.4, 26.5, 29.0, 29.0, 29.1, 29.3, 31.7 (7 x t, 8 x CH2), 43.0 (t, 
NHCH2α, NHCH2β), 52.2, 52.7 (t, C-5α, C-5β), 75.9 (d, C-2β), 76.3, 77.1 (2 x d, C-
3α, C-3β), 79.9 (d, C-2α), 81.9 (d, C-4β), 82.1 (d, C-4α), 85.2 (d, C-1β), 89.1 (d, C-













General Procedure A, using 1,2,3-tri-O-acetyl-5-fluoro-D-arabinofuranose 2.30 (60 
mg, 0.2 mmol) and N-(octyl)sulfamide
98
 (44 mg, 0.2 mmol), and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.35), afforded glycosyl sulfamide 2.37a (48 
mg, 53 %, α:β, 1:1) as a pale yellow waxy solid; υmax (neat) 3279 (N-H), 1735 (s, 
C=O), 1369 (s, S=O), 1152 (s, S=O) cm
-1
;δH (400 MHz, CDCl3) α anomer: 0.87 (3H, 
t, J 6.7 Hz, CH3), 1.20-1.36 (10H, m, 5 x CH2), 1.51-1.58 (2H, m, NHCH2CH2), 2.14, 
2.15 (6H, 2 x s, 2 x OAc), 3.01-3.13 (2H, m, CH2NH), 4.22-4.31 (1H, m, H-4), 4.51-
4.56 (1H, m, H-5), 4.63-4.67 (1H, m, H-5‟), 5.13 (1H, at, J 2.8 Hz, H-3), 5.16 (1H, at, 
J 2.3 Hz, H-2), 5.33 (1H, dd, JNH,1 9.6 Hz, J1,2 2.2 Hz, H-1), 5.37 (1H, d, JNH,1 11.0 Hz 
NH); β anomer: 0.87 (3H, t, J 6.7 Hz, CH3), 1.20-1.36 (10H, m, 5 x CH2), 1.51-1.58 
(2H, m, NHCH2CH2), 2.11, 2.13 (6H, 2 x s, 2 x OAc), 3.01-3.13 (2H, m, CH2NH), 
3.90-4.01 (1H, m, H-4), 4.51-4.56 (1H, m, H-5), 4.63-4.67 (1H, m, H-5‟), 5.05 (1H, 
dd, J3,4 3.5 Hz, J2,3 2.3 Hz, H-3), 5.22 (1H, dd, J1,2 4.1 Hz, J2,3 2.2 Hz, H-2), 5.48 (1H, 
dd, JNH,1 6.7 Hz J1,2 4.7 Hz, H-1), 5.45-5.46 (1H, m, NH); δC (100.5 MHz, CDCl3) 
14.0 (q, CH3), 20.6, 20.7, 20.7, 20.7 (4 x q, 2 x OAcα, 2 x OAcβ), 22.6, 26.7, 29.1, 
29.4, 29.4, 31.7 (6 x t, 6 x CH2), 43.4, 43.6 (2 x t, NHCH2α, NHCH2β), 75.2 (d, C-
2β), 75.4 (d, Jc3-F 6.1 Hz, C-3β), 75.9 (d, JC3-F 6.1 Hz, C-3α), 79.6 (d, C-2α), 81.5 (d, 
JC4-F 18.3 Hz, C-4β), 81.7 (d, JC4-F 19.8 Hz, C-4α), 82.1 (d, JC5-F 174.0 Hz, C-5β), 82.1 
(d, JC5-F 174.0 Hz, C-5α), 83.7 (d, C-1β), 88.1 (d, C-1α), 169.3, 169.8, 169.9, 170.0 (4 
x s, 2 x OAcα, 2 x OAcβ); δF (376.6 MHz, CDCl3) -229.14 (td, JF,H geminal 40.1 Hz, JF,H 
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vicinal 23.8 Hz, F-β), -229.34 (td, JF,H geminal 42.0 Hz, JF,H vicinal 23.8 Hz, F-α); HRMS 








General Procedure A, using 1,2,3-tri-O-acetyl-5-fluoro-D-arabinofuranose 2.30 (75 
mg, 0.3 mmol) and N-(decyl)sulfamide
98
 (63 mg, 0.3 mmol), and purification by flash 
chromatography (petrol: EtOAc, 2:1, Rf 0.4), afforded glycosylsulfamide 2.37b (74 
mg, 61 %, α:β, 1:1) as a pale yellow waxy solid;  υmax (neat) 3279 (N-H), 1735 (s, 
C=O), 1369 (s, S=O), 1152 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) α anomer: 0.78 
(3H, t, J 6.3 Hz, CH3), 1.13-1.30 (14H, m, 7 x CH2), 1.41-1.52 (2H, m, NHCH2CH2), 
2.00, 2.00 (6H, 2 x s, 2 x OAc), 2.87-2.96 (2H, m, CH2NH), 4.20-4.32 (1H, m, H-4), 
4.40-4.49 (1H, m, H-5), 4.51-4.61 (1H, m, H-5‟), 5.04 (1H, at, J 3.9 Hz, H-3), 5.14 
(1H, dd, JNH,1 9.0 Hz, J1,2 3.1 Hz, H-1), 5.21-5.24 (1H, m, H-2), 5.69-5.82 (1H, m, 
CH2NH), 6.93 (1H, d, JNH,1 9.0 Hz, NH); β anomer: 0.78 (3H, t, J 6.3 Hz, CH3), 1.13-
1.30 (14H, m, 7 x CH2), 1.41-1.52 (2H, m, NHCH2CH2), 1.95, 1.98 (6H, 2 x s, 2 x 
OAc), 2.87-2.96 (2H, m, CH2NH), 3.88-3.99 (1H, m, H-4), 4.40-4.49 (1H, m, H-5), 
4.51-4.61 (1H, m, H-5‟), 4.97 (1H, at, J 3.1 Hz, H-3), 5.16-5.19 (1H, m, H-2), 5.33 
(1H, dd, JNH,1 10.8 Hz J1,2 4.5 Hz, H-1), 5.69-5.82 (1H, m, CH2NH), 6.72 (1H, d, JNH,1 
11.0 Hz, NH); δC (100.5 MHz, CD3CN) 13.3 (q, CH3), 19.7, 19.7, 19.7 (3 x q, 2 x 
OAcα, 2 x OAcβ), 22.3, 26.5, 28.3, 28.5, 28.6, 28.8, 29.0, 31.6 (8 x t, 8 x CH2), 42.8, 
42.8 (2 x t, NHCH2α, NHCH2β), 74.6 (d, C-2β), 75.0 (d, Jc3-F 7.6 Hz, C-3β), 75.2 (d, 
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JC3-F 6.9 Hz, C-3α), 79.2 (d, JC4-F 19.8 Hz, C-4β), 79.5 (d, C-2α), 80.1 (d, JC4-F 19.8 
Hz, C-4α), 82.3 (d, JC5-F 171.7 Hz, C-5β), 82.3 (d, JC5-F 171.7 Hz, C-5α), 84.0 (d, C-
1β), 87.6 (d, C-1α), 168.9, 169.1, 169.3, 169.6 (4 x s, 2 x OAcα, 2 x OAcβ); δF (376.6 
MHz, CDCl3) -229.18 (td, JF,H geminal 46.7 Hz, JF,H vicinal 23.8 Hz, F-β), -229.52 (td, JF,H 
geminal 47.7 Hz, JF,H vicinal 26.7 Hz, F-α); HRMS (ESI) calculated for C19H35FN2NaO7S: 








General Procedure A, using 1,2,3-tri-O-acetyl-5-fluoro-D-arabinofuranose 2.30 (70 
mg, 0.3 mmol) and N-(dodecyl)sulfamide
98
 (66 mg, 0.3 mmol), and purification by 
flash chromatography (petrol: EtOAc, 2:1, Rf 0.4), afforded glycosyl sulfamide 2.37c 
(62 mg, 52 %, α:β, 1:1) as a pale yellow waxy solid; ;  υmax (neat) 3282 (N-H), 1755 
(s, C=O), 1368 (s, S=O), 1151 (s, S=O) cm
-1
; δH (400 MHz, CDCl3) α anomer: 0.87 
(3H, t, J 6.8 Hz, CH3), 1.22-1.36 (18H, m, 9 x CH2), 1.51-1.60 (2H, m, NHCH2CH2), 
2.14, 2.15 (6H, 2 x s, 2 x OAc), 3.03-3.15 (2H, m, CH2NH), 4.22-4.31 (1H, m, H-4), 
4.48-4.56 (1H, m, H-5), 4.61-4.68 (1H, m, H-5‟), 5.13 (1H, at, J 2.7 Hz, H-3), 5.14-
5.17 (1H, m, H-2), 5.33 (1H, s, H-1); β anomer: 0.87 (3H, t, J 6.8 Hz, CH3), 1.22-1.36 
(18H, m, 9 x CH2), 1.51-1.60 (2H, m, NHCH2CH2), 2.12 (6H, 1 x s, 2 x OAc), 3.03-
3.15 (2H, m, CH2NH), 3.90-4.01 (1H, m, H-4), 4.48-4.56 (1H, m, H-5), 4.61-4.68 
(1H, m, H-5‟), 5.06 (1H, dd, J2,3 2.3 Hz, J3,4 3.5 Hz,  H-3), 5.22 (1H, dd, J1,2 4.3 Hz, 
J2,3 2.0 Hz, H-2), 5.28 (1H, d, JNH,1 11.0 Hz, NH), 5.48 (1H, dd, JNH,1 11.0 Hz, J1,2 4.7 
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Hz, H-1); δC (100.5 MHz, CDCl3) 14.1 (q, CH3), 20.7, 20.8, (2 x q, 2 x OAcα, 2 x 
OAcβ), 22.6, 26.6, 29.2, 29.3, 29.4, 29.5, 29.5, 29.6, 29.6, 31.9 (10 x t, 10 x CH2), 
43.5, 43.7 (2 x t, NHCH2α, NHCH2β), 75.3 (d, C-2β), 75.4 (d, Jc3-F 6.9 Hz, C-3β), 
76.0 (d, JC3-F 6.1 Hz, C-3α), 79.5 (d, C-2α), 80.6 (d, JC4-F 18.3 Hz, C-4β), 81.9 (d, JC4-F 
19.8 Hz, C-4α), 82.1 (d, JC5-F 172.4 Hz, C-5β), 82.1 (d, JC5-F 175.5 Hz, C-5α), 83.7 (d, 
C-1β), 88.2 (d, C-1α), 169.2, 169.7, 169.8, 169.9 (4 x s, 2 x OAcα, 2 x OAcβ); δF 
(376.6 MHz, CDCl3) -229.15 (td, JF,H geminal 47.7 Hz, JF,H vicinal 23.8 Hz, F-β), -229.6 
(td, JF,H geminal 48.6 Hz, JF,H vicinal 27.7 Hz, F-α); HRMS (ESI) calculated for 








General Procedure B, using glycosyl sulfamide 2.37a (40 mg, 0.1 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-(octyl)-
N‟-(5-fluoro-α,β-D-arabinofuranosyl)sulfamide 2.38a (24 mg, 75 %, α:β, 1:1) as a 
white solid; m.p. 123-125 °C (MeOH/DCM); υmax (neat) 3290 (N-H), 1347 (s, S=O), 
1142 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) α anomer: 0.91 (3H, t, J 7.4 Hz, CH3), 
1.25-1.38 (10H, m, 5 x CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.93-3.02 (2H, m, 
CH2NH), 3.91 (1H, at, J 4.3 Hz, H-3), 3.96 (1H, at, J 4.3 Hz, H-2),  4.03-4.11 (1H, m, 
H-4), 4.38-4.48 (1H, m, H-5), 4.51-4.60 (1H, m, H-5‟), 4.91 (1H, d, J1,2 3.9 Hz, H-1), 
5.07 (1H, br s, NH); β anomer: 0.91 (3H, t, J 7.4 Hz, CH3), 1.25-1.38 (10H, m, 5 x 
CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.93-3.02 (2H, m, CH2NH), 3.81-3.89 (1H, m, 
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H-4), 3.91 (1H, at, J 4.3 Hz, H-3), 4.00-4.02 (1H, m, H-2),  4.38-4.48 (1H, m, H-5), 
4.51-4.60 (1H, m, H-5‟), 5.19 (1H, d, J1,2 4.3 Hz, H-1), 5.07 (1H, br s, NH);  δC (100.5 
MHz, CD3CN) 13.4 (q, CH3), 22.4, 26.5, 28.9, 28.9, 29.0, 31.6 (6 x t, 6 x CH2), 43.0 
(t, NHCH2α, NHCH2β), 74.7, 75.5 (2 x d, JC3-F 6.9 Hz, C-3β, C-3α), 75.7 (d, C-2β), 
79.9 (d, C-2α), 81.5 (d, JC4-F 19.8 Hz, C-4β), 81.6 (d, JC4-F 19.1 Hz, C-4α), 83.0 (d, 
JC5-F 200.7 Hz, C-5β), 83.3 (d, JC5-F 137.3 Hz, C-5α), 85.0 (d, C-1β), 89.1 (d, C-1α); δF 
(376.6 MHz, CDCl3) -226.26 (td, JF,H geminal 49.6 Hz, JF,H vicinal 19.1 Hz, F-β), -228.46 
(td, JF,H geminal 48.6 Hz, JF,H vicinal 21.0 Hz, F-α); HRMS (ESI) calculated for 








General Procedure B, using glycosyl sulfamide 2.37b (60 mg, 0.1 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-(decyl)-
N‟-(5-fluoro-α,β-D-arabinofuranosyl)sulfamide 2.38b (35 mg, 72 %, α:β, 3:1) as a 
white solid; m.p. 98-100 °C (MeOH/DCM); υmax (neat) 3293 (N-H), 1329 (s, S=O), 
1143 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) α anomer: 0.89 (3H, t, J 6.8 Hz, CH3), 
1.24-1.40 (14H, m, 7 x CH2), 1.49-1.56 (2H, m, NHCH2CH2), 2.94-3.04 (2H, m, 
CH2NH), 3.93 (1H, at, J 2.7 Hz, H-3), 3.97 (1H, at, J 3.5 Hz, H-2), 3.99-4.06 (1H, m, 
H-4), 4.37-4.47 (1H, m, H-5), 4.49-4.58 (1H, m, H-5‟), 4.93 (1H, d, J1,2 4.7 Hz, H-1); 
β anomer: 0.89 (3H, t, J 6.8 Hz, CH3), 1.24-1.40 (14H, m, 7 x CH2), 1.49-1.56 (2H, 
m, NHCH2CH2), 2.94-3.04 (2H, m, CH2NH), 3.82-3.89 (1H, m, H-4), 3.91 (1H, at, J 
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4.3 Hz, H-3), 3.98-4.00 (1H, m, H-2), 4.37-4.47 (1H, m, H-5), 4.49-4.58 (1H, m, H-
5‟), 5.24 (1H, d, J1,2 4.3 Hz, H-1); δC (100.5 MHz, CD3OD) 13.0 (q, CH3), 22.3, 26.5, 
29.0, 29.0, 29.1, 29.3, 31.7 (7 x t, 8 x CH2), 42.6 (t, NHCH2α, NHCH2β), 74.3, 75.6 (2 
x d, JC3-F 6.9 Hz, C-3β, C-3α), 75.7 (d, C-2β), 80.1 (d, C-2α), 80.9 (d, JC4-F 19.1 Hz, C-
4β), 81.7 (d, JC4-F 19.8 Hz, C-4α), 82.0 (d, JC5-F 170.9 Hz, C-5β), 82.7 (d, JC5-F 170.1 
Hz, C-5α), 85.2 (d, C-1β), 88.6 (d, C-1α); δF (376.6 MHz, CD3OD) -227.20 (td, JF,H 
geminal 47.7 Hz, JF,H vicinal 19.1 Hz, F-β), -230.70 (td, JF,H geminal 47.7 Hz, JF,H vicinal 23.8 









General Procedure B, using glycosyl sulfamide 2.37c (50 mg, 0.1 mmol) and 
purification by flash chromatography (petrol: EtOAc, 1:1, Rf 0.1), afforded N-
(dodecyl)-N‟-(5-fluoro-α,β-D-arabinofuranosyl)sulfamide 2.38c (32 mg, 78 %, α:β, 
1:1) as a white solid; m.p. 129-131 °C (MeOH/DCM); υmax (neat) 3293 (N-H), 1326 
(s, S=O), 1142 (s, S=O) cm
-1
; δH (400 MHz, CD3CN) α anomer: 0.90 (3H, t, J 6.8 Hz, 
CH3), 1.26-1.38 (18H, m, 9 x CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.91-3.04 (2H, 
m, CH2NH), 3.91 (1H, at, J 4.7 Hz, H-3), 3.96 (1H, at, J 4.3 Hz, H-2), 4.03-4.11 (1H, 
m, H-4), 4.38-4.48 (1H, m, H-5), 4.50-4.60 (1H, m, H-5‟), 4.91 (1H, d, J1,2 3.9 Hz, H-
1), 5.06 (1H, br s, NH); β anomer: 0.90 (3H, t, J 6.8 Hz, CH3), 1.26-1.38 (10H, m, 5 x 
CH2), 1.48-1.57 (2H, m, NHCH2CH2), 2.91-3.04 (2H, m, CH2NH), 3.80-3.89 (1H, m, 
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H-4), 3.91 (1H, at, J 4.3 Hz, H-3), 3.99-4.02 (1H, m, H-2),  4.38-4.48 (1H, m, H-5), 
4.50-4.60 (1H, m, H-5‟), 5.19 (1H, d, J1,2 4.3 Hz, H-1), 5.06 (1H, br s, NH);  δC (100.5 
MHz, CD3CN) 13.4 (q, CH3), 22.4, 26.5, 28.4, 29.0, 29.1, 29.3, 29.3, 29.4, 29.4, 31.6 
(10 x t, 10 x CH2), 43.0 (t, NHCH2α, NHCH2β), 74.7, 75.5 (2 x d, JC3-F 6.9 Hz, C-3β, 
C-3α), 75.7 (d, C-2β), 80.0 (d, C-2α), 81.5 (d, JC4-F 19.1 Hz, C-4β), 81.6 (d, JC4-F 19.1 
Hz, C-4α), 83.0 (d, JC5-F 168.6 Hz, C-5β), 83.3 (d, JC5-F 168.6 Hz, C-5α), 85.0 (d, C-
1β), 89.1 (d, C-1α); δF (376.6 MHz, CDCl3) -226.24 (td, JF,H geminal 49.6 Hz, JF,H vicinal 
19.1 Hz, F-β), -228.44 (td, JF,H geminal 48.7 Hz, JF,H vicinal 22.9 Hz, F-α); HRMS (ESI) 
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5.3  Experimental for chapter 3 
 
General procedure A 
Amine 3.23 (1 equiv.) was dissolved in dry acetonitrile and the mixture stirred at 0 °C 
under nitrogen (5 mL). Triethylamine (3 equiv.) and sulfamoyl chloride  (2 equiv.) 
were then added, the reaction was then allowed to warm to room temperature, and 
stirred for 2 h. Then the solvent was removed in vacuo to give a residue that was then 
purified by RP-HPLC (Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in 
H2O) and B MeCN; gradient: the sample was run at 1 mL/min with a gradient 0-45 % 








Conc. HNO3 (2.7 mL, 0.06 mol) was added dropwise to conc. H2SO4 (3.1 mL, 0.06 
mol). The resulting mixture was cooled to 20 °C and then 2-chlorobenzotrifluoride 
3.29 (1 g, 5.5 mmol) was added. The reaction was stirred for 1 h at 50 °C until gas 
evolution ceased. After this time, t.l.c. (Petrol) indicated the formation of a single 
product (Rf 0.1). Iced water (50 mL) was then added carefully. The solvent was then 
removed in vacuo to give a residue that was then purified by flash chromatography to 
afford nitro compound 3.30 (0.9 g, 72 %) as pale yellow oil. δH (400 MHz, CDCl3) 
7.72 (1H, d, J 9.0 Hz, Ar-H-3), 8.35 (1H, dd, J 8.6, 2.7 Hz, Ar-H-4), 8.58 (1H, d, J 
2.4 Hz, Ar-H-6). 









10 % Activated Pd-C (118 mg) was added to a solution of nitro compound 3.30 (1 g, 
4.5 mmol) in methanol (20 mL). The flask was evacuated and purged with nitrogen 
five times, before being placed under an atmosphere of hydrogen. The solution was 
stirred for 2 h at room temperature. After this time, t.l.c. (petrol: EtOAc 4:1) indicated 
the formation of a product (Rf 0.5), and complete consumption of starting material (Rf 
0.8). The reaction mixture was filtered through Celite
®
 (eluting with methanol, 20 
mL), and concentrated in vacuo to give a residue which was purified by flash column 
chromatography to afford aniline 3.28a (1.2 g, 68.9 %) as yellow oil.  δH (400 MHz, 
CDCl3) 6.72 (1H, dd, J 8.4 Hz, 2.5 Hz, Ar-H-6), 6.95 (1H, d, J 2.7 Hz, Ar-H-5), 7.22 








Sodium ascorbate (345 mg, 1.7 mmol, 0.3 equiv.), CuI (330 mg, 1.7 mmol, 0.3 
equiv.), L-proline (200 mg, 1.7 mmol, 0.3 equiv.) and NaOH (70 mg, 1.7 mmol, 0.3 
equiv.) were added to a solution of 4-bromoaniline 3.31 (1g, 5.8 mmol, 1 equiv.) in 
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EtOH: H2O (7:3, 30 mL). The resulting mixture was stirred for 15 minutes at room 
temperature. Then sodium azide (755mg, 11.6 mmol, 2 equiv.) was added and the 
reaction mixture was stirred at reflux for 3 h. After this time, t.l.c (DCM 100 %) 
indicated the formation of a single product (Rf 0.35), and complete consumption of 
starting material (Rf 0.4). The reaction mixture was cooled and concentrated in vacuo. 
The residue was dissolved in EtOAc (50 mL) and washed with water (3 x 50 mL). 
The combined organic extracts were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo, which was then purified by flash chromatography (DCM 100 
%) to afford aniline 3.28d (373 mg, 48 %) as brown solid. m.p 62-63 °C (DCM) [lit 
65-66 °C]
115,140
; δH (400 MHz, CD3OD)
140
 6.60 (2H, d, J 8.6 Hz, Ar-H), 7.15 (2H, d, 
J 8.6 Hz, Ar-H).     
 
General procedure for the synthesis of sulfamoyl chlorides 3.27a-d 
Triethylamine (9 equiv.) was added to a solution of aniline 3.28a-d (1 equiv.) in 
CHCl3 (20 mL). Chlorosulfonic acid (1 equiv.) was added dropwise at -9 °C (ice and 
salt water mixture). The solution was then stirred at -2 °C for 1 h before it was 
concentrated in vacuo. The crude residue was dissolved in NaOH (1N, 20 mL) and 
then the resulting mixture was concentrated in vacuo. The residue was suspended in 
boiling ethanol. The insoluble solids were filtered off, and the filtrate was 
concentrated in vacuo to afford N-phenylsulfamate. The crude residue N-
Phenylsulfamate was co-evaporated with toluene (3 x 30 mL) and then the residue 
was dissolved in toluene. PCl5 (1 equiv.) was added and the reaction mixture was 
refluxed for 2 h, and then cooled to room temperature. The resulting suspension was 
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filtered, and the filtrate was concentrated in vacuo to afford sulfamoyl chloride 3.27a-









Thymidine 3.26 (1.0 g, 4.1 mmol, 1 equiv.) was dissolved in dry THF (25 mL) and 
triphenylphosphine (2.16 g, 8.2 mmol, 2 equiv.), iodine (1.57 g, 6.1 mmol 1.5 equiv.) 
and imidazole (421 mg, 6.1 mmol, 1.5 equiv.) were then added sequentially. The 
reaction mixture was then heated to 50 °C and stirred at for 16 h under nitrogen. After 
this time, t.l.c. (DCM : MeOH, 19:1) indicated the formation of a single product (Rf 
0.2). The mixture was cooled, the solvent was removed in vacuo, and the residue was 
then dissolved in DCM (30 mL). The resulting solution was washed with 1 M 
aqueous HCl (20 mL). The organic extracts were dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo to give a residue that was then purified by flash 
chromatography (gradient elution, 100 % DCM to DCM: MeOH, 97:3) to afford 





+22.8 (c, 1.0 in CH3OH); δH (500 MHz, CD3OD) 1.90 (3H, d, J 1.3 Hz, 
5-CH3), 2.26-2.34 (2H, m, H-2a‟, H-2b‟), 3.43-3.53 (2H, m, H-5a‟, H-5b‟), 3.83-3.86 
(1H, m, H-4‟), 4.29-4.32 (1H, m, H-3‟), 6.28 (1H, t, J1,2  7.0 Hz, H-1‟), 7.61 (1H, d, J 
1.3 Hz, H-6). 










Iodide 3.25 (0.6 g, 1.7 mmol, 1 equiv.) was dissolved in dry DMF (10 mL), and NaN3 
(336 mg, 5.2 mmol, 3 equiv.) was then added. The reaction mixture was heated to 50 
°C and stirred for 16 h under nitrogen. After this time, t.l.c. (EtOAc) indicated the 
formation of a single product (Rf 0.1), and the complete consumption of starting 
material (Rf 0.2). The mixture was cooled, the solvent was removed in vacuo, and the 
residue was dissolved in ethyl acetate (30 mL). The solution was washed with water 
(3 × 20 mL) and brine (20 mL). The organic extracts were dried over anhydrous 
MgSO4, filtered, and concentrated in vacuo to give a residue that was then purified by 
flash chromatography (EtOAc 100%) to afford 5‟-azido-2‟,5‟-dideoxy-β-D-thymidine 





+66.4 (c, 0.5 in CH3OH) [lit. [α]D
22
 +89.5 (c, 0.94 in CH3OH)]
144
 ; δH (500 
MHz, CD3OD) 1.89 (3H, d, J 1.1 Hz, 5-CH3), 2.24-2.31 (2H, m, H-2a‟, H-2b‟), 3.50-
3.64 (2H, m, H-5a‟, H-5b‟), 3.96 (1H, aq, J 3.9 Hz, H-4‟), 4.33-4.37 (1H, m, H-3‟), 














Azide 3.24 (130 mg, 0.5 mmol, 1 equiv.) was dissolved in dry THF (10 mL). 
Triphenylphosphine (255 mg, 1.0 mmol, 2 equiv.) and water (0.02 mL, 1.0 mmol, 2 
equiv.) were then added. The reaction mixture was stirred at room temperature for 16 
h under nitrogen. After this time, t.l.c. (DCM: MeOH, 19:1) indicated the formation 
of a single product (Rf 0.0), and the complete consumption of starting material (Rf 
0.6). The solvent was removed in vacuo to give a residue that was then purified by 
flash chromatography (2 % to 10% MeOH/DCM) to afford amine 3.23 (70 mg, 60 %) 
as a white solid.  m.p 165-167 °C (EtOH/Et2O); [α]D
20  
+11.6 (c, 0.5 in CH3OH); δH 
(400 MHz, CD3OD) 1.75 (3H, s, 5-CH3), 2.16-2.34 (2H, m, H-2a‟, H-2b‟), 2.74-2.93 
(2H, m, H-5a‟, H-5b‟), 3.80-3.86 (1H, m, H-4‟), 4.22-4.29 (1H, m, H-3‟), 6.12 (1H, t, 







General Procedure A, using sulfamoyl chloride, and purification by RP-HPLC (Luna 
C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: 
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the sample was run at 1 mL/min with a gradient of 0-45 % B; column oven: 40 °C; 
detection: UV 210 nm and 280nm), afforded sulfamide 3.10 (68 mg, 74 %) as a pale 
yellow waxy solid. [α]D
20 
+14.3 (c, 0.35 in CH3OH); υmax (neat) 3268 (N-H), 1350 (s, 
S=O), 1170 (s, S=O) cm
-1
; δH (400 MHz, D2O) 1.76 (3H, s, 5-CH3), 2.55-2.75 (2H, m, 
H-2a‟, H-2b‟), 3.17-3.40 (2H, m, H-5a‟ and H-5b‟), 4.28-4.36 (1H, m, H-4‟), 5.03-
5.12 (1H, m, H-3‟), 6.01 (1H, t, J1,2 7.0 Hz, H-1‟), 7.34 (1H, s, H-6); δC (100 MHz, 
D2O)
 
11.3 (q, 5-CH3), 35.2 (t, C-2‟), 40.6 (t, C-5‟), 79.7 (d, C-3‟), 79.8 (d, C-4‟), 88.0 
(d, C-1‟), 111.2 (s, C-5), 139.4 (d, C-6), 151.4 (s, C-2), 166.5 (s, C-4); HRMS (ESI) 










General Procedure A, using sulfamoyl chloride 3.27a, and purification by RP-HPLC 
(Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; 
gradient: the sample was run at 1 mL/min with a gradient of 0-45 % B; column oven: 
40 °C; detection: UV 210 nm and 280nm), afforded sulfamide 3.11 (43 mg, 65 %) as 
a pale yellow solid.  m.p 105-107 °C (EtOH/Et2O); [α]D
20 
+10.3 (c, 0.35 in CH3OH); 
υmax (neat) 3273 (N-H), 1370 (s, S=O), 1165 (s, S=O) cm
-1
; δH (500 MHz, CD3OD) 
1.86 (3H, d, J 1.0 Hz, 5-CH3), 2.18 - 2.23 (2H, m, H-2a‟, H-2b‟), 3.19 (1H, dd, J5a‟,5b‟ 
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14.6 Hz, J4,5a‟6.6 Hz, H-5a‟), 3.28 (1H, dd, J5a‟,5b‟ 13.6 Hz, J4,5b‟ 4.5 Hz, H-5b‟ ), 3.85 
- 3.87 (1 H, m, H-4‟), 4.25 - 4.27 (1 H, m, H-3‟), 6.11 (1H, t, J1,2 6.8 Hz, H-1‟), 7.41 
(1H, dd, J 8.9 Hz, 2.7 Hz, Ar-H-6), 7.47 (1H, d, J 1.0 Hz, H-6), 7.49 (1H, d, J 8.9 Hz, 
Ar-H-5), 7.57 (1H, d, J 2.7 Hz, Ar-H-2); δC (100 MHz, CD3OD)
 
10.9 (q, 5-CH3), 38.7 
(t, C-2‟), 44.2 (t, C-5‟), 71.2 (d, C-3‟), 84.6 (d, C-4‟), 85.5 (d, C-1‟), 110.3 (s, C-5), 
117.3, 122.7, 131.9 (d, q, Ar(C)H, CF3), 136.9 (d, C-6), 137.0, 138.0 (2 x s,  3 x 
Ar(C)), 150.8 (s, C-2), 164.9 (s, C-4); HRMS (ESI) calculated for C17H19ClF3N4O6S: 









General Procedure A, using sulfamoyl chloride 3.27b, and purification by RP-HPLC 
(Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; 
gradient: the sample was run at 1 mL/min with a gradient of 0-45 % B; column oven: 
40 °C; detection: UV 210 nm and 280nm), afforded sulfamide 3.12 (26 mg, 49 %) as 
a white solid. m.p 105-107 °C (EtOH/Et2O); [α]D
20 
+22.4 (c, 0.25 in CH3OH); υmax 
(neat) 3207 (N-H), 1328 (s, S=O), 1150 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) 1.87 
(3H, s, 5-CH3), 2.20 (2H, at, J 6.3 Hz, H-2a‟, H-2b‟), 3.13 - 3.28 (2H, m, H-5a‟ and 
H-5b‟ ), 3.85(1 H, aq, J 4.7 Hz, H-4‟), 4.28 (1 H, aq, J 5.1 Hz, H-3‟), 6.12 (1H, t, J1,2 
7.0 Hz, H-1‟), 7.18, 7.26(4H, 2 x d, J 8.2 Hz, 4 x Ar-H), 7.50 (1H, s, H-6); δC (100 





10.9 (q, 5-CH3), 38.8 (t, C-2‟), 44.2 (t, C-5‟), 71.2 (d, C-3‟), 84.7 (d, 
C-4‟), 85.5 (d, C-1‟), 110.3 (s, C-5), 120.3, 128.6 (2 x d, 4 x Ar(C)H), 137.0 (d, C-6), 
137.2 (s, 2 x Ar(C)), 150.8 (s, C-2), 165.0 (s, C-4); HRMS (ESI) calculated for 








General Procedure A, using sulfamoyl chloride 3.27c, and purification by RP-HPLC 
(Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; 
gradient: the sample was run at 1 mL/min with a gradient of 0-45 % B; column oven: 
40 °C; detection: UV 210 nm and 280nm), afforded sulfamide 3.13 (24 mg, 41 %) as 
a white solid. m.p 115-117 °C (EtOH/Et2O); [α]D
20 
+15.2 (c, 0.25 in CH3OH); υmax 
(neat) 3208 (N-H), 1386 (s, S=O), 1150 (s, S=O) cm
-1
 δH (400 MHz, CD3OD) 1.87 
(3H, s, 5-CH3), 2.18 (2H, at, J  6.3 Hz, H-2a‟, H-2b‟), 3.14 - 3.28 (2H, m, H-5a‟ and 
H-5b‟ ), 3.85 (1 H, aq, J 5.1 Hz, H-4‟), 4.27 (1 H, aq, J 4.7 Hz, H-3‟), 6.11 (1H, t, J1,2 
7.0 Hz, H-1‟), 7.13 (2H, d, J 8.6 Hz, 2 x Ar-H), 7.40 (2H, d, J 9.0 Hz, 2 x Ar-H), 7.50 
(1H, s, H-6); δC (100 MHz, CD3OD)
 
11.0 (q, 5-CH3), 38.8 (t, C-2‟), 44.2 (t, C-5‟), 
71.2 (d, C-3‟), 84.7 (d, C-4‟), 85.5 (d, C-1‟), 110.3 (s, C-5), 120.5, 131.7 (2 x d, 4 x 
Ar(C)H), 137.0 (d, C-6), 137.7 (s, 2 x Ar(C)), 150.8 (s, C-2), 165.0 (s, C-4); HRMS 
(ESI) calculated for C16H20
79













General Procedure A, using sulfamoyl chloride 3.27d, and purification by RP-HPLC 
(Luna C-18 column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; 
gradient: the sample was run at 1 mL/min with a gradient of 0-45 % B; column oven: 
40 °C; detection: UV 210 nm and 280nm), afforded sulfamide 3.14 (18 mg, 34 %) as 
a light brown solid. m.p 133-135 °C (EtOH/Et2O); [α]D
20 
+10.4 (c, 0.25 in CH3OH); 
υmax (neat) 3219 (N-H), 1331 (s, S=O), 1148 (s, S=O) cm
-1
; δH (400 MHz, CD3OD) 
1.86 (3H, s, 5-CH3), 2.19 (2H, at, J  6.3 Hz, H-2a‟, H-2b‟), 3.13-3.28 (2H, m, H-5a‟ 
and H-5b‟ ), 3.86 (1 H, aq, J 4.7 Hz, H-4‟), 4.27 (1 H, aq, J 5.1 Hz, H-3‟), 6.11 (1H, t, 
J1,2 7.0 Hz, H-1‟), 6.98, 7.23 (4H, 2 x d, J 8.6 Hz, 4 x Ar-H), 7.49 (1H, s, H-6); δC 
(100 MHz, CD3OD)
 
12.8 (q, 5-CH3), 40.6 (t, C-2‟), 45.9 (t, C-5‟), 72.9 (d, C-3‟), 86.5 
(d, C-4‟), 87.3 (d, C-1‟), 112.1 (s, C-5), 117.3, 122.2 (2 x d, 4 x Ar(C)H), 138.7 (d, C-
6), 139.5 (s, 2 x Ar(C)), 152.6 (s, C-2), 166.8 (s, C-4); HRMS (ESI) calculated for 
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5.4  AB assay Protocol 
5.4.1  Preparation of Growth Medium 
5.4.1.1 Lysogeny Broth (LB) and LB/Tween 80 (LB/T)  
 
LB was prepared by adding 20 g/L LB base (Invitrogen) to dH2O. The pH was 
adjusted to 7 by the addition of 1 M NaOH as required. The resulting medium was 
sterilized by autoclaving in a culture flask or in individual 20 mL McCartney bottles. 
It was then stored at 4 °C for up to one month.  
To prevent clumping of mycobacteria, Tween 80 was added to the LB to make LB/T. 
Before inoculation, sterile filtered Tween 80 was added to give a final concentration 
of 0.05 %. In order to sterile filter Tween 80, it was dissolved in 10x in distilled 
water, heated in the microwave until it was lukewarm and then vortexed, before it was 
filtered through a 0.2 µm membrane filter under a laminar flow hood.  
5.4.1.2  LB Agar  
 
LB agar was prepared by adding 20 g/L LB base (Invitrogen) and 15 g/L 
bacteriological agar (Oxoid) to dH2O. 500 mL aliquots were autoclaved in 1000 mL 
bottles, and stored at room temperature until needed. The medium was then poured 
into sterile Petri dishes under a laminar flow hood, and stored at 4°C for up to one 
month. 
5.4.1.3  Glycerol Freezer Stocks 
 
A 50 % glycerol solution was made with distilled water and glycerol, and autoclaved.  
700 μL of an overnight culture (OD600 ~ 0.4-0.6) was mixed with 300 μL of a 50 % 
glycerol solution before being snap frozen in liquid nitrogen and stored at -80 °C. 
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5.4.2  Preparation of M. smegmatis stocks: 
 
A sterile LB agar plate was used to streak the M. smegmatis (mc
2
4517 strain), and it 
was then incubated at 37 °C until visible colonies appeared, typically after 2-3 days. 
After 2-3 days, a single colony was taken with a sterile pipette tip and transferred to a 
10 mL (LB/T) McCartney bottle as a starter culture. The culture was incubated at 37 
°C for 2-3 days at 160 rpm and until an OD600 of 0.4-0.6 was reached.  
The cells were harvested by centrifugation at 2,500g in 2 x 50 mL sterile tubes at 
room temperature for 15 minutes and the media was removed.  The cell pellets were 
re-suspended in sterile PBS + 0.05% Tween 80 (~ 25 mL per tube) and the cells were 
harvested by centrifugation by 2,500g at room temperature for 15 minutes. The 
supernatant was discarded and the cell pellets were re-suspended in 4 mL PBS + 
0.05% Tween 80 (per 50 mL cell pellet). The cell suspensions were combined, and 
aliquot of 100 µl per cryo-tube were snap frozen in liquid nitrogen. The cells were 
stored at -80 °C.  
5.4.3  Determine CFU/mL of Freezer Stocks 
 
A 100 µL cryo tube containing the bacteria was taken from the freezer and thawed. 
900 µL of LB/T was added and mixed by inverting 10-15 times. 100, 1000, 10,000 
fold serial dilutions were made from this 10 times diluted stock. 250 µL of each 
dilution was added to an LB agar plate and spread using a sterile spreader. After 




cfu = number of colonies on plate * dilution factor * (1 mL/0.25 mL) 
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5.4.4  Assay plates: 
In a sterile 96 well plate, 200 µl of dH2O was added to the peripheral wells to prevent 
evaporation of the test wells. Then, 100 µl of LB/T media was added to all the wells 
in the series in columns 4-10; 90 µl of the media was added to column 2 and 190 µl 
was added to column 3. 10 µl of the test compounds ethambutol (64 µg/mL) and 
isoniazid (64 µg/mL) were added to columns 2 and 3 and each compound was tested 
in triplicates (Figure 5.2). Using a multichannel auto pipette, 100 µl of diluted 
compound samples was taken from the column 3 and was added to the next well 
(column 4) which contained 100 µl of LB/T media. The well was then mixed 10 
times, 100 µl of mixed compound was transferred to the next well (column 5).  This 
step was then repeated four times progressing up to the column 9 and then 100 µl of 
the solution were discarded from the last well (column 9). Therefore the compounds 
were serially diluted by a factor of two across the plate, producing compound 
concentrations of 64, 32, 16, 8, 4, 2, 1 and 0.5 µg/ mL. Approximately 4.5 x 10
6
 cfu of 
M.smegmatis was added per well in a volume of 100 µl (apart from column 11). 
Control wells contained bacteria only (column 10), 200 µl of medium only (column 
11).  The plate was incubated at 37 
0
C for 18 hours. Thereafter, 10 µl of Alamar blue 
was added to all wells except the outer wells and the plate was then incubated for 
another 5 hours. The wells was observed after 5 hours for a colour change from blue 
to pink and the MIC value was determined by visual observation and also monitored 
spectrophotomerically at 595nm.  









(µg/mL)  32        16  8         4          2          1       0.5     0.25      0         0 
 














Figure 5.3: Alamar Blue assay plate for EMB and INH against M. smegmatis.
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5.4   Experimental for chapter 4 
 
General Procedure A: Reduction of polar azides 
Azide (1 equiv.) was dissolved in MeOH (1 mL), and the resulting solution was added 
to a stirred solution of NaI (4 equiv.) and Amberlite IR 120 (1.8 meq/mL by wetted 
bed volume of exchangeable H
+
 ions, 2 equiv.) in MeOH (1 mL). The reaction 
mixture was then concentrated on a rotary evaporator at 40 °C and 200 mbar until 
dryness (approx. 15 min.). The residue was dissolved in MeOH (5 mL), aqueous 1M 
HCl in MeOH (5 mL) and excess of Amberlite IR 120 (H
+
 form) were then added. 
The Amberlite was eluted with MeOH (100 mL), then with H2O (500 mL), and finally 
eluted with 2.5 M ammonia solution in MeOH.  
 
General Procedure B: Reduction of non-polar azides 
Azide (1 equiv.) was dissolved in CHCl3 (1.5 mL), and the resulting solution was 
added to a stirred solution of NaI (4 equiv.) and Amberlite IR 120 (1.8 meq/mL by 
wetted bed volume of exchangeable H
+
 ions, 2 equiv.) in MeOH (1 mL). The reaction 
mixture was then concentrated on a rotary evaporator at 40 °C and 200 mbar until 
dryness (approx. 15 min.). The residue was dissolved in MeOH (5 mL), aqueous 1M 
HCl in MeOH (5 mL) and excess of Amberlite IR 120 (H
+
 form) were then added. 
The Amberlite was eluted with MeOH (100 mL), then with H2O (500 mL), and finally 
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General Procedure C 
Methanesulfonyl chloride (1.5 equiv.) was added dropwise to a stirred solution of the 
alcohol (1 equiv.) and Et3N (1.5 equiv.) in anhydrous DCM (30 mL) at 0 ˚C under 
nitrogen. The reaction mixture was then allowed to warm to room temperature, and 
stirred for 2 hours. The reaction mixture was then poured into water (10 mL), and 
extracted with diethyl ether (3 x 20 mL). The combined organic extracts were dried 
over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
dissolved in DMF (25 mL), sodium azide (3 equiv.) was added, and the mixture was 
stirred at 60 ˚C for 16 hours. The reaction mixture was concentrated in vacuo, and the 
residue was extracted with diethyl ether (3 x 50 mL). The combined organic extracts 
were washed with distilled water (2 x 30 mL) and brine (30 mL), dried over 
anhydrous MgSO4, filtered, concentrated in vacuo, and the residue was purified by 
column chromatography. 
 
General Procedure D 
Sodium azide (3 equiv.) was added to a solution of the halide (1 equiv.) in DMF (10 
mL). The solution was then stirred at 50 ˚C for 16 hours. The reaction mixture was 
cooled, and diluted with diethyl ether (50 mL). The organic layer was separated and 
washed with water (2 x 30 mL) and brine (30 mL), dried over anhydrous MgSO4, 
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General Procedure E 
Glycoside (1 equiv.) was dissolved in dry THF (25 mL) and triphenylphosphine (2 
equiv.), iodine (1.5 equiv.) and imidazole (1.5 equiv.) were then added sequentially. 
The reaction mixture was then heated to 50 °C, and stirred at for 16 h under nitrogen. 
The reaction mixture was then cooled to room temperature and the solvent was 
removed in vacuo. The residue was then dissolved in ethyl acetate (30 mL), and the 
resulting solution was washed with 10% w/v aqueous Na2S2O3 (20 mL), and water (2 
x 20 mL). The organic extracts were dried over anhydrous MgSO4, filtered, and 






 D-Mannose (0.5 g, 2.7 mmol, 1 equiv.) was dissolved in dry DMF (5 mL) and 
triphenylphosphine (1.45 g, 5.5 mmol, 2 equiv.), iodine (1.05 g, 4.2 mmol 1.5 equiv.) 
and imidazole (280 mg, 4.1 mmol, 1.5 equiv.) were added sequentially. The reaction 
mixture was then stirred at 50 °C for 3 h under nitrogen. After this time, t.l.c. (EtOAc: 
MeOH: H2O, 7: 2: 1) indicated the formation of a single product (Rf 0.6). The solvent 
was removed in vacuo and the residue was dissolved in H2O (30 mL). This solution 
was then washed with DCM (3 x 20 mL). The aqueous extracts were concentrated in 
vacuo to afford crude 6-deoxy-6-iodo-D-mannopyranose, as a yellow oil. This crude 
material was dissolved in DMF (25 mL), sodium azide (3 equiv.) was added, and the 
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mixture was stirred at 60 ˚C for 16 h. After this time, t.l.c. (EtOAc: MeOH: H2O, 7: 2: 
1) indicated the formation of a single product (Rf 0.5). The mixture was cooled, the 
solvent was removed in vacuo, and the residue was dissolved in H2O (5 mL). This 
solution was then filtered through a column of Amberlite IR 120 (H
+
 form), and then 
concentrated in vacuo to give a residue, which was purified by RP-HPLC [Luna C-18 
column (Phenomenex); eluent: A (0.05 % TFA in H2O) and B MeCN; gradient: the 
sample was run at 1 mL/min with a gradient of 0-100 % B; column oven: 40 °C; 
detection: CAD], to afford 6-amino-6-deoxy-D-mannopyranose 4.1 as pale yellow 
waxy solid (0.28 g, 56 %).  υmax (neat) 3330 (O-H); δH (400 MHz, D2O) 2.97-3.12 
(2H, m, H-6α, H-6β), 3.30 - 3.38 (2H, m, H-6'α, H-6'β), 3.42 - 3.58 (3H, m, H-4α, H-
4β, H-3α/β), 3.73 (1H, dd, J2,3 2.3 Hz, J3,4 9.4 Hz, H-3α/β), 3.81 - 3.92 (4H, m, H-2α, 
H-2β, H-5α, H-5β), 4.81  (1H, s, H-1β), 5.08 (1H, s, H-1α); δC (100 MHz, D2O) 40.4, 
40.5 (t, C-6α, C-6β), 68.1, 68.1 (d, C-5α, C-5β), 68.4 (d, C-3α/β or C-4α/β), 69.8 (d, 
C-3α/β), 70.5, 71.0 (d, C-2α, C-2β), 71.7 (d, C-3α/β or C-4α/β), 72.6 (d, C-4α/β), 93.7 
(d, C-1β), 94.0 (d, C-1α). HRMS (ESI) calculated for C6H14NO5 (M+H
+
): 180.0866. 








 General procedure E, using methyl α-D-mannopyrannoside 4.3 (2 g, 10.3 mmol)  and 
purification by flash chromatography (ethyl acetate: methanol: water, 7:2:1, Rf 0.5) 
afforded methyl 6-deoxy-6-iodo-α-D-mannopyrannoside 4.4 (2.3 g, 74 %) as a white 
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+76.2  (c, 0.5 in 
CH3OH) [lit. [α]D
22
 +67.5 (c, 1.0 in CH3OH)]
145
;  δH (400 MHz, D2O)  3.25 (1H, dd, 
J6,6‟ 10.6 Hz, J5,6 7.0 Hz, H-6), 3.32 (3H, s, OCH3),  3.35-3.49 (1H, m, H-5), 3.45 (1H, 
t, J3,4 9.4 Hz, H-4), 3.52 (1H, t, J6,6‟ 11.0 Hz, H-6‟), 3.64 (1H, dd, J3,4 9.4 Hz, J2,3 3.1 








General procedure D, using methyl 6-deoxy-6-iodo-α-D-mannopyrannoside 4.4 (1 g, 
3.3 mmol), and purification by flash chromatography (ethyl acetate: methanol: water, 
7:2:1, Rf 0.5) afforded methyl 6-azido-6-deoxy-α-D-mannopyrannoside 4.5a (530 mg, 
74 %) as a yellow oil. [α]D
20 
+43 (c, 0.5 in CH3OH) [lit. [α]D
24.3
 +41 (c, 0.066 in 
CH3OH)]
146
; δH (400 MHz, CD3CN)  3.37 (3H, s, OCH3),  3.44 (1H, dd, J5,6 6.3 Hz, 
J6,6‟ 12.9 Hz, H-6), 3.48-3.62 (4H, m, H-3, H-4, H-5, H-6‟), 3.76 (1H, dd, J1,2 1.6 Hz, 














 General procedure C, using methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside 4.6 (1 g, 
2.2 mmol), and purification by flash chromatography (petrol: ethyl acetate, 2:1, Rf 
0.7) afforded methyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-α-D-glucopyranoside 4.8a (1 
g, 95 %) as a pale yellow oil. [α]D
20 
+51.3 (c, 1.0 in CHCl3) [lit. [α]D
20
 +53.1 (c, 2.4 in 
CHCl3)]
147
; δH (400 MHz, CDCl3)  3.33 (1H, dd, J6,6‟ 12.9 Hz, J5,6 5.5 Hz, H-6), 3.40 
(3H, s, OCH3), 3.42 - 3.46 (2H, m, H-6‟, H-4), 3.54 (1H, dd, J1,2 3.5 Hz, J2,3 9.4 Hz, 
H-2), 3.78 (1H, td, J 4,5 9.8 Hz, J5,6 5.9 Hz, J5,6‟ 2.3 Hz, H-5), 3.98 (1H, t, J2,3 9.2 Hz, 
H-3), 4.57 (1H, d, J 11.0 Hz, CH2Ph), 4.61 (1H, d, J1,2 3.5 Hz, H-1), 4.67 (1H, d, J 
12.1 Hz, CH2Ph), 4.77-4.84 (2H, m, CH2Ph), 4.90 (1H, d, J 11.0 Hz, CH2Ph), 5.0 








Sodium azide (511 mg, 7.9 mmol, 1.5 equiv.) was added to a solution of the 
toluenesulfonylchloride 4.9 (1 g, 5.2 mmol, 1 equiv.) in DMF (5 mL). The solution 
was then stirred at room temperature for 30 minutes. The reaction mixture was diluted 
with ethyl acetate (20 mL), and then the organic layer was separated and washed with 
water (2 x 30 mL) and brine (30 mL), dried over anhydrous MgSO4, filtered, 
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concentrated in vacuo, and the residue was purified by column chromatography 
(Petrol 100 %, Rf 0.1) afforded toluenesulfonylazide 4.13a (0.7 g, 68 %) as a clear oil. 






 General procedure D, using methyl 4-chlorobutyrate 4.10 (1 g, 1.1 mmol), and 
purification by flash chromatography (petrol 100 %, Rf 0.4) afforded methyl 4-
azidobutyrate 4.14a (0.73 g, 70 %) as a clear oil. δH (400 MHz, CDCl3) 1.87-1.95 









General procedure D, using 1-chloromethyl-4-nitrobenzene 4.11 (1 g, 5.8 mmol), and 
purification by flash chromatography (petrol: ethyl acetate, 5:1, Rf 0.4) afforded 1-
azidomethyl-4-nitrobenzene 4.15a (0.7 g, 67 %) as a pale yellow oil. δH (400 MHz, 
CDCl3) 4.50 (2H, s, PhCH2), 7.50, 8.25 (4H, 2 x d, J 8.6 Hz, 4 x Ar(C)H). 
 
 









 General procedure D, using 11-bromoundecene 4.12 (1 g, 4.3 mmol), and 
purification by flash chromatography (petrol: ethyl acetate, 2:1, Rf 0.9) afforded 11-
azidoundecene 4.16a (0.6 g, 71 %) as a pale yellow oil. δH (400 MHz, CDCl3) 1.23-
1.45 (12H, m, 6 x CH2), 1.53-1.65 (2H, m, CH2), 2.04 (2H, q, J 7.0 Hz, CH2), 3.26 







General procedure D, using 1,10-dibromodecane 4.17 (1 g, 3.4 mmol), and 
purification by flash chromatography (petrol 100 %, Rf 0.4) afforded 1,10-
diazidodecane  4.18a (0.6 g, 80 %) as a clear oil. δH (400 MHz, CDCl3) 1.23-1.41 













General procedure A using methyl 6-azido-6-deoxy-α-D-mannopyrannoside 4.5a (50 
mg, 0.3 mmol), afforded methyl 6-amino-6-deoxy-α-D-mannopyrannoside 4.5b (40 
mg, 91 %) as a white foam. [α]D
20 
+81 (c, 1.0 in CH3OH) [lit. [α]D
23





υmax (neat) 3340 (w, NH and OH)  cm
-1
; δH (400 MHz, CD3OD)  2.96-
3.03 (1H, m, H-6), 3.23 (1H, dd, J6,6‟ 13.1 Hz, J5,6‟ 2.9 Hz, H-6‟), 3.39 (3H, s, OCH3), 
3.51 (1H, at, J 9.4 Hz, H-4),  3.56-3.62 (1H, m, H-5), 3.66 (1H, dd, J3,4 9.2 Hz, J2,3 3.3 
Hz, H-3), 3.79 - 3.81 (1H, m, H-2), 4.66 (1H, d, J1,2 1.6 Hz, H-1); δC (100 MHz, 
CD3OD) 41.2 (t, C-6), 54.2 (q, OCH3), 68.4 (d, C-4), 70.1 (d, C-5), 70.5 (d, C-2), 70.7 










General procedure B, using methyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-α-D-
glucopyranoside 4.8a (100 mg, 0.2 mmol), afforded methyl 6-amino-6-deoxy-2,3,4-
tri-O-benzyl-α-D-glucopyranoside 4.8b (88 mg, 93 %) as white solid. m.p 89-91 °C 




+41.2 (c, 0.25 in CH3OH) [lit. [α]D
20
 +54.8 (c, 1.0 in 
CHCl3)]
155
; υmax (neat) 3392 (w, NH) cm
-1
; δH (400 MHz, CD3OD) 2.83 (1H, dd, J6,6‟ 
13.1 Hz, J5,6 9.2 Hz, H-6), 3.15 (1H, dd, J6,6‟ 13.1 Hz, J5,6‟ 2.5 Hz, H-6‟), 3.32-3.36 
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(1H, m, H-4), 3.41 (3H, s, OCH3), 3.57 (1H, dd, J1,2 3.5 Hz, J2,3 9.4 Hz, H-2), 3.74 
(1H, td, J4,5 9.4 Hz, J5.6 9.4 Hz, J5,6‟ 2.7 Hz, H-5), 3.89 (1H, at, J 9.2 Hz, H-3), 4.62 
(1H, d, J 11.0 Hz, CH2Ph), 4.70 (1H, d, J 11.0 Hz, CH2Ph), 4.75 (2H, d, J 11.0 Hz, 
CH2Ph), 4.77 (1H, d, J1,2 3.5 Hz, H-1), 4.87-4.95 (2H, m, CH2Ph), 7.20 - 7.46 (15H, 
m, Ar-H); δC (100 MHz, CD3OD) 40.9 (t, C-6), 54.7 (q, OCH3), 67.8 (d, C-5), 72.7 (t, 
CH2Ph), 74.5 (t, CH2Ph), 75.1 (t, CH2Ph), 78.8 (d, C-4), 79.9 (d, C-2), 81.2 (d, C-3), 
97.8 (d, C-1), 127.3, 127.5, 127.6, 127.7, 127.8, 127.9, 128.1, 128.4, 128.6, 128.7 (10 
x d, 15 x Ar(C)H), 138.0, 138.1, 138.5 (3 x s, 3 x Ar(C)CH2); HRMS (ESI) calculated 
for C28H34NO5 (M+H
+








 General procedure B, using toluenesulfonylazide 4.13a (100 mg, 0.5 mmol), 
toluenesulfonamide 4.13b (82 mg, 95 %) as a pale yellow solid; m.p 118-120 °C 
(Ethanol/Et2O) [lit 125-126 °C]
157
; υmax (neat) 3258, 3355 (w, NH), 1385, 1154 (s, 
S=O) cm
-1
; δH (400 MHz, CD3OD) 2.41 (3H, s, CH3), 7.34 (2H, d J 7.8 Hz, Ar(C)H), 
7.77 (2H, d J 8.2 Hz, Ar(C)H) ; δC (100 MHz, CD3OD) 20.0 (q, CH3), 125.7, 129.1 (2 
x d, 2 x Ar(C)H), 140.7, 142.7 (2 x s, Ar(C)SO2, Ar(C)CH3); HRMS (ESI) calculated 
for C7H9NNaO2S (M+Na
+
) 194.0246. Found 194.0245. 
 
 








General procedure B, using methyl 4-azidobutyrate 4.14a (100 mg, 0.7 mmol), 
afforded methyl 4-aminobutyrate 4.14b (59 mg, quantitative yield) as a white waxy 
solid.; υmax (neat) 1654 (s, C=O) cm
-1
; δH (400 MHz, CD3OD) 2.13-2.24 (2H, m, 
CH2), 2.48 (2H, t, J 8.2 Hz, COCH2), 3.50 (2H, t, J 7.0 Hz, NCH2); δC (100 MHz, 
CD3OD) 20.0  (t, CH2), 29.8 (t, COCH2), 43.3 (t, NCH2), 180.9 (s, C=O); HRMS 
(ESI) calculated for C4H8NO (M+H
+








 General procedure B, using 1-azidomethyl-4-nitrobenzene 4.15a (100 mg, 0.6 
mmol), afforded (4-nitrophenyl)methanamine 4.15b (85 mg, quantitative yield) as a 
pale yellow waxy solid. υmax (neat) 3308 (w, NH), 1541, 1350 (s, NO2) cm
-1
; δH (400 
MHz, DMSO-d6) 4.16 (2H, s, PhCH2), 7.74 (2H, d, J 8.6 Hz, 2 x Ar(C)H), 8.27 (2H, 
d, J 8.2 Hz, 2 x Ar(C)H); δC (100 MHz, DMSO-d6) 42.0 (t, PhCH2), 124.0, 130.5 (2 x 
d, 4 x Ar(C)H), 142.5, 147.8 (2 x s, 2 x Ar(C)CH2); HRMS (ESI) calculated for 
C7H9N2O2 (M+H
+
) 153.0659. Found 153.0659. 
 








 General procedure B, using 11-azidoundecene 4.16a (100 mg, 0.5 mmol), afforded 
10-undeceneamine 4.16b (75 mg, 87 %) as a pale yellow waxy solid. υmax (neat) 3426 
(w, NH), 3119 (m, =CH), 1641 (m, C=C) cm
-1
; δH (400 MHz, DMSO-d6) 1.18-1.37 
(12H, m, CH2), 1.46-1.56 (2H, m, CH2), 1.99 (2H, q, J 6.7 Hz, CH2), 2.72 (2H, t, J 7.6 
Hz, NCH2), 4.88-5.01 (2H, m, =CH2),  5.71-5.84 (1H, m, =CH); δC (100 MHz, 
DMSO-d6) 26.3, 27.4, 28.7, 28.9, 29.2, 29.2, 33.6 (7 x t, 8 x CH2),  39.2 (t, CH2N),  
115.1 (t, =CH2), 139.3 (d, =CH); HRMS (ESI) calculated for C11H24N (M+H
+
) 







 General procedure B, using 1,10-diazidodecane 4.18a (100 mg, 0.4 mmol) and 8. 
equiv. of NaI and 4 equiv. of acid,  afforded 1,10-diaminodecane 4.18b (70 mg, 92 %) 
as a white solid.  m.p 66-68 °C (MeOH/Et2O) [lit 62-64 °C]
161
; υmax (neat) 3420 (w, 
NH) cm
-1
; δH (400 MHz, CD3OD) 1.32-1.43 (12H, m, 6 x CH2), 1.60-1.70 (4H, m, 2 x 
CH2), 2.91 (4H, t, J 7.4 Hz, 2 x NCH2); δC (100 MHz, CD3OD) 26.0, 27.2, 28.8, 29.0 
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